CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF FIELD OF THE INVENTION The present invention relates to compounds of formula (I), which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity, pharmaceutical compositions containing compounds of formula (I) and methods to treat or prevent pain, inflammatory thermal hyperalgesia, bladder overactivity, and urinary incontinence, using the compounds of formula (I), BACKGROUND OF INVENTION Nociceptors are primary sensory afferent (C and A5 fibers) neurons that are activated by a wide variety of noxious stimuli including chemical, mechanical, thermal, and proton (pH < 6) modalities. The lipophillic vanilloid, capsaicin, activates primary sensory fibers via a specific cell surface capsaicin receptor, cloned as VR1. The intradermal administration of capsaicin is characterized by an initial burning or hot sensation followed by a prolonged period of analgesia. The analgesic component of VR1 receptor activation is thought to be mediated by a capsaicin-induced desensitization of me primary sensory afferent terminal. Thus, the long lasting anti-nociceptive effect of capsaicin has prompted the clinical use of capsaicin analogs as analgesic agents. Further, capsazepine, a capsaicin receptor antagonist can reduce inflammation-induced hyperalgesia in animal models. VR1 receptors are also localized on sensory afferents, which innervate the bladder. Capsaicin or resiniferatoxin has been shown to ameliorate incontinence symptoms upon injection into the bladder. The VR1 receptor has been called a "polymodal detector" of noxious stimuli since it can be activated in several ways. The receptor channel is activated by capsaicin and other vanilloids and thus is classified as a ligand-gated ion channel. VR1 receptor activation by capsaicin can be blocked by the competitive VR1 receptor antagonist, capsazepine. The channel can also be activated by protons. Under mildly acidic conditions (pH 6-7), the affinity of capsaicin for the receptor is increased, whereas at pH <6, direct activation of the channel occurs. In addition, when membrane temperature reaches 43 °C, the channel is opened. Thus heat can directly gate the channel in the absence of ligand. The capsaicin analog, capsazepine, which is a competitive antagonist of capsaicin, blocks activation of the channel in response to capsaicin, acid, or heat The channel is a nonspecific cation conductor. Both extracellular sodium and calcium enter through the channel pore, resulting in cell membrane depolarization. This depolarization increases neuronal excitability, leading to action potential firing and transmission of a noxious nerve impulse to the spinal cord. In addition, depolarization of the peripheral terminal can lead to release of inflammatory peptides such as, but not limited to, substance P and CGRP, leading to enhanced peripheral sensitization of tissue. Recently, two groups have reported the generation of a "knock-out" mouse lacking the VR1 receptor. Electrophysiological studies of sensory neurons (dorsal root ganglia) from these animals revealed a marked absence of responses evoked by noxious stimuli including capsaicin, heat, and reduced pH. These animals did not display any overt signs of behavioral impairment and showed no differences in responses to acute non-noxious thermal and mechanical stimulation relative to wild-type mice. The VR1 (-/-) mice also did not show reduced sensitivity to nerve injury-induced mechanical or thermal nociception. However, the VR1 knock-out mice were insensitive to the noxious effects of intradermal capsaicin, exposure to intense heat (50-55 °C), and failed to develop thermal hyperalgesia following the intradermal administration of carrageenan. The compounds of the present invention are novel VR1 antagonists and have utility in treating pain and urinary disorders, especailly acute pain, chronic pain, inflammatory pain, osteoarthritic pain, cancer pain, lower back pain, bladder overactivity and urinary incontinence. SUMMARY OF THE PRESENT INVENTION The present invention discloses chromanylurea compounds of formula (I), a method for inhibiting the VR1 receptor in mammals using these compounds, pharmaceutical compositions including these compounds, and methods for controlling pain and urinary disorders in mammals, especailly acute pain, chronic pain, inflammatory pain, osteoarthritic pain, cancer pain, lower back pain, bladder overactivity and urinary incontinence, using these-compounds. More particularly, the present invention is directed to compounds of formula (I) (Formula Removed) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1is Nor CR1; A2 is N or CR2; A3 is N or CR3; . A4 is N or CR4; provided that only one or two of A1, A2, A3 and A4 can be N; R1, R2, R3 and R4 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, halogen, hydrogen, hydroxy, alkoxy, -ORc, haloalkoxy, -NRARB, -C(O)Ra, -C(O)OH, -C(O)Oalkyl, -S(alkyl), -S(O)alkyl, -S(O)2Ra, Rc, -O-alkyl-Rc and -alkyl-Rc; X is O or NR5; Y is O, NR6, S or a bond; L is a bond or C1-10 alkyl; R5 and R6 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, -C(O)Ra, -S(O)2Ra, Rc and -alkyl-Rc; Ra is allcyl, haloalkyl, -NH2, -N(H)(alkyl), -N(alkyl)2j RC, or -alkyl-Rc; m is O, 1,2,3 or 4; n is 0,1, 2, 3 or 4; provided that when Y is a bond, then the sum of m and n is 1,2, 3 or 4, or when Y is O, NR6 or S, then the sum of m and n is 0,1,2 or 3; R7 and R8, at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and -alkyl-Rc, wherein the aryl, heteroaryl, cycloalkyl and cycloalkenyl are each independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, hydroxy, alkoxy, haloalkoxy, -NH2, -N(H)(alkyl), -N(alkyl)2, -N(H)C(O)alkyl, -N(alkyl)C(O)alkyl, -N(H)C(O)Oalkyl, -N(alkyl)C(O)Oalkyl, -C(O)alkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)N(H)(alkyl), -C(O)N(alkyl)2, -S(alkyl), -S(O)alkyI, -S(O)2alkyl, -S(O)2N(H)2, -S(O)2N(H)(alkyl) and-S(O)2N(alkyl)2; R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or haloalkoxy; RA and RB are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, RC and -alkyl-Rc, Z is a monocyclic or bicyclic ring selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, heteroaryl and aryl; wherein each Z is Uldependently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, hydroxy, alkoxy, haloalkoxy, -NH2, -N(H)(alkyl), -N(alkyl)2> -C(O)alkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)N(H)(alkyl), -C(O)N(alkyl)2, -S(alkyl), -S(O)alkyl, -S(O)2alkyl, -S(O)2N(H)2, -S(O)2N(H)(alkyl), -S(O)2N(alkyl)2, RC, and alkoxyalkyl; • provided that when A1 is CR1, A2 is CR2, A3 is CR3, A4 is CR4, Y is a bond, L is a bond, X is O, and the sum of m and n is 2, 3 or 4, then Z is a bicyclic ring selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle and heteroaryl; wherein each Z is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, hydroxy, alkoxy, haloalkoxy, -NH2, -N(H)(alkyl), -N(alkyl)2, -C(O)alkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)N(H)(alkyl), -C(O)N(alkyl)2, -S(alkyl), -S(O)alkyl,-S(O)2alkyl, -S(O)2N(H)2, -S(O)2N(H)(alkyl), -S(O)2N(alkyl)2, Rc, and alkoxyalkyl; and Rc at each occurrence is Uldependently a monocyclic or bicyclic ring, Uldependently selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, heteroaryl and aryl; wherein each RC is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, oxo, hydroxy, alkoxy, haloalkoxy, -NH2, -N(H)(alkyl), -N(alkyl)2, -N(H)C(O)alkyl, -N(alkyl)C(O)alkyI, -N(H)C(O)Oalkyl, -N(alkyl)C(O)OaIkyl, -C(O)alkyl, -C(O)OH, -C(O)OaIkyl, -C(O)NH2, -C(O)N(H)(alkyl), -C(O)N(alkyl)2, -S(alkyl), -S(O)alkyl, -S(O)2alkyl, -S(O)2N(H)2, -S(O)2N(H)(alkyl) and -S(O)2N(alkyI)2. (1) Compounds and Methods of the Invention The present invention relates to compounds having formula (I) as described above. The invention includes compounds having the formula (I) in which Z is a bicyclic ring selected form the group consisting of cycloalkenyl, cycloalkyl, heterocycle and heteroaryl. Preferred compounds include those in which Z is heteroaryl, selected from the group consisting of benzimidazolyl, indazolyl, isoquinolinyl, and quinolinyl. The present invention includes compounds in which Z is indazolyl; R7 and R8, at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and -alkyl-Rc, in which Rc at each occurrence is independently a monocyclic or bicyclic ring, independently selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, heteroaryl and aryl; wherein each Rc is independently unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from the group consisting of alkyl, haloalkyl, halogen, oxo, hydroxy, alkoxy, haloalkoxy, -NH2, -N(H)(alkyl), -N(alkyl)2, -N(H)C(O)alkyl, N(alkyl)C(O)alkyl, -N(H)C(O)Oalkyl, -N(alkyl)C(O)Oalkyl, -C(O)alkyl, -C(O)OH, -C(O)Oalkyl, -C(O)NH2, -C(O)N(H)(aIkyl), -C(O)N(alkyl)2, -S(alkyl), -S(O)alkyl, -S(O)2alkyl, -S(O)2N(H)2, -S(O)2N(H)(alkyl) and -S(O)2N(alkyl)2 and A1 is CR1; A2 is CR2; A3 is CR3; and A4 is CR4; wherein R1, R2, R3 and R4 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, halogen, hydrogen, hydroxy, alkoxy, -ORc, haloalkoxy, -NRARB, -C(O)Ra, -C(O)OH, -C(O)Oalkyl, -S(alkyl), -S(O)alkyl, -S(O)2Ra, RC, -O-alkyl-Rc and -aJkyl-Rc; and Rc is as described above; preferably where L is a bond; X is O; Y is a bond; m is 0; and n is 2. Other preferred compound sin this subgenus are those in which L is a bond; X is NR5 and R5 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, -C(O)Ra, -S(O)2Ra, Re, and -alkyl-Rc, where RC is as described above; Y is a bond; m is 0; and n is 3. Other preferred compounds include those in which L is a bond; X is NR5 and R5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, -C(O)Ra, -S(O)2Ra, RC, and -alkyl-Rc, wherein RC is as described above; Y is a bond; m is 0; and n is 2; or those in which m is 1; and n is 1. Other preferred compounds include those in which L is C1-10 alkyl; X is O; Y is a bond; m is 1; and n is 0; or those in which m is 2; and n is 0. Other preferred compounds include those in which L is CMO alkyl; X is NR5; R5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloallcyl, -C(O)Ra, -S(O)2Ra, RC, and -alkyl-Rc; Y is a bond; m is 1; and n is 0. Other compounds comprise those in which L is C1-10 alkyl; X is NR5; R5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloallcyl, -C(O)Ra, -S(O)2Ra, Rc, and -alkyl-Rc; Y is O; m is 0; and n is 1. Other compounds included in the present invention are those in which L is C1-10 alkyl; X is O; Y is NR6; R6 is each, independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, -C(O)Ra, -S(O)2Ra, Rc, and -alkyl-Rc and, RC, is as described above; m is 1; and n is 0. Other compounds are those in which L is CMO alkyl;X is NR5; R5 is as described above; Y is a bond; m is 2; and n is 0. Also, compounds where L is C1-10 alkyl; X is O; Y is O; m is 1; and n is 0 are included The present invention also includes compounds where Z is isoquinolinyl; R7 and R8, at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and -alkyl-Rc as described in claim 1; A1 is CR1; A2 is CR2; A3 is CR3; and A4 is CR4; wherein R1, R2, R3 and R4 are as described above. Preferred compounds in this group include those in which L is a bond; X is 0; Y is a bond; m is 0; and n is 2. Other preferred compounds include those in which L is a bond; X is 0; Y is a bond; m is 1; and n is 1. The present invention also includes compounds where Z is quinolinyl; R7 and R8, at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and -alkyl-Rc as described in claim l;.A1 is CR1; A2 is CR2; A3 is CR3; and A4 is CR4; wherein R1, R2, R3 and R4 are as described above. Preferred compounds in this group are those in which L is a bond; X is 0; Y is a bond; m is 0; and n is 2. The present invention also comprises compounds where Z is isoquinolinyl; R7 and R8, at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and -alkyl-Rc as described in claim 1; A1 is CR1; A2 is CR2; A3 is CR3; and A4 is CR4; wherein R1, R2, R3 and R4 are as described above. Preferably where L is CMO allcyl; X is NR5; R5 is as described above; Y is a bond; m is 2; and n is 0. Compounds and compositions of the invention are useful for modulating the effects of vanilloid receptor activity, and more particularly the receptor type VR1. In particular, the compounds and compositions of the invention can be used for treating and preventing disorders modulated by VR1. Typically, such disorders can be ameliorated by selectively modulating the VR1 receptor in a mammal, preferably by administering a compound or composition of the invention, either alone or in combination with another active agent, for example, as part of a therapeutic regimen. The compounds of the invention, including but not limited to those specified in the examples, possess an affinity for VRls. As VR1 ligands, the compounds of the invention can be useful for the treatment and prevention of a number of diseases or conditions mediated by the VR1 activity. For example, VR1 have been shown to play a significant role in the release of inflammatory peptides such as, but not limited to, substance P and CGRP, leading to enhanced peripheral sensitization of tissue. As such, VR1 ligands are suitable for the treatment of disorders associated with several types of pain and with inflammation. Further, capsazepine, a capsaicin receptor antagonist can reduce inflammation-induced hyperalgesia in animal models. Therefore the compounds and compositions of the present invention are useful for treatment of disorders like acute pain, chronic pain, inflammatory pain, osteoarthritic pain, cancer pain, lower back pain. VRls are also localized on sensory afferents, which innervate the bladder. Capsaicin or resiniferatoxin has been shown to ameliorate incontinence symptoms upon injection into the bladder. Therefore, VR1 ligands are suitable for the treatment of disorders associated with urinary incontinence and bladder dysfunction. (2) Definition of Terms As used throughout this specification and the appended claims, the following terms have the following meanings: The term "alkenyl" as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl. The term "alkyl" as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylbutyl, 3-methylhexyl, 3,3-dimethylbutyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. The term "alkynyl" as used herein, refers to a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl. The term "alkoxy" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy. The term "alkoxyalkyl" as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. The term "aryl" as used herein, means a phenyl group, a bicyclic aryl or a tricyclic aryl. The bicyclic aryl or the tricych'c aryl is a hydrocarbon fused ring system containing zero heteroatom wherein one or more of the fused rings is a phenyl group. Bicyclic aryl is a phenyl group fused to a monocyclic cycloalkyl group, as defined herein, a monocyclic cycloalkenyl group, as defined herein, or another phenyl group. Tricyclic aryl is a bicyclic aryl fused to a monocyclic cycloalkyl group, as defined herein, a monocyclic cycloalkenyl group, as defined herein, or another phenyl group. The phenyl group, the bicyclic aryls and the tricyclic aryls of the present invention are appended to the parent moiety through any substitutable atoms in the phenyl group, the bicyclic aryls and the tricyclic aryls respectively. The phenyl group, the bicyclic aryls and the trieyclic aryls of the present invention can be unsubstituted or substituted. Representative examples of aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, 2,3-dihydro-lH-inden-l-yl, 2,3-dihydro-lH-inden-4-yl, inden-1-yl, inden-4-yl, naphthyl, phenyl, 5,6,7,8-tetrahydronaphthalen-l-yl, 1,2,3,4-tetrahydronaphthalen-2-yl and tetrahydronaphthyl. The term "cycloalkyl" or "cycloalkane" as used herein, means a monocyclic cycloalkyl or a bicyclic cycloalkyl. The monocyclic cycloalkyl is a saturated hydrocarbon ring system having three to eight carbon atoms and zero heteroatom. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The bicyclic cycloalkyl is a fused ring system wherein the monocyclic cycloalkyl ring is fused to another monocyclic cycloalkyl group, as defined herein The monocyclic cycloalkyls and the bicyclic cycloalkyls of the present invention can be unsubstituted or substituted, and are connected to the parent molecula moiety through any substitutable carbon atom of the monocyclic cycloalkyls and the bicyclic cycloalkyls respectively. The term "cycloalkenyl" or "cycloalkene" as used herein, means a monocyclic cycloalkenyl or a bicyclic cycloalkenyl. The monocyclic cycloalkenyl is a non-aromatic, partially unsaturated hydrocarbon ring system, having 4, 5, 6, 7 or 8 carbon atoms and zero heteroatom. The 4-membered ring systems have one double bond, the 5-or 6-membered ring systems have one or two double bonds, and the 7- or 8-membered ring systems have one, two or three double bonds. Representative examples of monocyclic cycloalkenyl groups include, but not limited to, cyclobutenyl, cyclopentenyl, and cyclohexenyl. The bicyclic cycloalkenyl is a hydrocarbon fused ring system wherein the monocyclic cycloalkenyl ring is fused to a monocyclic cycloalkyl group, as defined herein, or another monocyclic cycloalkenyl group, as defined herein. Representative examples of the bicyclic cycloalkenyls include, but not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl and 1,6-dihydro-pentalene. The monocyclic cycloalkenyls and the bicyclic cycloalkenyls of the present invention can be unsubstituted or substituted, and are attached to the parent molecular moiety through any substitutable carbon atom of the monocyclic cycloalkenyls and the bicyclic cycloalkenyls respectively. The term "halo" or "halogen" as used herein, means -Cl, -Br, -I or -F. The term "haloalkoxy" as used herein, refers to an alkoxy group, as defined herein, in which one, two, three, four, five or six hydrogen atoms are replaced by halogen. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, 2-chloro-3-fluoropentyloxy, and pentafluoroethoxy. The term "haloalkyl" as used herein, refers to an alkyl group, as defined herein, in which one, two, three or four, five, or six hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl. The term "heterocycle" or "heterocyclic" as used herein, refers to a monocyclic heterocycle or a bicyclic heterocycle. The monocyclic heterocycle is a non-aromatic, saturated or partially unsaturated hydrocarbon ring system containing at least one heteroatom selected from the group consisting of oxygen, nitrogen and sulfur. Monocyclic ring systems are exemplified by a 4-membered ring containing three carbon atoms and one heteroatom selected from oxygen, nitrogen and sulfur,; or a 5-, 6-, 7-, or 8-membered ring containing one, two, three or four heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur, and the remaining atoms are carbon atoms. The 5-membered ring has 0 orl double bond. The 6-memebered ring has 0,1 or 2 double bonds. The 7- or 8-membered ring has 0,1,2 or 3 double bonds. The monocyclic heterocycle of the present invention can be unsubstituted or substituted. Representative examples of unsubstituted and susbstituted monocyclic ring systems include, but are not limited to, azetidinyl, azepanyl, azepinyl, diazepinyl, dioxolanyl, dioxanyl, dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, 3-oxo-morpholinyl, oxadiazotinyl, oxadiazolidinyl, oxazolinyl, 2-oxo-oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl (piperidyl), pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydropyridyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, 1,4-diazepanyl and trithianyl. Bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, a monocyclic cycloalkenyl group, as defined herein, a monocyclic cycloalkyl group, as defined herein, or a monocyclic heterocycle group. The bicyclic heterocycles of the present invention can be unsubstituted or substituted. Representative examples of bicyclic heterocycles include but are not limited to, benzodioxinyl, benzopyranyl, benzothiopyranyl, 2,3-dihydroindolyl, indolizinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 3-azabicyclo[3.2.0]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrolyl, hexahydro-1 H-furo[3,4-c]pyrrolyl, and octahydropyrrolo[3,4-c]pyrrolyl. The monocyclic heterocycles and the bicyclic heterocycles of the present invention are connected to the parent molecular moiety through any substitutable carbon or nitrogen atom in the monocyclic heterocycles and the bicyclic heterocycles respectively. The nitrogen heteroatom may or may not be quaternized, and the nitrogen or sulfur heteroatom may or may not be oxidized. In addition, the nitrogen containing heterocyclic rings may or may not be N-protected. The term "heteroaryl" as used herein, means a monocyclic heteroaryl or a bicyclic heteroaryl. The monocyclic heteroaryl is an aromatic, five- or six-membered ring where at least one atom is selected from the group consisting of N, O, and S, and the remaining atoms are carbon. The five membered rings have two double bonds, and the six membered rings have three double bonds. The bicyclic heteroaryl is a monocyclic heteroaryl fused to a phenyl group, a monocyclic cycloalkyl, as defined herein, a monocyclic cycloalkenyl, as defined herein, a monocyclic heterocycle, as defined herein, or a monocyclic heteroaryl. Representative examples of monocyclic and bicyclic heteroaryls include, but not limited to, benzothienyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, 6,7-dihydro-l,3-benzothiazolyl, furanyl (furyl), imidazolyl, imidazo[l,2-a]pyridinyl, indazolyl, indolyl, isorndolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyridoimidazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, thiazolyl, thienyl, triazolyl, thiadiazolyl, tetrazolyl, l,2,3,4-tetrahydro-l,8~ naphthyridin-2-yl, and 5,6,7,8-tetrahydroquinolin-5-yl. The monocyclic and the bicyclic heteroaryls of the present invention can be substituted or unsubstituted, and are connected to the parent molecular moiety through any substitutable carbon or nitrogen atom in the monocyclic and the bicyclic heteroaryls respectively. In addition, the nitrogen heteroatom may or may not be quatemized, the nitrogen and the sulfur atoms in the group may or may not be oxidized. Also, the nitrogen containing rings may or may not be N-protected. The term "heteroatom" as used herein, refers to nitrogen, oxygen and sulfur atoms. The term "hydroxy" or "hydroxyl" as used herein, means an -OH group. The term "oxo" as used herein, means an =O group. (3) Preparation of Compounds of the Present Invention The compounds and processes of the present invention will be better understood in connection with the following synthetic Schemes and Examples, which illustrate a means by which the compounds of the present invention can be prepared. Scheme 1 (Scheme Removed) Ureas of general formula (I), wherein X, Y, Z, A1, A2, A3, A4, m, n, L, R7, R8 and R9 as defined in formula (I), can be prepared as described in Scheme 1. The amines of general formula (1), purchased commercially or prepared using standard chemistry known to those skilled in the art, can be treated with trichloracetyl chloride and a base such as, but not limited to, triethylamine in a solvent such as dichloromethane to provide trichloroacetamides of general formula (2). The reaction can be carried out at ambient temperature for a period of about 1 hour to about 24 hours. Trichloroacetamides of general formula (2) can be treated with amines of general formula (3) and a non-nucleophilic base such as, but not limited to, 1,8-diazabicyclo[5 AO]undec-7-ene (DBU) in a solvent such as, but not limited to, acetonitrile to provide ureas of general formula (I). The reaction can be performed at a temperature from about room temperature to about the reflux temperature of the solvent employed, for a period of about 30 minutes to about 10 hours. Scheme 2 (Scheme Removed) Ureas of general formula (I), wherein X, Y, Z, A1, A2, A3, A4, m, n, L, R7, R8 and R9 are as defined in formula (I), can also be prepared as described in Scheme 2. The amines of general formula (3), purchased commercially or prepared using standard chemistry known to those slcilled in the art, can be treated with trichloracetyl chloride using the conditions for the transformation of compounds of formula (1) to compounds of formula (2) as described in Scheme 1. The trichloroacetamides of general formula (4) can be converted to ureas of formula (I) by treatment with amines of formula (1), using the conditions as outlined in Scheme (1) for the conversion of compounds of formula (2) to compounds of formula (I). Scheme 3 (Scheme Removed) Ureas of general formula (I), wherein X, Y, Z, A1, Aa, AS, A4, m, n, L, R7, R8 and R9 are as defined in formula (I), may be prepared as described in Scheme 3. Amines of general formula (3) can be treated with phosgene or triphosgene and 4-(dimethylamino)pyridine (DMAP) in a solvent such as, but not limited to, dichloromethane to provide isocyanates of general formula (5). The reaction is generally performed at a temperature from about -10°C to about room temperature for a period of about 1 hour to about 24 hours. Amines of general formula (1) can be treated with isocyanates of general formula (5) in a solvent such as, but not limited to, dichloromethane, acetonitrile, toluene or tetrahydrofuran or a combination thereof to provide ureas of general formula (4). The reaction is generally performed at a temperature from about room temperature to about 40C, for a period of about 1 hour to about 24 hours. Scheme 4 (Scheme Removed) Ureas of general formula (I), wherein X, Y, Z, A1, A2, A3, A4, m, n, L, R7, R8 and R9 are as defined in formula (I), can be prepared as described in Scheme 3. Amines of general formula (1) can be treated with phosgene or triphosgene and 4-(dimemylamino)pyridine (DMAP) using conditions for the transformation of compounds of formula (3) to compounds of formula (5) as described in Scheme 2. Isocyanates of general formula (6) can be treated with amines of general formula (3) in a solvent such as, but not limited to, dichloromethane, acetonitrile, toluene or tetrahydrofuran or a combination thereof to provide ureas of general formula (I). The reaction is generally performed at a temperature from about room temperature to about 40C, for a period of about 1 hour to about 24 hours. Scheme 5 . (Scheme Removed) Ureas of formula (I), wherein X, Y, Z, Ab A2, A3, A4, m, n, L, R7, R8 and R9 are as defined in formula (I), can be prepared as described in Scheme 5. Amines of formula (3) can be converted to compounds of formula (7) by reacting with disuccinimidylcarbonate in a solvent such as, but not limited to, acetonitrile, dichloromethane, or tetrahydrofuran, at a temperature from about room temperature to about 50°C, for a period of about 2 hours to about 48 hours. Compounds of formula (7) can be converted to ureas of formula (I) by treatment with amines of formula (1) in the presence of a base such as, but not limited to, diisopropylethylamine or triethylamine, in a solvent such as, but not limited to, N,N-dimethylformamide. The reaction can be performed at a temperature from about room temperature to about 50°C, for a period of about 2 hours to about 24 hours. Scheme 6 (Scheme Removed) Amines of formula (12) wherein A1, A2, A3, A4, R7 and R8 are as defined in formula (I) and r is 2 or 3, can be obtained from alcohols of formula (8) as shown in Scheme 6. Alcohols of formula (8) can be converted to ketones of formula (10) by (a) treating with acids of formula (9) wherein R2 is Cl, Br or I, in the presence of a base such as, but not limited to, metal hydroxide (for example sodium hydroxide, potassium hydroxide and the like) or metal hydrides (for example sodium hydride and the like) in a solvent such as, but not limited to, water, dichloromethane, or tetrahydrofuran, and (b) treating product from step (a) with an acid such as polyphosphosphoric acid. The transformation in step (a) can be performed at a temperature from about room temperature to about 100°C for a period of about 1 hour to about 24 hours. Step (b) is generally performed at a temperature from about 60°C to about 120°C for a period of about 30 minutes to about 5 hours. Ketones of formula (10) can be converted to oximes of formula (11) wherein R101 is hydrogen or methyl, by reaction with hydroxylamine hydrochloride or methoxyamine hydrochloride in the presence of a base such as, but not limited to, pyridine or triethylamine, and optionally in the presence of a solvent such as, but not limited to, dichloromethane, acetonitrile or tetrahydrofuran. The reaction can be carried out at a temperature from about room temperature to about 50°C for a period of about 1 hour to about 18 hours. Oximes of formula (11) wherein R101 is hydrogen can be converted to oximes of formula (11) wherein wherein R101 is acetyl by treatment with acetic anhydride and a base such as, but not limited to, pyridine. The reaction can be conducted optionally in a solvent and at about room temperature. Oximes of formula (11) wherein RIOI is methyl or acetyl can be converted to amines of formula (12) when stirred in the presence of a hydrogen source such as hydrogen gas, and a catalyst such as 10% palladium in carbon, optionally in the presence of ammonia. The reaction can be conducted in an alcoholic solvent such as, but not limited to, methanol. The reaction is generally performed under a pressure of about 60 p.s.i. and at a temperature of about room temperature to about 50°C, for a period of about 1 hour to about 12 hours. Alternatively, conversion of (11) to (12) can also be facilitated in a hydrogen source such as hydrogen gas and a catalyst such as Raney nickel, in a solvent such as, but not limited to, methanol or ethanol, and optionally in the presence of ammonia. The reaction is generally conducted at a temperature from about room temperature to about 50 °C. Scheme 7 (Scheme Removed) Alternatively, ketones of formula (10) wherein r is 2 or 3 and A1, A2, A3, A4, R7 and R8 are as defined in formula 0) can be obtained from alcohols of formula (8) as shown in Scheme (7) by (a) reacting with compounds of formula (13) wherein Rz is Br, Cl or I, in the presence of a base such as, but not limited to, organic amines (for example, triethylamine, diisopropylethylamine, N-methylimidazole, pyridine and the like) or alkali metal carbonates (for example sodium carbonate and the like) in a solvent such as, but not limited to, acetonitrile, dichloromethane or ethyl acetate, (b) treating the product from step (a) with an acid in a solvent such as, but not limited to, acetonitrile, dichloromethane or tetrahydrofuran, and (c) treating the product of step (b) with an oxidizing agent in a solvent such as, but not limited to, acetonitrile, dichloromethane or tetrahydrofuran. Step (a) can be performed at a temperature from about room temperature to about 100°C for a period of about 1 hour to about 12 hours. Examples of the acid employed in step (b) include, but are not limited to, hydrochloric acid, sulfuric acid or nitric acid. The reaction can be performed at a temperature from about room temperature to about 50°C for a period of about 1 hour to about 10 hours. Examples of the oxidizing agent used in step (c) include, but are not limited to, pyridinium chlorochromate or manganese dioxide. The reaction can be performed at a temperature from about room temperature to about 50°C for a period of about 1 hour to about 10 hours. Scheme 8 (Scheme Removed) Amines of formula (19) wherein A1, A2, A3, A4, R7 and R8 are as defined in formula (I), can be prepared as shown in Scheme 8. Phenols of formula (14) when reacted with propargyl bromides of formula (15), in the presence of a base such as, but not limited to potassium carbonate, can be converted to propargyl compounds of formula (16). Halogenation of propargyl compounds of formula (16) can be achieved by reacting with an halogenating agent such as, but not limited to, N-chlorosuccinimide or N-bromosuccinimide, in the presence of catalytic amount of silver acetate, and in a solvent such as, but not limited to, acetone, to afford halides of formula (17) wherein Xa is Cl or Br. The reaction is generally carried out at elevated temperature such as, but not limited to, the reflux temperature of the solvent employed. Cyclization of the halides of formula (17) to provide chromanones of formula (18) can be facilitated in the presence of an acid such as, but not limited to, concentrated sulfuric acid or a mixture of sulfuric acid and methanesulfonic acid. The reaction can be conducted at ambient temperature to about 50 °C. Alternatively, chromanones of formula (18) can be obtained from halides of formula (17) under neutral conditions at elevated temperature. Typically, the reaction mixture is refluxed in ethylene glycol. Chromanones of formula (18) can also be obtained from the treatment of acetophenones of formula (20) with ketones of formula R7C(O)R8, in the presence of a base such as, but not limited to, pyrrolidine. The reaction is generally performed in a solvent such as, but not limited to, toluene, at reflux. Conversion of chormanones of formula (18) to amines of formula (19) can be achieved using the reaction conditions as described in Scheme 6 for the conversion of (10) to (12). Amines of formula (24) can be prepared from phenols of formula (14) as shown in Scheme 8. Treatment of compounds of phenols of formula (14) with sodium acetate in refluxing acetic anhydride, followed by heating with aluminum chloride, provides the acetophenones of formula (20). Upon treatment with diethyl oxalate, in the presence of a base such as, but not limited to, sodium ethoxide, acetophenones of formula (20) can be transformed to esters of formula (21). The reaction is generally conducted in a solvent such as, but not limited to, ethanol, and at a temperature of about 60 °C to about 90 °C. Esters of formula (21) can be converted to acids of formula (22) in the presence of glacial acetic acid and a hydrogen source such as, but not limited to, hydrogen gas, and a catalyst such as, but not limited to, Pd/C. The reaction is generally performed at a temperature of about 50 °C to about 80 °C. Acids of formula (22) can be converted to amides of formula (23) by(a) treating the acid with oxalyl chloride in the presence of catalytic amount of N,N-dimethylformamide at ambient temperature; and (b) treating the product of step (a) with ammonia in dioxane at ambient temperature. Reduction of the amides to amines of formula (24) can be accomplished by treatment with a reducing agent such as, but not limited to, lithium aluminum hydride, at a temperature of about 40 °C to about 70 °C. The reaction is generally conducted in a solvent such as, but not limited to, tetrahydrofuran. Scheme 9 (Scheme Removed) Amines of formula (27) can be obtained from nitriles of formula (25) wherein Y is O or S, and R5, A1, A2, A3, and A4 are as defined in formula (I) as depicted in Scheme 9. Alkylation of nitriles of formula (25) with halides of formula R5X1, and X1-alkyl-Rc, wherein X1 is Cl, I or Br, and R5 is alkyl, alkenyl, haloalkyl or RC and RC is as defined in formula (I), in the presence of a base such as, but not limited to, diisopropylethylamine and in a solvent such as, but not limited to, acetonitrile, provides nitriles of formula (26) wherein R5 is alkyl, alkenyl, haloalkyl, RC or -alkyl-Rc and Rc- is as defined hi formula (I). The reaction can be facilitated in a microwave reactor at elevated temperature. Acylation of nitriles of formula (25) to compounds of formula (26) wherein R5 is -C(O)Ra and Ra is as defined in formula (I) can be achieved by treatment with acid chlorides of formula RaCOCl or acid anhydride of formula (RaCO)2Oin the presence of a base such as, but not limited to, triethylamine, at a temperature of 0 °C to about room temperature. Sulfonylation of nitriles of formula (25) to compounds of formula (26) wherein R5 is -S(O)2Ra and Ra is as defined in formula (I) can be achieved by treatment with anhydrides such as trifluoromethanesulfonic anhydride, in the presence of a base such as, but not limited to, triethylamine, and in a solvent such as, but not limited to, dichloromethane, at a temperature of 0 °C to about room temperature. Conversion of compounds of formula (26) wherein R5 is as defined in formula (I) to amines of formula (27) can be achieved by treatment with ammonia in methanol, in the presence of a hydrogen source such as, but not limited to, hydrogen gas, and a catalyst such as Raney Nickel. The reaction is generally performed under a pressure of about 60 p.s.i. and at a temperature of about room temperature. Scheme 10 (Scheme Removed) Compounds of formula (33) wherein R5, A1, A2, A3, and A4 are as denned in formula (I) can be prepared from aldehydes of formula (28) as shown in Scheme 10. Reductive amination of aldehydes of formula (28) with amines of formula C6H5CH2NH2, in the presence of a reducing agent such as, but not limited to, sodium triacetoxy borohydride, and an acid such as, but not limited to, glacial acetic acid, provides amines of formula (29). Removal of the benzyl protective group in compounds of formula (29) followed by protection with tert-butoxycarbonyl group provides compounds of formula (30). The benzyl group can be removed by shaking in 3,0 psi of hydrogen and catalytic amount of palladium hydroxide and in a solvent such as, but not limited to, ethanol, at about 50 °C. Protection of the amines with tert-butoxycarbonyl group can be facilitated by stirring with di-tert-butyl carbonate and a base such as, but limited to, triethyl amine, in a solvent such as, but not limited to, tetrahydrofuran. Partial reduction of the compounds of formula (30) affords tetrahydroquinolines of formula (31). Such conversion can be facilitated with stirring the compounds of formula (30) with 30 psi hydrogen -in the presence of palladium hydroxide, and in a solvent such as, but not limited to, ethanol. Derivatization of compounds of formula (31) using the reaction conditions as described in Scheme 9 for the conversion of (25) to (26), affords compounds of formula (32). Removal of the tert-butoxycarbonyl group of (31) and (32) can be achieved by treatment with an acid such as, but not limited to, trifluoroacetic acid, in a solvent such as, but not limited to, dichloromethane, to provide compounds of formula (33) wherein R5 is as defined in formula (I). Scheme 11 (Scheme Removed) Amines of formula (36) wherein A1, A2, A3, A4,and R5 are as defined as formula (I), Y is a bond, m is 1 and n is 1, or m is 0 and n is 2 can be prepared from the corresponding acids of formula (35) by treatment with tert-butanol and an azide such as, but not limited to, diphenylphosphorazide, and in the presence of an amine such as, but not limited to, triethyl amine, at reflux. Acids of formula (35) wherein Y is a bond, m is 1 and n is 1 or Y is a bond, m is 0 and n is 2, can be prepared from the hydrolyzing the corresponding esters qf formula (34) using reaction conditions known to one skilled in the art. For example, treatment of the esters with a base such as, but not limited to, lithium hydroxide, in a mixed solvent of tetrahydrofuran and water, at a temperature of about 0 °C to about 60 °C, affords acids of formula (35). Acids of formula (35) wherein Y is a bond, m is 0 and n is 2, can be prepared from the partial reduction of the corresponding quinoline 4-carboxylic acid using the reaction conditions for the conversion of (30) to (31) as described in Scheme 10. Esters of formula (34) wherein Y is a bond, m is 1 and n is 1 can be prepared from the corresponding quinoline-3-carboxylic acid ethyl ester by (a) heating in the presence of phosphorus oxychloride; and (b) treating the product from step (a) with hydrogen, palladium on carbon, and in a solvent such as, but not limited to, ethanol. Scheme 12(Scheme Removed) Amines of formula (42) wherein R5, A1, A2, A3, and A4 are as defined in formula (I) can be prepared from amines of formula (37) as shown in Scheme 12. Acylation of amines of formula (37) with 3-bromopropionyl chloride in the presence of a base such as, but not limited to, potassium carbonate, in a solvent such as, but not limited to, dichloromethane, provides compounds of formula (38). Cyclization of compounds of formula (38) is facilitated by potassium tert-butoxide and in a solvent such as, but not limited to, N,N-dimethylformamide. Treatment of compounds of formula (39) with trifluoromethanesulfonic acid in a solvent such as, but not limited to, dichloromethane, at a temperature of about 50 °C to about 80 °C, provides ketones of formula (40). Derivatization of compounds of formula (40) to compounds of formula (41) wherein R5 is alkyl, alkenyl, haloalkyl, -C(O)Ra, -S(O)2Ra, Rc, and -alkyl-Rc and wherein Rc and Ra are as defined in formula (I) can be achieved using reaction conditions as described in Scheme 9 for the conversion of (25) to (26). The compounds of formula (40) and (41) wherein RS is alkyl, alkenyl, haloalkyl, -C(O)Ra, -S(O)2R.a, RC, and -alkyl-Rc and wherein RC and Ra are as defined in formula (I) can be converted to the corresponding amines of formula (42) using the reaction conditions as described Scheme 6 for the conversion of (10) to (12). (4) Examples The following Examples are intended as an illustration of and not a limitation upon the scope of the invention as defined in the appended claims. Example 1 N-(7-tert-butvl-3.4-dihvdro-2H--chromen-4-yl)-N'-lH- indazol-4-ylurea Example 1A 7-tert-Butyl-chroman-4-one A. 3-tert-butyl-phenol (1.50 g, 10 mmol), 2-(2-bromo-ethyl)-[l,3]dioxane (1.38 g, 10 mmol) and potassium carbonate (2.15 g, 11 mmol) in 20 ml acetonitrile was heated to reflux for 16 hours. After cooling, the solvent was removed under reduced pressure and the residue partitioned between diethyl ether and water. The isolated organic layer was washed with water, dried with magnesium sulfate, filtered and the solvent removed under reduced pressure to give 2.97 g of crude 2-[2-(3-tert-butyl-phenoxy)-ethyl]-[l ,3]dioxane, which was used without further purification. B. The intermediate from step A was dissolved in 20 ml tetrahydrofuran. Concentrated hydrochloric acid (20 mL) was added, and the reaction mixture was stirred at ambient temperature for 4 hours, diluted with diethyl ether and washed with water. The isolated organic layer was dried with magnesium sulfate, filtered and the solvent removed under reduced pressure to give 2.87 g of crude 7-tert-butyl-chroman-4-ol which was used without further purification. C. The crude 7-tert-butyl-chroman-4-ol from step B was dissolved in 50 ml dichloromethane. Pyridinium chlorochromate (4.3 1g, 20 mmol) was added and the reaction mixture was stirred at ambient temperature for 3 hours, diluted with hexanes and filtered through a pad of celite. Solvent was removed from the filtrate under reduced pressure and the residue filtered through a pad of silica gel, eluting with 20% ethyl acetate:hexanes. Removal of solvent gave 2.37 g of crude product, which was chromatographed on silica gel with an eluent of 10% ethyl acetate: hexanes to give 1.50 g of the title compound (73% for 3 steps). 1H NMR (300 MHz, CDC13) δ 7.83 (d, 1H, J=8.1 Hz), 7.07 (dd, 1H, J=8.3 and 1.9 Hz), 6.97 (d, 1H, J=1.7 Hz), 4.62 (m, 2H), 2.78 (m, 2H), 1.31 (s, 9H). MS (DCI) m/e 205 Example IB 7-tert-Butyl-chroman-4-one O-methyl-oxime The product of Example 1A (1.50 g, 7.3 mmol) and methoxyamine hydrochloride (0.69 g, 8 mmol) were dissolved in 7 mL of pyridine. The reaction mixture was stirred at ambient temperature for 16 hours, and the pyridine removed under reduced pressure. The residue was taken in diethyl ether and sequentially washed with water and 1N aqueous hydrochloric acid. The isolated organic layer was then dried with magnesium sulfate, filtered and the solvent removed under reduced pressure to give 1,53 g of the title compound, which was used without further purification. MS (DCI) m/e 234 (M+H)+ Example 1C 7-tert-Butyl-chroman-4-ylamine The product of Example 1B (1.53g) was taken into a solution of 20% ammonia in methanol, and hydrogenated for 4 hours at 60 psi at 50°C in the presence of 1.55 g of 10% palladium on carbon as catalyst. The reaction mixture was filtered to remove catalyst, and the solvent removed under reduced pressure to give 1.40 g of the title compound (93% for two steps). 1HNMR (300 MHz, CDC13) δ 7.25 (d, 1H, J=6.8 Hz), 6.96 (dd, 1H, J=2.0 and 8.1 Hz), 6.85 (d, 1H, J=2.0 Hz), 4.18-4.32 (m, 2H), 4.04 (t, 1H), 2.11-2.21 (m, 1H), 1.80-1.90 (m, IH), 1.29 (s, 9H). MS (DCI) m/e 206 (M+H)+. Example ID 4-[3-(7-tert-Butyl-chroman-4-yl)-ureido]-indazole-l-carboxylic acid methyl ester A mixture of the product of Example 1C, (513 mg, 2.5 mmol), the product of Example 24D (830 mg, 2.5 mmol), and diisopropylethylamine (390 mg, 0.52 ml, 3 mmol) in 5 ml dimethylformamide was stirred at ambient temperature for 16 hours, diluted with water, and the percipitate collected by filtration to give 1.00 g of the title compound (95% yield). 1HNMR (300 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.36 (s, 1H), 7.88 (d, 1H, J=7.1 Hz), 7.69 (d, 1H, J=8.5 Hz), 7.50 (t, 1H, J=8.1 Hz), 7.23 (d, 1H, J=8.5 Hz), 6.97 (dd, 1H, J=2.0 and 8.1 Hz), 6.84 (d, 1H, J=7.2 Hz), 6.79 (d, 1H, J=2.0 Hz), 4.85 (m, 1H), 4.26 (m, 1H), 4.09-4. 19 (m, 1H), 4.03 (s, 3H), 2.09 (m, 2H), 1.24 (s, 9H). MS (ESI) m/e 423(M-H)+. Example 1E N-(7-tert-butyl-3.4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea A solution of the product of Example 1D (1.00g, 2.37 mmol) in a mixture of 5 mL methanol and 5 mL tetrahydrofuran was treated with 5M sodium hydroxide (2 mL )in methanol, and stirred at ambient temperature for 90 minutes. The reaction mixture was diluted with water, and the resulting precipitate was collected by filtration to give 0.75 g of the title compound (86% yield). 1H MMR. (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.59 (s, 1H), 8.03 (s, 1H), 7.66 (d, J=7.5 Hz, 1H), 7.20 (m, 2H), 7.10-6.90 (m, 4H), 4.91 (m, 1H), 4.30 - 4. 12 (m, 2H), 2.20 - 2.00 (m, 2H), 1 .22 (s, 9H). MS (ESI) m/e 365 (M+H)+ . Calc'd. For C17H16N4O2-1.0 H2O: C 65.95, H 6.85, N 14.65; Found: C 65,93, H 6.69, N 14.41 . Example 2 A solution of phosgene (20% in toluene, 2.9 mL, 5.5 mmol) was added to 30 mL of dichloromethane and cooled to 0°C, treated with dropwise addition of a solution of 4-dimethylaminopyridine (1.43g, 11.7 mL) in 15 mL of dichloromethane. A thick white suspension formed. A solution of 5-aminbquinoline in 15 mL of dichloromethane was then added dropwise to this suspension. The reaction mixture was allowed to warm to ambient temperature and stirred overnight. At the end of this time, a solution formed, and the solvent was removed under reduced pressure. The residue was titurated with 50 mL of diethyl ether to give an approximately 0.1 M solution of 5-isocyanato-isoquinoline. 6 mL of the 5-isocyanato-isoquinoline solution was added to the product of Example 1C (123 mg, 0.6 mmol). The reaction mixture was stirred overnight, and the precipitate formed was collected by filtration and washed with diethyl ether to give 132 mg of the title compound (55% yield). 1H NMR (300 MHz, DMSO-d6) δ ppm 8.89 (dd, J=4.0 and 1.4 Hz, 1H), 8.56 (s, 1H), 8.46 (dd, J=8.6 and 1.5 Hz, 1H), 8,15 (dd, J=6.1 and 2.71 Hz, 1H), 7.65 -7.71 (m, 2H), 7.55 (dd, J=8,6 and 4.2 Hz, 1H), 7.24 (d, J-8.1 Hz, 1H), 7.06 (d, J=7.1 Hz, 1H), 6.97 (dd, J=8.0 and 1 .9 Hz, 1H), 6.79 (d, J=2.0 Hz, 1 H), 4.83 - 4.89 (m, 1H), 4.23 - 4.31 (m, 1H), 4.14 (ddd, J-11.3, 8.9, amd 2.9 Hz, 1H), 4.02 (d, J=1.7 Hz, 1H), 1.99 - 2.15 (m, 2H), 1.25 (s, 9H). MS (ESI) m/e 376 (M+H)+. Calcd. For C23H25N3O2-0.7 H2O: C 71.18, H 6.86, N 10.83; Found: C 71.14, H 6.65, N 10.61. Example 3 N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-N'-quinolin-8-ylurea Example 3A 2.2.2-Trichloro-N-quinolin-8-yl-acetamide A solution of 8-aminoquinoline (2.88 g, 20 mmol) in dichloromethane (100 mL) was treated sequentially with triethylamine (3.1 mL, 2.23 g, 22 mmol) and trichloroacetyl chloride (2.5 mL, 4.0 g, 22 mmol). The reaction mixture was allowed to stir at ambient temperature for 16 hours, and the solvent removed under reduced pressure. The residue was taken into ethyl acetate, washed sequentially with water and saturated aqueous ammonium chloride. The isolated organic layers were dried with magnesium sulfate, filtered and the solvent removed under reduced pressure to give 5.79g of the title compound (99% yield) which was used without further purification. 1HNMR(300MHz,DMSO-d6)δ 11.18 (brs, 1H, NH), 9.00 (dd, 1H, J=4.4 and 1.7 Hz), 8.53 (m, 2H), 7.89 (d, 1H, 7.1 Hz), 7.73 (m, 2H). MS (ESI) m/e 289 (M+H)+: Example 3B N-(7-tert-butyl-3.4-dihydro-2H-chromen-4-yl)-N'-quinolin-8-ylurea A mixture of the product of Example 3A (145mg, 0.5 mmol), the product of Example 1C (103mg, 0.5 mmol) and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 190mg, 1.25 mmol) in acetonitrile (15 mL) was heated at reflux for 3.5 hours, cooled, and the acetonitrile removed under reduced pressure. The residue was taken up in ethyl acetate and washed with water. The isolated organic layer was dried with magnesium sulfate, filtered and the solvent removed under reduced pressure. The resulting residue was purified by reverse-phase HPLC (acetonitrile/water) to give 27 mg of the title compound (14% yield). 1H NMR (300 MHz, DMSO-d6) 8 ppm 9.37 (s, 1H), 8.83 (dd, J=4.1 and 1.7 Hz, 1H), 8.54 (dd, J=7.3 and 1.9 Hz, 1H), 8.34 (dd, J=8.5 and 1.7 Hz, 1H), 7.91 (d, J-7.8 Hz, 1H), 7.55 - 7.60 (m, 1H), 7.46 - 7.53 (m, 2H), 7.22 (d, J=8.1 Hz, 1H), 6.94 (dd, J=8.1 and 2.0 Hz, 1H), 6.77 (d, J=2.0 Hz, 1H), 4.87 - 4,93 (m, 1H), 4.22 - 4,29 (m, 1H), 4.12 - 4.20 (m, 1H), 2.07 - 2.16 (m, 1H), 1.91 - 2.00 5.03 (m, 1H), 4.38 (m, 1H), 4.27 (m, 1H), 4.03 (s, 3H), 2.19 (m, 1H), 2.09 (m, 1H). MS (ESI)m/e 435(M+H)+. Example 4F N-lH-indazol-4-yl-N'[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea The title compound was prepared using the procedure as described in Example 1E, substituting the product of Example 4E for the product of Example 1D. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.67 (s, 1H), 8.04 (s, 1H), 7.67 (d, J=7.5 Hz, 1H), 7.55 (d, J=7.5 Hz, 1H), 7.22 (m, 2H), 7.10 (m, 2H), 7.00 (d, J=7.5 Hz, 1H), 5.00 (m, 1H), 4.41 - 4.20 (m, 2H), 2.22 - 2.00 (m, 2H). S (ESI) m/e 377 (M+H)+. Calcd. For C18H15N4O2F3.0.7 H2O: C 55.59, H 4.25, N 14.40; Found: C55.51, H 3.98, N 14.65. Example 5 N-isoquinolin-5-yl-N'-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea A solution of phosgene (20% in toluene, 2.9 mL, 5.5 mmol) in dichloromethane (30 mL) at 0°C was treated with dropwise addition of 4-dimethylaminopyridine (1.43 g, 11.7 ml) in dichloromethane (15 mL). A thick white suspension formed. A solution of 5-aminoisoquinoline in 15 mL of dichloromethane was then added dropwise to this suspension. The reaction mixture was allowed to warm to ambient temperature and stirred overnight. At the end of this time, a solution formed, and the solvent was removed under reduced pressure. The residue was titurated with 50 mL of diethyl ether to give an approximately 0.1 M solution of 5-isocyanato-isoquinoline. 3 ml of the 5-isocyanato-isoquinoline solution was added to the product of Example 4D (49 mg, 0.3 mmol) and stirred at ambient temperature overnight, and the precipitate formed was collected by filtration and washed with diethyl ether to give 23 mg of the title compound (23% yield). H NMR (300 MHz, DMSO-d6) δ 9.28 (s, 1H), 8.63 (s, 1H), 8.55 (d, J=6.0 Hz, 1H), 8.32 (m, 1H), 7.90 (d, J=6.0 Hz, 1H), 7.77 (d, J=7.5 Hz, 1H), 7.60 (m, 2H), 7.30 - 7.12 (m, 3H), 5.02 (m, 1H), 4.42 - 4.20 (m, 2H), 2.30 - 2.00 (m, 2H). MS (ESI) m/e 388 (M+H)+. Calcd. For C20H16N3O2F3-0.2 H2O: C 62.01, H 4.16, N 10.85; Found: C 61.29, H 3.94, N 10.64. Example 6 The title compound was prepared using the procedure as described for Example 5, substituting 5-aminoquinoline for 5-aminoisoquinoline. 1H NMR (300 MHz, DMSO-d6) δ 8.90 (m, 1H), 8.63 (s, 1H), 8.45 (m, 1H), 8.11 (t, J=4.0 Hz, 1H), 7.68 (d, J=4.0 Hz, 2H), 7.57 (m, 2H), 7.23 (m, 1H), 7. 12 (m, 1H), 5.02 (m, 1H), 4.42 - 4.20 (m, 2H), 2.30 - 2.00 (m, 2H). MS (ESI) m/e 388 (M+H)+ Calcd. For C20H16N3O2F30.25 H2O: C 61.30, H 4.24, N 10.72; Found: C 61.25, H 3.99, N 10.55, Example 7 N-lH-indazol-4-yl-N'-(6-methyl-3.4-dihydro-2H-chromen-4-yl)urea Example 7A 6-Methyl-chroman-4-one O-methyl-oxime The title compound was prepared following the procedure as described in Example 1B, substituting 6-methyl-chroman-4-one for the product of Example 1B. MS (DCI) m/e 192 (M+H)+. Example 7B 6-Methyl-chroman-4-ylamine A solution of the product of Example 7A (4.24 g) in 50 mL of a mixture of 20% ammonia in methanol was treated with 40g Raney Nickle under 60 psi hydrogen for 4 hours at ambient temperature. The reaction mixture was filtered, and the solvent evaporated under reduced pressure. The residue was taken in diethyl ether, washed sequentially with water and saturated aqueous sodium bicarbonate, dried with magnesium sulfate, filtered and concentrated to give 2.22 g of the title compound. H NMR (300 MHz, CDC13) δ 7.1 1 (s, 1H), 6.95 (d, 1H, J=8.5 Hz), 6.71 (d, 1H, J=8.5 Hz), 4.22 (m, 2H), 4.01 (m, 1H), 2.27 (s, 3H), 2.10-2.21 (m, 1H), 1.78-1.88 (m, IH). MS (DCI) m/e 164 (M+H)+. Example 7C 4-[3-(6-Methyl-chroman-4-yl)-ureido]-indazole-l-carboxylic acid methyl ester The title compound was prepared using the procedure as described in Example ID, substituting the product of Example 7B for the product of Example 1C. 1HNMR (300 MHz, DMSO-d6) δ 8.83 (s, 1H), 8,38 (s, 1H), 7.89 (d, 1H, J=7.1 Hz), 7.69 (d, 1H, J=8.5 Hz), 7.51 (m, 1H), 7.11 (d, 1H, J=2.0 Hz), 7.00 (dd, 1H, J=8.3 and 2.2 Hz), 6.86 (d, 1H, J=7.5 Hz), 6.71 (d, 1H, J=8.5 Hz), 4.86 (m, 1H), 4.25 (rn, 1H), 4.12 (m, 1H), 4.03 (s, 3H), 2.22 (s, 3H), 2.12 (m, 1H), 2.03 (m, 1H). MS (ESI) m/e 381 (M+H)4. Example 7D N-lH-indazol-4-yl-N'-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea The title compound was prepared using the procedure as described in Example 1E, substituting the product of Example 7C for the product of Example 1D. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.56 (s, 1H), 8,02 (s, 1H), 7,67 (d, J=7,5 Hz, 1H), 7.20 (m, 1H), 7.12-6.94 (m, 3H), 6.86 (d, J=7,5 Hz, 1H), 6.70 (d, J=7.5 Hz, 1H), 4.92 (m, 1H), 4.33 -4.00 (m, 2H), 2.22 (s, 3H), 2.20 - 1.93 (m, 2H). MS (ESI) m/e 323 (M+H)+. Calcd. For C18H18N4O2-0.9 H2O 0.25 NaCl: C 61.21, H 5.65, N 15.86; Found: C 61.02, H 5.74, N 15.84. Example 8 N-isoquinolin-5-yl-N'-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea The title compound was prepared using the procedure as described in Example 5, substituting the product of Example 7B for the product of Example 4D. 1H NMR (300 MHz, DMSO-d6) δ 9.26 (s, 1H), 8.60 (s, 1H), 8.56 (d, J=6.0Hz, 1H), 8.40 (m, 1H), 7.90 (d, J=6.0 Hz, 1H), 7.78 (d, J=7,5 Hz, 1H), 7.61 (m, 1H), 7.13 (m, 2H), 7.00 (m, 1H), 6.73 (d, J=7.5 Hz, 1H), 4.85 (m, 1H), 4.33 - 4.06 (m, 2H), 2.21 (s, 3H), 2.20 -1.95 (m, 2H). MS (ESI) m/e 334 (M+H)+ Calcd. For C20H19N3O2-0.2 H2O C 71.28, H 5.80, N 12.47; Found C 71.45, H 5.57, N 12.31. Example 9 N-(6-methyl-3,4-dihydro-2H-chromen-4-yl)-N'-quinolin-5-ylurea This compound was made following the procedure of Example 5, except substituting 5-aminoquinoline for 5-aminoisoquinoline and 6-methyl-chroman-4-ylamine for 7-trifluoromethyl-chroman-4-ylamine. 1HNMR (300 MHz, DMSO-d6) δ 8.90 (m, 1H), 8.60 (s, 1H), 8.47 (m, 1H), 8.18 (m, 1H), 7.68 (m, 2H), 7.57 (m, 1H), 7.16 (m, 1H), 7.08 (d, J=7.5 Hz, 1H), 7.00 (m, 1H), 6.71 (d, J=7.5 Hz, 1H), 4.93 (m, 1H), 4.31 - 4.10 (m, 2H), 2.21 (s, 3H), 2.20 - 1.93 (m, 2H). MS (ESI) m/e 334 (M+H)+. Calcd. For C20H19N3O2-0.1 H2O: C 71.67, H 5.77, N 12.54; Found: C 71,65, H 5.83, N 12.30. Example 10 N-(6-fluoro-3.4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea Example 10A 6-FIuoro-chroman-4-one O-methyl-oxime The title compound was prepared using the procedure as described in Example 1B, substituting 6-fluoro-chroman-4-one for the product of Example 1 A. MS (DCI) m/e 196 Example 10B 6-Fluoro-chroman-4-ylamine The title compound was prepared using the procedure as described in Example 7B, substituting the product of Example 10A for the product of Example 7 A. 1H NMR (300 MHz, CDC13) δ 7.03 (dd, 1H, J=9.1 and 3.1 Hz), 6.85 (m, 1H), 6.74 (m, 1H,), 4.15-4.29 (m, 2H), 4.02 (m, 1H), 2.10-2.20 (m, 1H), 1.79-1.89 (m, 1H). MS (DCI) m/e 168 (M+H)+ Example 10C 4-[3-(6-Fluoro-chroman-4-yl)-ureido]-indazole-l-carboxylic acid methyl ester The title compound was prepared using the procedure as described in Example 1D, substituting the product of Example 10B for the product of Example 1C. 1H NMR (300 MHz, DMSO-d6) δ 8.86 (s, 1H), 8.40 (s, 1H), 7.93 (s, 1H), 7.86 (d, 1H, J=7.5 Hz), 7.72 (d, 1H, J=7.5 Hz), 7.51 (m, 1H), 7.15-6.80 (m, 3H), 4.91 (m, 1H), 4.30-4.13 (m, 2H), 4.03 (s, 3H), 2.20-1.97 (m, 2H). MS (DCI) m/e 385 (M+H)+. Example 10D N-(6-fluoro-3.4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 1E, substituting the product of Example 10C for the product of Example 1D. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.60 (s, 1H), 8.02 (s, 1H), 7.67 (d, J=7.5 Hz, 1H), 7.21 (m, 1H), 7.08-7.00 (m, 3H), 6.92-6.80 (m, 2H), 4.92 (m, 1H), 4.35 - 4.11 (m, 2H), 2.20 -1,93 (m, 2H). MS (DCI) m/e 327 (M+H)+. Calcd. For C17H15N4O2F-0.1 H2O: C 62.23, H 4.67, N 17.07; Found: C 6231, H 4.46, N 16.74. Example 11 N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N'-isoquinolin-5-ylurea The title compound was prepared using the procedure as described in Example 5, substituting the product of Example 10B for the product of Example 4D. 1H NMR (300 MHz, DMSO-d6) δ 9.23 (s, 1H), 8.61 (s, 1H), 8.53 (d, J=6.0 Hz, 1H), 8.37 (m, 1H), 7.91 (d, J=6.0 Hz, 1H), 7.78 (d, J=7.5 Hz, 1H), 7.60 (m, 1H), 7.18 (m, 2H), 7.05 (m, 1H), 6.83 (m, 1H), 4.92 (m, 1H), 4,38 - 4.10 (m, 2H), 2.20 -1.95 (m, 2H). MS (ESI) m/e 338 (M+H)+ Calcd. For C19H16N3O2F'0.2 H2O: C 66.93, H 4.85, N 12.32; Found: C 66.94, H 4.57, N 12.18. Example 12 N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N'-quinolin-5-ylurea The title compound was prepared using the procedure as described in Example 5, substituting 5-aminoquinoline for 5-aminoisoquinoline and substituting the product of Example 10B for the product of Example 4D. 1H NMR (300 MHz, DMSO-d6) δ 8.90 (m, 1H), 8.62 (s, 1H), 8.46 (m, 1H), 8.12 (m, 1H), 7.68 (m, 2H), 7.57 (m, 1H), 7.18-7.00 (m, 3H), 6.83 (m, 1H), 4.91 (m, 1H), 4.33-4.06 (m, 2H), 2.20 - 1.95 (m, 2H). MS (ESI) m/e 336 (M-H)+. caled. ForC19H16N3O2P-0.2 Nacl: C65.38,H4.62,N 12,04; Found C 65.31, H4.51,N 11.77. Example 13 N-(6-chloro-7-methyl-3.4-dihydro-2H-chromen-4-yl)N'-lH-indazol-4-ylurea Example 13A 6-Chloro-7-methyl-chroman-4-one O-methyl-oxime The compound was prepared using the procedure as described in Example 1B, substituting 6-chloro-7-methyl-chroman-4-one for the product of Example 1A. MS (DCI) m/e226(M+H)+. Example 13B 6-Chloro-7-methyl-chroman-4-ylamine The title compound was prepared using the procedure as described in Example 7B, substituting the product of Example 13A for the product of Example 7 A. 1H NMR (300 MHz, CDC13) δ 7.27 (s, 1H), 6,68 (s, 1H), 4.15-4.29 (m, 2H), 3.98 (m, 1H), 2.29 (s, 3H), 2.07-2.17 (m, 1H), 1.75-1,85 (m, 1H). MS (DCI) m/e 198(M+H)+. Example 13C 4-[3-(6-Chloro-7-methyl-chroman-4-yl)-ureido]-indazole-l-carboxylic acid methyl ester The title compound was prepared using the procedure as described in Example 1D, substituting the product of Example 13B for the product of Example 1C. 1H HMR (300 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.40 (s, 1H), 7.85 (d, 1H, J=7.5 Hz), 7.70 (d, 1H, J=8.1 Hz), 7.51 (t, 1H, J=8.1 Hz), 7.31(s, 1H), 6.89 (d, 1H, J=7.5 Hz), 6.83 (s, 1H), 4.90 (m, 1H), 4.26 (m, 1H), 4.18 (m, 1H), 4.03 (s, 3H), 2.26 (s, 3H), 2.08-2.18 (m, 1H), 1.95-2.05 (m, 1H). MS (ESI)m/e 415(M+H)+. Example 13D N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 1E, substituting the product of Example 13C for the product of Example 1D. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.62 (s, 1H), 8.03 (s, 1H), 7.63 (d, J=7.5 Hz, 1H), 7.30 (s, 1H), 7.21 (m, 1H), 7.08 (d, J=7.5 Hz, 1H), 6.91 (d, J=7.5 Hz, 1H), 6.82 (s, 1H), 4.92 (m, 1H), 4.32-4.11 (m, 2H), 2.23 (s, 3H), 2.20-1.93 (m, 2H). MS (DCI) m/e 357 (M+H)+. Calcd. For C18H17ClN4O2-03 H2O0.1 C4H8O: C 59.82, H 5.02, N 15.17; Found: C 59.75, H 4.76, N 15.00. Example 14 N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N'-isoquinolin-5-ylurea The title compound was prepared using the procedure as described in Example 5, substituting the product of Example 13B for the product of Example 4D. 1H NMR (300 MHz, DMSO-d6) δ 9.28 (s, 1H), 8.61 (s, 1H), 8.55 (d, J=6.0 Hz, 1H), 8.37 (m, 1H), 7.89 (d, J=6.0 Hz, 1H), 7.74 (d, J=7.5 Hz, 1H), 7.61 (m, 1H), 7.32 (s, 1H), 7,18 (d, J=7.5 Hz, 1H), 6.83 (s, 1H), 4.90 (m, 1H), 4.34 - 4.11 (m, 2H), 2.23 (s, 3H), 2.20 - 1.90 (m, 2H). MS (ESI) ni/e 368 (M+H)+. Calcd. For C20H18N3O2Cl 0.25 H2O-0.1diethyl ether: C 64.52, H 5.18, N 11.07; Found C 64.28, H 4.85, N 10.84. Example 15 N-(6-chloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N'-quinolin-5-ylurea The title compound was prepared using the procedure as described in Example 5, substituting 5-aminoquinoline for 5-aminoisoquinoline and substituting the product of Example 13B for the product of Example 4D. 1H NMR (300 MHz, DMSO-d6) δ 8.90 (m, 1H), 8.62 (s, 1H), 8.47 (m, 1H), 8.12 (m, 1H), 7.70 (m, 2H), 7.58 (m, 1H), 7.31 (s, 1H), 7.07 (d, J=7.5 Hz, 1H), 7.18-7.00 (m, 3H), 6.82 (s, 1H), 4.91 (m, 1H), 4.33-4.10 (m, 2H), 2.24 (s, 3H), 2.20 - 1.92 (m, 2H). MS (ESI) m/e 368 (M-H)+. Calcd. For C20H18N3O2Cl-0.2 H2O: C 64.67, H 4.99, N 11.31; Found: C 64.85, H 4.90, N 11.02. Example 16 N-3.4-dihydro-2H-chromen-4-yl-N'-lH-indazol-4-ylurea Example 16A Chroman-4-one O-methyl-oxime The title compound was prepared using the procedure as described in Example 1B, substituting chroman-4-one for the product of Example 1 A. 1H NMR (300 MHz, d6-DMSO) δ 7.79 (dd, J = 1.0 and 7.5 Hz, 1H), 7.28 (m, 1H), 6.90 (m, 2H), 4.18 (t, J 6.0 Hz, 2H), 3.90 (s, 3H, minor), 3.88 (s, 3H, major), 2.82 (t. J 6.0 Hz, 2H). MS (DCI/NH3) m/e 178 (M+H)+. Example 16B Chroman-4-ylamine The title compound was prepared using the procedure as described in Example 7B, substituting the product of Example 16A for the product of Example 7A. 1H NMR (300 MHz,DMSO-d6) δ ppm 7.32 (dd, J 1.0 and 7,5 Hz, 1H), 7. 05 (m, 1H), 6.81 (m, 1H), 6.70 (dd, J 1.0 and 7.5 Hz, 1H), 4.27 - 4.08 (m, 2H), 3.83 (t, J 6.0 Hz, 1H), 2.03-1.66 (m, 4H). MS (DCI/NH3) m/e 150 (M+H)+. Example 16C 4-(-Chroman-4-yl-ureido)-indazole-l-carboxylic acid methyl ester The title compound was prepared according to the procedure as described in Example 1D, substituting the product of Example 16B for the product of Example 1C. 1H NMR (300 MHz, DMSO-ds) δ 8.82 (s, 1H), 8.40 (s, 1H), 7.88 (d, J 7.5 Hz, 1H), 7.70 (d, J 7.5 Hz, 1H), 7.52 (m, 1H), 7.32 (d, J 7.5 Hz, 1H), 7.20 (m, 1H), 6.86 (m, 3H), 4.90 (m, 1H), 4.35 - 4.10 (m, 2H), 4.00 (s, 3H), 2.10 -1.92 (m, 2H). MS(DCI/NH3) m/e 150 (M+H)+. Example 16D N-3.4-dihydro-2H-chromen-4-yl-N'-1H-indazol-4-ylurea The title compound was prepared according to the procedure as described ha Example 1E, substituting the product of Example 16C for the product of Example 1D. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.58 (s, 1H), 8.03 (s, 1H), 7.65 (d, J=7,5 Hz, 1H), 7.30 (d, J=7.5 Hz, 1H), 7.20 (m, 2H), 7.05 (d, J=6 Hz, 1H), 6.95 - 6.80 (m, 3H), 4.90 (m, 1H), 4.30 - 4.17 (m, 2H), 2.20 - 2.00 (m, 2H). MS (DCI) m/e 309 (M+H)+. Calcd. For C17H16N4O2-0.6 H2O: C 63.98, H 5.43, N 17.56; Found: C 63.85, H 5.07, N 17.62. Example 17 N-(6-methyl-3.4-dihydro-2H-chromen-4-yl)-N'-quinolin-8-ylurea The title compound was prepared using the procedure as described in Example 3B, substituting the product of Example 7B for the product of Example 1C. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.39 (s, 1H), 8.84 (dd, J=4,0 and 1.7 Hz, 1H), 8.56 (dd, J-7.1 and 2.0 Hz, 1H), 8.35 (dd, J=8.5 and 1.7 Hz, 1H), 7.93 (d, J=7.8 Hz, 1H), 7.47 - 7.61 (m, 3H), 7.09 (s, 1H), 6.97 (dd, J=8.3 and 2.2 Hz, 1H), 6.69 (d, J=8.5 Hz, 1H), 4.88 - 4,95 (m, 1H), 4.21 - 4.28 (m, 1H), 4.14 (ddd, J-11.3,8.9, and 2.9 Hz, 1H), 2.51 (s, 3H), 2.20 (s, 3 H), 2.05 - 2.17 (m, 1H), 1.89 - 2.00 (m, 1H). MS (ESI) m/e 334 (M+H)+. Calcd. For C20H19N3O2.0.33 CF3CO2H: C 66.88, H 5.25, N-l 1.33; Found: C 67.06, H 5.09, N 11.07. Example 18 N-(6-fluoro-3.4-dihydro-2H-chromen-4-yl)-N'-quinolin-8-ylurea The title compound was prepared using the procedure as described in Example 3B, substituting the product of Example 10B for the product of Example 1C. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.42 (s, 1H), 8.S3 - 8,88 (m, 1H), 8.55 (dd, J=6.8 and 2.0 Hz, 1H), 8.36 (dd, J-8.3 and 1.5 Hz, 1H), 7.97 (d, J=7.8 Hz, 1H), 7.55 - 7.64 (m, 1H), 7.48 - 7,55 (m, 2H), 7.11 (dd, J=9.3 and 2.9 Hz, 1H), 7.02 (td, J=8.6 and 3.2 Hz, 1H), 6.83 (dd, J=9.0 and 4.9 Hz, 1H), 4.92 - 4.99 (m, 1H), 4.14 - 4.30 (rn, 2H), 2.09- 2.20 (m, 1H),.1.91 - 2.01 (m, 1H). MS (ESI) m/e 338 (M+H)+. Calcd. For C20H19N3C20.1 CF3CO2H: C 66.12, H 4.65, N 12.05; Found: C 65.97, H 4.63, N11.99. Exampte 19 N-(7-tert-butyl-3.4-dihydro-2H-chromen-4-yl)-N'-(3-methylisoquinolin-5-yl)urea A solution of phosgene (20% in toluene, 2.9 mL, 5.5 mmol) of dichloromethane (30 rnL)was cooled to 0°C and treated dropwise with a solution of 4-dimethylaminopyridine (1.43 g, 11.7 mL) in dichloromethane (15 mL). A thick white suspension formed. A solution of 3-methyl-isoqumolin-5-ylamine (0.79 g, 5 rnmol) in tetrahydrofuran (20 mL) was then added dropwise to this suspension. The reaction mixture was allowed to warm to ambient tcmperature and stated ovemight, the solvent was removed under reduced pressure, and the residue titurated with 50 mL of diethyl ether to give an approximately 0,1 M solution of 3-methyl-5-isocyanato-isoquinoline. 6 mL of the 3-methyl-5-isocyanato-isoquinoline solution was added to the product of Example 1C (123 rag, 0.6 mmol). The reaction mixture was stirred overnight, and the percipitate formed was collected by filtration and washed with diethyl ether to give 0.15g of the title compound (64% yield). 1H NMR (300 MHz, DMSO-d6) δ ppm 9.17 (s, 1 H), 8.46 (s, 1 H), 8.34 (d, J=6.8 Hz, 1 H), 7.66 - 7.73 (m, 2 H), 7.51 (t, J=8,0 Hz, 1 H), 7.25 (d, J=8.5 Hz, 1H), 7.12 (d, J=7.1 Hz, 1 H), 6.98 (dd, J=8.0,1.9 Hz, 1 H), 6.80 (d, J=2.0 Hz, 1 H), 4.82 - 4.89 (m, 1 H), 4.24 - 4.31 (m, 1 H), 4.10 - 4.18 (m, 1 H), 2.63 (s, 3 H), 1.99 - 2.14 (m, 2 H), 1.25 (s, 9 H). MS (ESI) m/e 390 (M+H)+. Calc'd. For C24H27N3O2-0.5 H2O: C 72.34, H 7.08, N 10.54; Found C 72.52, H 7.23, N 10.53. Example 20 N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N'-(3-methylisoquinolin-5-yl)urea The title compound was prepared using the procedure as described for Example 19, substituting the product of Example 10B for the product of Example 1C. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.13 - 7.18 (m, 2 H), 7.71 (d, J=10.5 Hz, 2 H), 9.18 (s, 1H), 8.53 (s, 1H), 4.17 (ddd, J=11.3, 8.4, 3.0 Hz, 1 H), 8.30 (d, J=6.4 Hz, 1 H), 4.93 (q, J=6.1 Hz, 1H), 7.05 (td, J=8.6, 3.4 Hz, 1 H), 4.25 - 4.33 (m, 1 H), 2.10 - 2.21 (m, 1 H), 7.52 (t, J=8.0 Hz, 1 H), 6.85 (dd,J=9.0,4.9 Hz, 1 H), 2.02 (ddd, J=13.4, 6.8, 2.9 Hz, 1 H), 2.64 (s, 3 H). MS (ESI4) m/e 352 (M+H)+ Calc'd. For C20H18N3O20.1 H2O-0.1 Et2O: C 67.95, H 5.37, N 11,65; Found C 67.88, H 5.33, N 11,56. Example 21 N-(6-methyl-3.4-dihydro-2H-chromen-4-yl)-N'-(3-methylisoquinlin-5-yl)urea The title compound was prepared using the procedure as described for Example 19, substituting the product of Example 7B for the product of Example 1C. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.49 (s, 1 H), 9.17 (s, 1 H), 8.34 (d, J=7.8 Hz, 1 H), 7-67 - 7.73 (m, 2 H), 7.52 (t, J=8.0 Hz, 1 H), 7.10 - 7.15 (m, 2 H), 7.01 (dd, J=8.3,2.2 Hz, 1 H), 6.72 (d, J=8.5 Hz, 1 H), 4.83 - 4.90 (m, 1 H), 4.22 - 4.30 (m, 1 H), 4.12 (ddd, J=11.4, 9.0,2.7 Hz, 1 H), 2.63 (s, 3 H), 2.23 (s, 3 H), 2.10 (dd, J=9.7,4.2 Hz, 1 H), 2.02 (tt, J=5.4,2.9 Hz, 1 H). MS (ESI+) m/e 348 (M+H)+. Calc'd. For C21H21N3O2-0,l H2O0.1 Et2O: C 72.07, H 6.27, N11.78; Found C 72.20, H 6.25, N 11.78. Example 22 N-[(l-benzyl-1.2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-lH-indazol-4-ylurea Example 22 A tert-butyl 2-{[({[1-(methoxycarbonyl)-lH-indazol-4-yl]amino}carbonyl)amino]methyl}-3.4- dihydroquinoline-1 (2H)-carboxylate To a solution of 2-aminomethyl-3,4-dihydro-2H-quinoline-l-carboxylic acid tert-butyl ester (0.6 g, 2.29 mmol) in N,N-dimemylformamide (15 mL) and diisopropylethylamine was added the product of Example 24D (0.69 g, 2.1 mmol) and the mixture was stirred for 2 hrs at room temperature. Water was added to the reaction mixture and the organic phase was separated from the aqueous phase. The isolated organic phase was diluted with ethyl acetate and washed twice with water. Organic layer was separated and concentrated to afford the title compound (0.72 g, 73%) as an amorphous solid. 1HNMR (300 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.40 (s, 1H), 7.78 (d, J=7.5 Hz, 1H), 7.67 (d, J=7,5 Hz, 1H), 7.49 (m, 2H), 7.15 (m, 2H), 7.00 (m, 1H), 6.40 (m, J=6.0 Hz, 1H), 4.60 (m, 1H), 4.02 (s, 3H), 3.27 (m, 1H), 3.00 (m, 1H), 2.78-2.51 (m, 2H), 2.12 (m, 1H), 1.65 (m, 1H), 1.40 (s, 9H); MS (DCI/NH3)m/e480(M+H)+. Example 22B methyl 4-({ [(1,2,3,4-tetrahydroquinlin-2-ylmethyl)amino]carbonyl} amino)lH'-indazole-l- carboxylate A solution of the product of Example 22A (0.72 g, 1.5 mmol) in dichloromethane (10 mL) was treated with trifluoroacetic acid (2 mL) at 0°C, stirred for 18 hrs, and concentrated under vacuo. Toluene was added to the resulting residue and concentrated to obtain the title compound (0.72 g, 99%) as a pink trifluoroacetate salt. 1H NMR (300 MHz, DMSO-d6) δ 9.04 (s, 1H), 8.44 (s, 1H), 7.81 (d, J=7,5 Hz, 1H), 7.70 (d, J=7.5 Hz, 1H), 7.46 (m, 1H), 6.92 (m, 2H), 6.60 (m, 3H), 4.02 (s, 3H), 3.40 (m, 2H), 3.22 (m, 1H), 2.72 (m, 2H), 1.90 (m, 1H), 1.64 (m, 1H). Example 22C methyl 4-[({[(1-benzyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]amino}carbonyl)amino]-1H- indazole-l-carboxylate A mixture of the product of Example 22B (0.72 g, 1.5 mmol), benzyl bromide (0.26 g, 1. 5 mmol) and potassium carbonate (3.0 g in 3 mL of H2O) in tetrahydrofuran (6 mL) was stirred at room temperature for 72 hrs, diluted with ethyl acetate, washed with water and partitioned. The isolated organic layer was concentrated and the residue was chromatographed on silica gel, eluting with 60% -100% ethyl acetate/hexanes to afford the title compound (0.58 g, 72%) as an amorphous solid. 1H NMR (300 MHz, d6-DMSO) 9.00 (s, 1H), 8.42 (s, 1H), 7.80 (d, J=7.5 Hz, 1H), 7.68 (d, J=7,5 Hz, 1H), 7.48 (m, 1H), 7.28 (m, 5H), 6.95 (d, J=7.5 Hz, 1H), 6,83 (m, 1H), 6.58 (m, J=6.0 Hz, 1H), 6.50 (m, 1H), 6.36 (d, J=7.5 Hz, 1H), 4.64 (m, 2H), 4,01 (s, 3H), 3.57 (m, 1H), 3.41-3.20 (m, 2H), 2.90 (m, 1H), 2.67 (m, 1H), 2.03 (m, 1H), 1.82 (m, 1H); MS (DCI/NH3) m/e 470 (M+H)+. Example 22D N-[(1-benzyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-1H-indazol-4-ylurea A solution of the product of Example 22C (0.55 g, 1.17 mmol) in methanol (5mL) was treated with a solution of NaOH in methanol (5M, 1 mL), and stirred for 2 hrs at ambient temperature. Water was added to the reaction mixture filtered. The isolated solid was washed with water and dried under vacuo to afford the title compound (0.32 g, 65%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.75 (s, 1H), 8.10 (s, 1H), 7.59 (d, J=7.5 Hz, 1H), 7.25 (m, 6H), 7.03 (d, J=7.5 Hz, 1H), 6.95 (d, J=7.5 Hz, 1H), 6.83 (m, 1H), 6.60 (m, J=6.0 Hz, 1H), 6.48 (m, 1H), 6.36 (d, J=7.5 Hz, 1H), 4.64 (m, 2H), 3.57 (m, 1H), 3.41-3.20 (m, 2H), 2.92 (m, 1H), 2.67 (m, 1H), 2,05 (m, 1H), 1.82 (m, 1H); MS (DCI/NH3) m/e 412 (M+H)+. Anal. Calc'd. For C25H25N5O-0.7 H2O: C 70.80; H 6.27; N 16.51. Found: C 70.67; H 6.19; N 16.26. Example 23 N-(1-benzyl-1,2,3,4-tetrahydroquinolin-3-yl)-N'-1H-indazol-4-ylurea Example 23 A tert-butyl 1-benzyl-1,2,3,4-tetrahydroquinolin-3-ylcarbamate A mixture of (1,2,3,4-tetrahydroquinolin.-3~yl)-carbamic acid tert-butyl ester (507mg, 2,04mmol) and potassium carbonate (367mg, 2.65rnmol) in ethanol (15mL) was treated with benzyl bromide (367mg, 2.14mmol)and stirred overnight at ambient temperature. The reaction mixture was partitioned between ethyl acetate (100mL) and water (100mL). The isolated organic phase was washed with brine and dried over anhydrous sodium sulfate, filtered and concentrated. The resulting oil was chromatographed on silica gel, eluting with 5-to-50% ethyl acetate in hexane to afford the title compound (529mg, 77%) as a white solid. 1H NMR (300MHz, DMSOd6) δ:138 (s, 9H), 2.65-2.75 (dd, 1H), 2.83-2.92 (dd, 1H), 3.11-3.22 (dd, 1H), 335-3.42 (dd, 1H), 3.77-3,90 (m, 1H), 439-4.51 (q, 2H), 6.45-6.52 (m, 2H), 6.82-6,94 (m, 3H), 7.20-7.34 (m, 5H). MS (ESI) m/z 222.2,283.1,339.1 (M+H)+. Example 23B 1 -benzyl-1, 2,3,4-tetrahydroquinolin-3-amine Trifluoroacetic acid (3mL) was added to a solution of (1-benzyl-1,2,3,4-tetrahydroquinolin-3-yl)-carbamic acid tert-butyl ester (481mg, 1.42mmol) in dichloromethane (6mL), stirred for 30 minutes at ambient temperature, and concentrated. A solution of the resulting oil in methanol (10mL) was treated with potassium carbonate (393mg, 2,84mmol), stirred for an hour at room, temperature, and concentrated to afford the title compound as yellow residue. MS (DCI/NH3) m/z: 239.1 [M+H]+. Example 23C N-(1-benzyl-l,2,3,4-tetrahydroquinolin-3-yl)-N'-1H-indazol-4-ylurea A solution of the product of Example 23B and diisopropylethylamine (0.3 mL, 1.72 mmol) in N,N-dimethylformamide (10 mL) was treated with the product of Example 24D (472mg, 1.42 mmol) under nitrogen atmosphere at ambient temperature, stirred at room temperature for 30 minutes, diluted with water (100 mL), and filtered. The isolated solid was washed with water and air-dried, A mixture of the solid and a solution of methanol (25 mL), water (3 mL) and triethylamine (0.4mL, 2.87 mmol) was refluxed for an hour, cooled to room temperature, diluted with water (200mL), and filtered. The isolated solid was rinsed with water and air-dried. The wet cake was vacuum dried to constant weight to afford the title compound (483mg, 85%) as a white solid. 1H NMR (300 MHz, DMSO-de) δ: 2-68-2.76 (dd, 1H), 3.09-3.17 (dd, 1H), 3.57 (dd, 1H), 4.24 (m, 1H), 4.46-4.61 (q, 2H), 6.51-6.58 (m, 3H), 6.92-7.06 (m, 3H), 7.16-7.21 (m, 2H), 7.23-7.33 (m, 4H), 7.65 (d, 1H), 8.06 (s, 1H), 8,81 (s, 1H), 12.98 (s., 1H). MS (ESI) m/z 222.1,398.2 (M+H)+. Anal. Calc'd for C24H23N5O0.9 H2O: C, 69.68; H, 6.04; N, 16.93. Found: C, 69.73; H, 5.74; N, 16.67. Example 24 4-(2.5-dioxo-pyrrolidin-l-yloxycarbonylamino')-indazole-l-carboxylic acid methyl ester Example 24A 4-nitro-lH-indazole 2-Memyl-3-nitroaniline (20 g) in acetic acid (200 mL) was treated with NaNO2 (20 g) in water (50 mL) at 4 °C (mechanical stirring). The reaction mixture was allowed to warm to room temperature and stir overnight The solvent was removed under reduced pressure. The residue was treated with water (700 mL) and the mixture was filtered. The solid was dried at 45 °C in a vacuum oven overnight to provide the title compound. 1H NMR (DMSO-d6) δ 8.56 (s, 1H), 8.2-8.05 (dd, 2H), 7.6 (t, 1H), Alternatively, to a 4-necked 5-L jacketed round bottom flask fitted with a mechanical stirrer and a thermocouple was charged the nitroaniline (100 g, 1.0 equiv.) and acetic acid (2000 mL). The solution was cooled to 14 °C. A chilled to about 1 °C (ice-water bath) solution of sodium nitrite (100 g, 2.2 equiv.) in water (250 mL) was added quickly in one portion. The internal temperature rose from 14 °C to 27.6 °C oyer 5 min., stayed at this temperature for 5 min. before gradually cooling to 15 °C. The mixture was stirred for 24 h after which it was concentrated in vacua to an approximate volume of 500 mL. The residue was re-slurried in water (1800 ml,) at ambient temperature for 21 hours. The orange solid was filtered, washed with water (3X250 ml,), and dried in a vacuum oven at 70 °C to afford 97.0 g of the title compound as a bright orange solid. Example 24B methyl 4-nitro-lH-indazole-1 -carboxvlate NaH (0.3 g, 12.5 mmol) in N,N-dimethylformamide (5 mL) was treated with the product of Example 24A (1.33 g, 10 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature and stir for 1 hour. The mixture was treated with methyl chloroformate (0.9 mL) and stirred at room temperature for 3 hours. The mixture was treated with water and filtered to provide the title compound as a solid. 1H NMR (300 MHz, DMSO-d6) δ 4,1 9 (s, 3H), 7.9 (t, 1H), 8,38 (A, 1H), 8.62 (d, 1H), 8.85 (s, 1H). Alternatively, to a 3-necked 2-L jacketed flask fitted with a mechanical stirrer, a thermocouple, and an addition funnel was charged 95.2 g of the product of Example 24A and N,N-dimethylformamide (650 mL). The dark solution was cooled to 10 °C and DBU (96.0 g, 1.1 equiv.) was added via addition funnel so that the internal temperature did not go beyond 15 °C. After cooling the mixture back to 10 °C, methyl chloroformate (108.5 g, 2.0 equiv.) was added via addition funnel so that the internal temperature did not go beyond 25 °C. After 1 hour stirring at 10 °C, aqueous 10 % potassium phosphate diacid in water (500 mL) was added and the mixture was stirred for 15 hours,. The resulting brown solid was filtered and the reaction vessel rinsed with aqueous 10 % potassium phosphate diacid in water (2X150 mL). The rinses were added to the solid on the filter. The resulting solid was washed with aqueous 10 % potassium phosphate diacid in water (2X200 mL), water (2X200 mL), dried in a vacuum oven at 70 °C to afford 122.2 g of a dark brown solid. The solid was reslurried in isopropyl acetate (2000 mL) for 2 hours. The solid was filtered, washed with fresh isopropyl acetate (2X250 mL), and dried in a vacuum oven at 70 °C to afford 110.2 g of the title compound as a light brown solid. Example 24C methyl 4-amino-lH-indazole-1-carboxylate The product of Example 24B (1.66 g, 7,5 mmol) and 10% Pd/C were combined in ethanol (20 mL) and exposed to a hydrogen atmosphere, The reaction mixture was heated at 80 °C for 20 minutes, allowed to cool to room temperature, and filtered through Celite. The filtrate was evaporated to provide title compound. 1H NMR (300 MHz, DMSO-d6) δ 6.1 (s, 2H), 6.41 (dd, 1H), 7.21 (m, 2H), 8.42 (s, 1H). Alternatively, to the reaction vessel was charged the product of Example 24B, MeOH (2000 mL), and 5% Pd/C (10.6 g). The mixture was pressured with H2 (40 psi) and shaken at ambient temperature. The reaction was completed in 1.5 hours. The mixture was filtered to obtain the product in MeOH. Cone., 37 % HC1 (100 mL) was added to the reaction mixture. The product solution was concentrated to furnish a light brown solid. The solid was reslurried in isopropyl alcohol (200 mL) for 15 minutes. The solid was filtered and washed with fresh isopropyl alcohol (3X50 mL), and dried in a vacuum oven to provide 94.9 g of 4-aminoindazole-l-carboxylic acid methyl ester, HC1 salt as a light brown solid. Example 24D 4-(2.5-dioxo-pyrrolidin-l-yIoxycarbonylamino)-indazole-l-carboxylic acid methyl ester The product of Example 24C (1.9 g, 10 mmol) and disuccinimidylcarbonate (2.8 g, 11 mmol) were mixed in acetonitrile (100 mL) for 48 hours under nitrogen atmosphere. The solid was isolated by filtration, washed with acetonitrile (10 mL) and dried under vacuum at ambient temperature to give the title compound (2.56 g, 77%) as off-white solid. Examp1e 25 N-(2,3-dihydro-l,4-benzodioxin-2-ylmethyl)-N'-lH-indazol-4-ylurea The product of Example 24D (635 mg, 1.9 mmol) was added to a solution of 1-(2,3-dihydro-l,4-benzodioxin-2-yl)methanamine (315 mg, 1.9 mmol) and diisopropylethylamine (0.34 mL, 1.9mmol) in N,N-dimethylformamide (5 mL) under nitrogen atmosphere at ambient temperature. After 30 minutes the reaction solution was diluted with water (50 mL), the resulting precipitate was filtered off, washed with water and air-dried. The wet cake was added to a solution of methanol (25 mL), water (3 mL) and triethylamine (0.54 mL, 3.8 mmol). The mixture was refluxed for an hour, cooled to room temperature, diluted with water (100 mL), collected the white precipitate by filtration, rinsed with water and air-dried. The wet cake was vacuum dried to constant weight to provide the title compound (568 mg, 92%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ:3.41-3.56 (m, 2H), 3.98 (dd, 1H), 4.26-4.33 (m, 1H), 4.36 (dd, 1H), 6.68 (t, 1H), 6,81-6.94 (m, 4H), 7.06 (d, 1H), 7.20 (t, 1H), 7.62 (d, 1H), 8.09 (s, 1H), 8.80 (s, 1H), 13.00 (s, 1H). MS (ESI) m/z: 325.1 (M+H)+; Anal. Calc'd for C17H16N4O3: C, 62.95; H, 4.97; N, 17.27. Found: C, 62.66; H, 4.83; N, 16.99. Example 26 N-( 1 -benzyl-2,3,4,5-tetrabydro-lH- l-benzazepin-5 -yl)-N'- lH-indazol-4-ylurea Example 26A A mixture of 0.45 g (2.80 mmol) of l,2,3,4-tetrahydro-benzo[b]azepin-5-one and 0.5 g (2.94 mmol) benzyl-bromide in 4 mL of acetonitrile and 1 mL (5.74 mmol) of diisopropylethylamine was heated in a microwave oven at 180°C for 30 minutes. The mixture was cooled to about room temperature and partitioned between ethyl acetate and sodium bicarbonate solution. The organic phase was concentrated, and the residue was chromatographed on silica gel, eluted with 5 to 50% ethyl acetate in hexane to provide 662 mg (94% yield) of Example 26A as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.56 (dd, 1H), 7.22-7.36 (m, 6H), 6.90 (d, 1H), 6.76 (t, 1H), 4.73 (s, 2H), 3.27-3.31 (m, 2H), 2.69 (t, 2H), 2.06-2.15 (m, 2H). MS (DCI) m/e 252.1 (M+H)+. Example 26BA mixture of 0.61 g (2.41 mmol) of Example 26A and 0,22 g (2.65 mmol) methoxylamine hydrochloride in 10 mL pyridine was stirred overnight at ambient temperature, concentrated and partitioned between ethyl acetate and sodium bicarbonate solution. The organic phase was concentrated and the residue was chromatographed on silica gel, eluting with 0 to 50% ethyl acetate in hexane to provide 0.62 g (92% yield) of Example 26B as a yellow oil, 1HNMR (300 MHz, DMSO-d6) δ ppm 7.23-7.36 (m, 6H), 7.16 (t, 1H), 6.84 (d, 1H), 6.78 (t, 1H), 4.47 (ss 2H), 3.88 (s, 3H), 3.12 (t, 2H), 2.68 (t, 2H), 1.78-1.86 (m, 2H). MS (DCI) m/e 281.1 (M+H)+. Example 26C 0.59 g (2.09 mmol) of Example 26B was added to 20 mL 20% ammonia in methanol and 1.0 g Raney nickel in a Parr shaker. The reactor was sealed and flushed with nitrogen, and then was pressurized with 60-psi hydrogen. The mixture was shaken at ambient temperature for 13 hours. After the reactor was flushed with nitrogen, the Raney nickel was filtered off and washed with methanol. The filtrate was concentrated to a yellow oil to provide 0.47 g (89% yield) of Example 26C. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.30-7.40 (m, 5H), 7.23 (t, 1H), 7.09 (t, 1H), 6.97 (d, 1H), 6.92 (t, 1H), 4.31-4.39 (m, 1H), 4.15-4.23 (m, 2H), 2.87-2.97 (m, 1H), 2.60-2.68 (m, 1H), 1.99-2,17 (m, 2H), 1.75-1.85 (m, 1H), 1.41-1.62 (m, 2H), 1.27-1.37 (m, 1H). MS (DCI) rn/e 253.2 (M+H)+. Example 26P N-(l-benzyl-2,3,4,5-tetrahydro-lH-l-benzazepin-5-yl)-N-lH-indazol-4-ylurea A mixture of 0.47 g (1.86 mmol) of Example 26C and 0.62 g (1.86 mmol) Example 24D in 10 mL of N,N-dimethylfoimamide and 0.33 mL (1,89 mmol) of diisopropylethylamine was stirred for an hour at ambient temperature, diluted with water, filtered off the precipitate and rinsed with water. The wet cake was added to 30 mL of methanol, 4 mL water, and 0.52 mL (3.73 mmol) of triethylamine. The mixture was refluxed for two hours, cooled and diluted with water, filtered off the precipitate and rinsed with water. The wet cake was vacuum dried to constant weight, yielding 0.73 g (95% yield) of title compound as a white solid. 1H NMR (300 MHz, DMSO-d5) δ ppm 13.01 (s, 1H), 8.80 (s, 1H), 8.12 (s, 1H), 7.63 (d, 1H), 7.47 (d, 2H), 7.32 (t, 2H), 7.12-7.27 (m, 4H), 7.04 (t, 2H), 6.94 (t, 2H), 5.21 (ddd, 1H), 4.38-4.47 (m, 1H), 4.23-4.32 (m, 1H), 2.96-3.06 (m, 1H), 2.71- 2.79 (m, 1H), 1.86-1.97 (m, 1H), 1.51-1.71 (m, 3H). MS (ESI) m/e 412.2 (M+H)+. Calcd. for C25H25N5O0.27H2O: C 72.12, H 6.18, N 16.82; Found C 72.20, H 6.37, N 16.48. Example 27 N-(2,3-dihydro-1-benzofuran-2-ylmethyl)-N'-lH-indazol-4-ylurea Example 27A A mixture of 0.5 g (3.05 mmol) of 2,3-dihydro-benzofuran-2-carboxylic acid and 0,83 g (6.09 mmol) of isobutyl chloroformate in 20 mL of tetrahydrofuran and 1.43 mL (10.3 mmol) of triethylamine was stirred for an hour at ambient temperature and filtered. The filtrate was added to 61 mL (30.5 mmol) of 0.5 M ammonia in dioxane and stirred overnight at ambient temperature, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 20 to 80% ethyl acetate in hexane. The residue obtained was again • chromatographed on silica gel with 0 to 10% methanol in dichloromethane to provide 0.26 g (52% yield) of Example 27A as a light yellow solid, 1H NMR (300 MHz, DMSO-d6) δ ppm 7.52 (s, 1H), 7.37 (s, 1H), 7.21 (d, 1H), 7.12 (t, 1H), 6.85 (t, 1H), 6.82 (d, 1H), 5.06 (dd, 1H), 3.45 (dd, 1H), 3.21 (dd, 1H). MS (DCI) m/e 164.0 (M+H)+. Example 27B A mixture of 4.65 mL (4.65 mmol) of 1.0 M lithium aluminum hydride in tetrahydrofuran and 0.25 g (1.55 mmol) of Example 27A in 10 mL of tetrahydrofuran was stirred for two hours at ambient temperature, then refluxed for two hours. The mixture was chilled to 0°C, and added 0.3 mL water dropwise 10mL tetrahydrofuran, 0.3 ml 3N sodium hydroxide, and 0.8 mL water. The slurry was filtered and the solid was rinsed with ethyl acetate. The filtrate was concentrated to provide 0.14 g (61% yield) of Example 27B. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.17 (d, 1H), 7.05 (t, 1H), 6.78 (t, 1H), 6.72 (d, 1H), 4.65-4,74 (m, 1H), 3.18 (dd, 1H), 2.96 (dd, 1H), 2,76 (d, 2H). MS (DCI) m/e 150.0 (M+H)+. Example 27C N-(2,3-dihydro-l-benzofuran-2-ylmethyl)-N'-1H-indazol-4-ylurea A mixture of 0.14 g (0.95 mmol) of Example 27B and 0.32 g (0.95 mmol) Example 24D in 9 mL of N,N-dimethylformamide and 0.17 mL (0.98 mmol) of diisopropylethylamine was stirred for an hour at ambient temperature, diluted with water, and filtered. The wet cake was added to 12 mL methanol, 1 mL water, and 0.27 mL (1.94 mmol) of triethylamine. The mixture was refluxed for two hours, cooled to ambient temperature, and partitioned between ethyl acetate and water. The organic layer was filtered through silica gel and rinsed with ethyl acetate. The filtrate was concentrated to a yellow solid and vacuum dried to constant weight, yielding 0,18 g (62% yield) of the titled compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.99 (s, 1H), 8.78 (s, 1H), 8.08 (s, 1H), 7.64 (d, 1H), 7.22 (d, 1H), 7.19 (d, 1H), 7,03-7.13 (m, 2H), 6.84 (d, 1H), 6.79 (d, 1H), 6.68 (tf 1H), 4.85-4.94 (m, 1H), 3.55 (ddd, 1H), 3.39 (dt, 1H), 3.28 (dd, 1H), 2.97 (dd, 1H). MS (ESI) m/e 309.1 (M+H)+. Calcd. for C17H16N4O2●0.38C4H8O2: C 65.08, H 5.61, N 16.39; Found C 65.36, H 5.47, N 16.20. Example 28 N-(3.4-dihydro-2H-cliromen-2-ylmemyl)-N-1H-indazol-4-ylurea Example 28A 2.0 g (10.5 mmol) of 4-oxo-4H-chromene-2-carboxylic acid was added to 25 mL of acetic acid and 200 mg of 10% palladium on carbon (dry) in a Parr shaker. The reactor was sealed and flushed with nitrogen, and then was pressurized with 60-psi hydrogen. The mixture was shaken at 70°C for 2.5 hours. After cooling the reactor was flushed with nitrogen, the palladium was filtered off and washed with acetic acid, and the filtrate was concentrated to a yellow oil. The yellow oil was chromatographed on silica gel, eluting with 0 to 10% methanol in ethyl acetate, yielding 2.04 g of Example 28A as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.94 (br s; 1H), 7.03-7.11 (m, 2H), 6.82 (td, 1H), 6.79 (d, 1H), 4.76 (dd, 1H), 2.79 (dt, 1H), 2.62 (dt, 1H), 2.10-2,20 (m, 1H), 2.01-2.08 (m, 1H). MS (DCI) m/e 196.0 (M+NH4)+. Example 28B 1.0 g (5.6 mmol) Example 28A was added to 20 mL of dichloromethane, and then 1.47 mL (16.9 mmol) oxalyl chloride and a few drops of N,N-dimethylformamide were added. Stirred for 30 minutes at ambient temperature and concentrated. The residue was dissolved in dichloromethane and added to 80 mL of 0.5 M ammonia in dioxane. The mixture was stirred overnight, filtered, and concentrated. The residue was chromatographed on silica gel, eluting with 50 to 100% ethyl acetate in hexane to pro-vide 0.77 g (77% yield) of Example 28B as a white solid. JH NMR (300 MHz, DMSO-d6) 6 ppm 7.40 (s, 1H), 7.35 (s, 1H), 7.04-7.12 (m, 2H), 6.80-6.86 (m, 2H), 4.46 (dd, 1H), 2.80 (ddd, 1H), 2.67 (dt, 1H), 2.10-2.20 (m, 1H), 1.83-1.95 (m, 1H). MS (DCI) m/e 178.0 (M+H)+. Example 28C 12.4 mL (12.4 mmol) 1.0 M lithium aluminum hydride in tetrahydrofuran was added to 0.73 g (4,12 mmol) of Example 28B in 20 mL tetrahydrofuran. The mixture was stirred for 3.5 hours at ambient temperature, refluxed for two hours,chilled to 0°C, and added 1.0 mL water dropwise, 30 mL tetrahydrofuran, 1,0 ml 15% sodium hydroxide, and 2.0 mL water. The slurry was filtered and the solids rinsed with ethyl acetate. The filtrate was concentrated to provide Example 28C as a colorless oil (0.67 g). 1H NMR (300 MHz, DMSO-d6) δ ppm 7.00-7.06 (m, 2H), 6.78 (td, 1H), 6,72 (dd, 1H), 3.82-3.91 (m, 1H), 2.66-2.82 (rn, 4H), 1.96-2.05 (rn, 1H), 1.47-1.68 (m, 3H). MS (DCI) m/e 164.0 (M+H)+. Example 28D N-(3.4-dihydro-2H-chromen-2-ylmethyl)-N'-lH-indazol--4-ylurea A mixture of 0.34 g (2.10 mmol) of Example 28C and 0.7 g (2,10 mmol) of Example 24D in 10 mL of N,N-dimethylformamide and 0.37 mL (2.12 mmol) of diisopropylethylamnie was stirred for an hour at ambient temperature, diluted with water, filtered off the precipitate and rinsed with water. The wet cake was added to 40 mL methanol, 3 mL water, and 0.59 mL (4.23 mmol) triethylamine. The mixture was refluxed for two hours, cooled and diluted with water, filtered off the precipitate and rinsed with water. The wet cake was vacuum dried to constant weight, yielding 0.54 g (80% yield) of the titled compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.99 (s, 1H), 8.79 (s, 1H), 8.09 (s, 1H), 7,65 (d, 1H), 7.20 (t, 1H), 7.03-7.11 (m, 3H), 6.82 (td, 1H), 6.79 (dd, 1H), 6.66 (t, 1H), 4.08-4.16 (m, 1H), 3.37-3.53 (m, 2H), 2.75-2.87 (m, 2H), 1.97-2.05 (m, 1H), 1.64-1.78 (m, 1H). MS (ESI) m/e 323.1 (M+H)+. Calcd. for C18H18N4O2●0.lH2O: C 66.69, H 5.66, N 17.28; Found C 66.71, H 5.44, N 17.21. Example 29 N-[(l-benzyl-2,3-dihydro-lH-indol-2-yl)methyl]-N'-lH-indazol-4-ylurea Example 29A A mixture of 0.65 g (4.0 mmol) 2,3-dihydro-lH-indole-2-carboxylic acid and 2,05 g (12.0 mmol) benzyl bromide in 3 mL acetonitrile and 2.79 mL (16.0 mmol) diisopropylethylamine was heated in a microwave oven at 180°C for 15 minutes, cooled to about room temperature and partitioned between ethyl acetate and water. The organic phase was concentrated. The residue was chromatographed on silica gel, eluting with 5 to 20% ethyl acetate in hexane to provide 1.496 g of Example 29A as a yellow oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.22-7.38 (m, 10H), 7.01 (d, 1H), 6.96 (t, 1H), 6.58 (t, 1H), 6.43 (d, 1H), 5.10 (s, 2H), 4.52 (d, 1H), 4.34 (dd, 1H), 4.21 (d, 1H), 3.39 (dd, 1H), 3.05 (dd, 1H). MS (ESI) m/e 344.4 (M+H)+. Example 29B A mixture of 1.496 g of Example 29A and 11 mL of N,N-dimethylformamide and 11 mL of 30% ammonium hydroxide was stirred for 3 days at ambient temperature, diluted with water, and extracted with ethyl acetate and dichloromethane sequentially. The combined organic phases were concentrated. The residue was chromatographed on silica gel, eluting with 40 to 100% ethyl acetate in hexane, yielding 0,48 g (48% yield) of Example 29B as a white solid 1H NMR (300 MHz, DMSO-d6) 5 ppm 7.46 (s, 1H), 7.31 (d, 4H), 7.22-7.28 (m, 1H), 7.13 (s, 1H), 6.99 (d, 1H), 6.94 (t, 1H), 6.56 (t, 1H), 6.41 (d, 1H), 4.53 (d, 1H), 4.10 (d, 1H), 4.06 (t, 1H), 3.27 (dd, 1H), 2.93 (dd, 1H). MS (DO) m/e 253.1 (M4H)+. Example 29C 5.75 mL (5.75 mmol) of 1.0 M lithium aluminum hydride in tetrahydrofuran was added to 0.48 g (1.92 mmol) of Example 29B in 20 mL tetrahydrofuran. The mixture was stirred for 2.5 hours at ambient temperature, refluxed for one hour, chilled to 0°C, and followed by the addition of 0.5 mL of water dropwise, 15 mL of tetrahydrofuran, 0.5 ml of 15% sodium hydroxide, and 1.0 mL water. The slurry was filtered and the solid was rinsed with ethyl acetate. The filtrate was concentrated to provide 0.47 g of Example 29C as an orange oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.27-735 (m, 4H), 7.21-7.26 (m, 1H), 6.99 (d, 1H), 6.90 (t, 1H), 6.52 (t, 1H), 6.34 (d, 1H), 4.44 (d, 1H), 4.21 (d, 1H), 3.56-3.66 (m, 1H), 3.03 (dd, 1H), 2.87 (dd, 1H), 2.68-2.80 (m, 2H), 1.40-1.64 (m, 2H). MS (DCI) m/e 239.1 (M+H)+, Example 29D N-[(l-benzyl-2.3-dihydro-lH-indol-2-yl)methyl]-N'-lH-indazol-4-ylurea A mixture of 0.47 g of Example 29C and 0.64 g (1.92 mmol) of Example 24D in 10 mL of N,N-dimethylformamide and 034 mL (1.95 mmol) of diisopropylethylamine was stirred for an hour at ambient temperature, diluted with water and filtered. The wet cake was rinsed with water and added to 50 ml. methanol, 5 mL water, and 0.54 mL (3.87 mmol) triethylamine. The mixture was reiluxed for two hours, cooled and diluted with water, filtered off the precipitate and rinsed with water. The solid was purified on reverse phase preparative liquid chromatography with 20 to 100% acetonitrile in water (with 0.1 % trifluoroacetic acid). The trifluoroacetic acid salt isolated was dissolved in methanol and treated with 0.54 mL (3.87 mmol) of triethylamine, precipitated with water, filtered and the wet cake rinsed with water and vacuum dried to constant weight, yielding 0.43 g (56% yield) of title compound as an off-white solid. 1H NMR (300 MHz, DMSO-d6) δ ppin 12.97 (s, 1H), 8.79 (s, 1H), 8.07 (s, 1H), 7.62 (d, 1H), 7.29-7.38 (m, 4H), 7.16-7.26 (m, 2H), 7.01-7.06 (m, 2H), 6.95 (t, 1H), 6.57 (t, 1H), 6.44-6.49 (m, 2H), 4.57 (d, 1H), 4.26 (d, 1H), 3.75-3.85 (m, 1H), 3.57 (ddd, 1H), 3.33-3.40 (m, 1H), 3.09 (dd, 1H), 2.85 (dd, 1H). MS (ESI) m/e 398.1 (M+H)+. Calcd. for C24H23N5O●0.23H2O: C 71.77, H 5.89, N 17.44; Found C 71,83, H 5.77, N 17.17. Examplg'30 N-[(4-berizyl-3,4-dihydro-2H-l,4-benzoxazin-2-yl)methyl]-N'-lH-indazol-4-ylurea Example 30A A mixture of 0.36 g (2.26 mmol) of 3,4-dihydro-2H-benzo[l,4]oxazine-2-carbonitrile and 0.41 g (2.37 mmol) of benzyl bromide in 4 mL acetonitrile and 0.79 mL (4.54 mmol) of diisopropyl-ethylamine was heated in a microwave oven at 140°C for one hour, cooled to about room temperature and partitioned between ethyl acetate and water. The organic phase was concentrated to an oil, and chromatographed on silica gel, eluting with 10 to 50% ethyl acetate in hexane to provide 0.44 g (78% yield) of Example 30A as an orange solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 731-738 (m, 4H), 7.23-739 (m, 1H), 6,79-6.86 (to, 2H), 6.72 (dd, 1H), 6.63 (td, 1H), 5.66 (t, 1H), 4.48-4.60 (m, 2H), 3.66 (qd, 2H). MS (DCI) m/e 251.1 (M+H)+. Example 30B 0.44 g (1.75 mmol) of Example 30A was added to 20 mL of 20% ammonia in methanol and 2.0 g of Raney nickel in a Parr shaker. The reactor was sealed and flushed with nitrogen, and then was pressurized with 60-psi hydrogen. The mixture was shaken at ambient temperature for 90 minutes. After the reactor was flushed with nitrogen, the Raney nickel was filtered off and washed with methanol, and the filtrate was concentrated to provide 0.40 g (90% yield) of Example 30B. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.22-736 (m, 5H), 6.62-6.72 (m, 3H), 6.48-6.54 (m, 1H), 4.46 (q, 2H), 4.01 (ddd, 1H), 4.43 (dd, 1H), 3,17 (dd, 1H), 2.74 (qd, 2H), 1.57 (br s, 2H). MS (DCI) m/e 255.1 (M+H)+. Example 30C N-[(4-benzyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl)methyl]-N'-lH-indazol-4-ylurea A mixture of 0.40 g (1.58 mmol) of Example 30B and 0.53 g (1.58 mmol) of Example 24D in 10 mL N.,N-dimethylformamide and 030 mL (1.72 mmol) diisopropylethylamine was stirred for an hour at ambient temperature and partitioned between ethyl acetate and water. The organic layer was filtered through silica gel and rinsed with ethyl acetate. The filtrate was concentrated to a brown oil, then added 50 mL methanol, 5 mL water, and 0.44 mL (3.16 mmol) triethylamine. The solution was refluxed for two hours, cooled to ambient temperature, and partitioned between ethyl acetate and water. The organic layer was washed with brine and dried over sodium sulfate, filtered and the filtrate concentrated to a brown residue. A solution of the residue in 1:1 methanol :ethanol was added to water and freeze-dried to provide 0.62 g (94% yield) of title compound as an off-white powder. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.98 (s, 1H), 8.78 (s, 1H), 8.09 (s, 1H), 7.61 (d, 1H), 7.27-735 (m, 4H), 7.17-7.26 (m, 2H), 7.06 (d, 1H), 6.78 (dd, 1H), 6.63-6.75 (m, 3H), 6.53-6.58 (m, 1H), 4.49 (q, 2H), 4.23-4.30 (m, 1H), 337-3.53 (m, 2H), 3.20-3.28 (m, 2H). MS (ESI) m/e 414.1 (M+H)+. Calcd. for C24H23N5O2● 0.35H2O; C 68.67, H 5.69, H 16.68; Found C 68.71, H 5.62, N 16.53, Examle 31 Example 31A 4.35 g (25.1 mmol) quinoline-4~carboxylic acid was added to 125 mL methanol and 8.7 g Raney nickel in a Parr shaker. The reactor was sealed and flushed with nitrogen, and then was pressurized with 60-psi hydrogen. The mixture was shaken at ambient temperature for 19 hours. After the reactor was flushed with nitrogen, the Raney nickel was filtered off and washed with methanol, and the filtrate was concentrated to provide 5.25 g of Example 31A. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.26 (br s, 1H), 6.94 (d, 1H), 6.88 (t, 1H), 6.39-6.48 (m, 2H), 5.76 (s, 1H), 3.61 (t, 1H), 3.10-3.25 (m, 2H), 2.00-2.10 (m, 1H), 1.74-1.87 (m, IH). MS (DCI) m/e 178. 1 (M+H)+. Example 3 1B A mixture of 1.45 g (8.18 mmol) of Example 31 A, 1.54 g (9.00 mmol) benzyl bromide in 30 mL ethanol and 2,83 g (20.5 mmo!) potassium carbonate was stirred at ambient temperature overnight, treated with water, and the pH was adjusted to about 6 with the addition of 1N hydrochloric acid. The mixture was extracted with ethyl acetate and the organic phase concentrated and chromatographed on silica gel, eluting with 20 to 100% ethyl acetate in hexane to provide 1.379 g (63% yield) of Example 31B as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.41 (s, 1H), 7.27-7.33 (m, 2H), 7.18-7.25 (m, 3H), 7.00-7.03 (m, 1H), 6.90-6.95 (m, 1H), 6.46-6.52 (m, 2H), 4.50 (q, 2H), 3.72 (t, 1H), 3.43-3.52 (m, 1H), 2.13-2.22 (m, 1H), 1.94-2.05 (m, 1H). MS (DCI) m/e 267.8 (M+H)+. Example 3 1C A mixture of 1.07 g (4.0 mmol) of Example 31B, 1.21 g (4.4 mmol) diphenyl phosphoryl azide in 30 mL tert-butanol and 0.37 ml, (4.8 mmol) triethylamine was refluxed 90 minutes, stirred at ambient temperature overnight, and concentrated. The residue was chromatographed on silica gel, eluting with 5 to 30% ethyl acetate in hexane, yielding 0.69 g (51% yield) of Example 31C as a colorless oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.22-7.36 (m, 5H), 7.01 (d, 1H), 6.92 (t, 1H), 6.51 (t, 1H), 6.43 (d, 1H), 4.66 (q, 1H), 4.48 (s, 2H), 3.39 (q, 2H), 1.88-1.99 (m, 2H), 1.43 (s, 9H). MS (DCI) m/e 339.1 '(M+H)+. Example 3 ID A solution of 0.69 g (2.03 mmol) Example 31C in 10 mL dichloromethane and 2 mL trifluoroacetic acid was stirred overnight at ambient temperature, and concentrated. The residue was dissolved in 10 mL methanol and treated with 281 mg (2.03 mmol) potassium carbonate. The mixture was stirred for 30 minutes at ambient temperature, filtered and the filtrate concentrated. The residue was chromatographed on silica gel with 1% triethylamine in dichloromethane, yielding 0.36 g (74% yield) of Example 3 ID as a yellow oil. ]H NMR (300 MHz, DMSO-d6) δ ppm 7.49 (br s, 2H), 7.21-7.36 (m, 6H), 7.05 (t, 1H), 6.59 (t, 1H), 6.53 (d, 1H), 4.47-4.59 (m, 2H), 4.36 (t, 1H), 3.35-3.54 (m, 2H), 2.01-2.17 (m, 2H). MS (DCI) m/e 239.2 (M+H)+. Example 3 IE N-(1 -benzyl-1,2,3.,4-tetrahydroquinolin-4-yl)-N1-lH-indazol-4-ylurea - Amixture of 0.36 g (1.51 mmol) of Example 31D, 0.50 g (1.51 mmol) of Example 24D in 10 mL N,N-dimethylformamide and 0.27 mL (1.55 mmol) diisopropylethylamine was stirred for an hour at ambient temperature, and partitioned between ethyl acetate and water. The organic layer was filtered through silica gel and rinsed with ethyl acetate. The filtrate was concentrated. The residue was treated with 50 mL methanol, 5 mL water, and 0.43 mL (3.09 mmol) triethylamine, refluxed for two hours, cooled and diluted with water and filtered. The wet cake was rinsed with water and vacuum dried to constant weight, yielding 0.39 g (64% yield) of title compound as an off-white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 13.00 (s, 1H), 8.58 (s, 1H), 8.02 (s, 1H), 7.71 (d,1H), 7.16-7.38 (rn, 7H), 7.06 (d, 1H), 7.01 (t, 1H), 6.73 (d, 1H), 6.54-6.59 (m, 2H), 4.84 (q, 1H), 4.50-4.62 (m, 2H), 3.41-3.47 (m, 2H), 2.01-2.10 (m, 2H). MS (ESI) m/e 398.3 (M+H)+. Calcd. for C24H23N5O●0.47H2O: C 71.01, H 5.94, N 17,25; Found C 70.94, H 5.75, N 17.47. Example 32 N-(3,4-dihydro-2H-l,4-benzoxazin-2-ylmethyl)-Nl-lH-indazol-4-ylurea 0.38 g (0.92 mmol) of Example 30C was added to 10 mL methanol and 76 mg 20% palladium hydroxide on carbon (wet) in a Parr shaker. The reactor was sealed and flushed with nitrogen, and then was pressurized with 50-psi hydrogen. The mixture was shaken at 50°C for 24 hours. After cooling, the reactor was flushed with nitrogen, and the palladium was filtered off and washed with raethanol. The filtrate was concentrated to a brown residue. The residue was dissolved in 1:1 methanol: acetonitrile and to which was water and freeze-dried to provide 0.31 g of title compound as a beige powder. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.99 (s, 1H), 8.78 (s, 1H), 8.09 (s, 1H), 7.63 (d, 1H), 7:20 (t, 1H), 7,06 (d, 1H), 6.56-6.72 (m, 4H), 6.49 (td, 1H), 5.75 (s, 1H), 4.06-4.13 (m, 1H), 3.35-3.51 (m, 3H), 3.06 (dd, 1H). MS (ESI) m/e 324.1 (M+H)+. Calcd. for C17H17N5O2●0.07H2O●0.38CH4O: C 61,98, H 5.58, N 20.79; Found C 61.98, H 5.39, N 20.72. Example 33 N-isoquinolin-5-yl-N'-(8-piperidin-l-yl-3,4-dihydro-2H-chromen-4-yl)urea Example 33A A solution of 6-chloro-chroman-4-one (0.91 g, 5 mmol) in 12 ml of concentrated sulfuric acid was treated with N-bromosuccinimide (0.94 g, 5.3 mmol) and stirred at ambient temperature for 3 hours. The reaction mixture was poured onto ice and extracted with diethyl ether. The combined organic layers were dried with magnesium sulfae, filtered and the solvent evaporated under reduced pressure to give 1.42 g of Example 33 A which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.83 (d, .J=2.71 Hz, 1 H), 7.71 (d, .7=2.71 Hz, 1 H), 4.62 - 4,68 (m, 2 H), 2.83 - 2.88 (m, 2 H). MS (DCI) m/e 261.8 (M+H)+ (Br+Cl pattern) A solution of Example 33 A (1 .66 g, 6.3 mmol) in 6 ml pyridine was treated with methoxylamine hydrochloride (0.84 g, 10 mmol) and stirred at ambient temperature for 3 days. The pyridine was removed under reduced pressure, and the residue partitioned between water and diethyl ether. The mixture was extracted with diethyl ether, and the combined organic layers dried with magnesium sulfate and filtered. The solvent was removed under reduced pressure to give 1.50 g of Example 33B which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.86 (d, J=237 Hz, 1 H), 7.48 (d, .7=2.71 Hz, 1 H), 4.23 - 4.32 (m, 2 H), 4.00 (s, 3 H), 2.86 - 2.92 (m, 2 H). MS (DCI) m/e 291.8 (M+H)+ (Br+-C1 pattern) mg of the titled compound as the trifluoroacetate salt. 1H NMR (300 MHz, DMSO-D6) δ ppm 9.54 (s, 1 H), 8.89 (s, 1 H), 8,60 (d, .7=6.44 Hz, 1 H), 8.52 (d, J=6.78 Hz, 1 H), 8.15 (d, J=6.44 Hz, 1 H), 7.92 (d, .J=8.14 Hz, 1 H), 7.77 (t, ,7=7.97 Hz, 1 H), 7.10 - 7.17 (m, 2 H), 6.98 (d, ,7=7.46 Hz, 1 H), 6.83 - 6.93 (m, 2 H)5 4.19 - 4.28 (m, 1 H), 4.08 - 4.19 (m, 2 H), 3.16 (dd, .7=46.44,5.26 Hz, 1 H), 2.75 (dd, .7=16.44,3.56 Hz, 1 H). MS (ESI) m/e 320 (M+H)+, Calcd. For C19H17N3O2●1.4trifluoroacetic acid: C 54.66, H 3.87, N 8.77; Found C 54,74, H 3.77, N 8.82. Example 35 (+)-N-isoquinolia-5-yl-N'-[7-(trifluoromethyl)3,4-dihydro-2H-chromen-4-yl]urea Example 35A 3-Trifluoromethylphenol (8.75 g, 6.5 ml, 54 mmol), propargyl bromide (7.1 ml of 80% in toluene, 64 mmol), and potassium carbonate (8.83 g, 64 mmol) were stirred together in 100 ml of acetonitrile at ambient temperature for four days. The solvent was removed under reduced pressure, and the residue taken hi water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 11.24 g of Example 35A which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.42 (t, J=7.97 Hz, 1 H), 7.20 - 7.29 (m, 2 H), 7.13 - 7.19 (m, 1 H), 4.74 (d, J=2.37 Hz, 2 H), 2.54 (t, J=2.37 Hz, 1 H) Example 35B Example 35A (5.00 g, 25 mmol) was dissolved in 100 ml acetone. N-chlorosuccinimide (4.00g, 40 mmol) and silver acetate (334 mg, 2 mmol) were added, and the reaction heated to reflux for 3 hours. After cooling, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was taken up in diethyl ether, washed with water, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 7.98 g of Example 35B which was used without further purification. IHNMR (30O MHz,CDCL3)δ ppm 7.42(t, J=7.97Hz, 1H)7.26(m, 1H),7.19 (s, 1H), 7.11 - 7.16 (m, 1 H), 4.74 (s, 2 H) Example 35C Example 35B (0.94 g, 4 mmol) was dissolved in 25 ml of concentrated sulfuric acid. The reaction was stirred at ambient temperature for 30 minutes, then poured onto ice. The mixture was extracted with diethyl ether, and the combined organic layers washed with saturated aqueous sodium bicarbonate, dried with magnesium sulfate and filtered. The solvent was removed under reduced pressure to give 0.73 g of Example 35C containing the 5-trifluoromethyl regioisomer as an impurity, 1H NMR (300 MHz, d6-DMSO) δ 7.96 (d, J=7.5 Hz, 1H), 7.40 (m, 2H), 4.62 (t, J=6.0Hz, 2H), 2.88 (t, J=6.0 Hz, 2H). MS (DCI) m/e 234 (M+NEL,)+ Example 35D Example 35C (1.29 g, 6 mmol) was dissolved in 6 ml pyridine. Methoxylamine hydrochloride (l.00g, 12 mmol) was added and the reaction stirred at ambient temperature for 1 day. The pyridine was removed under reduced pressure, and the residue partitioned between water and diethyl ether. The mixture was extracted with diethyl ether, and the combined organic layers dried with magnesium sulfate. The solvent was removed under reduced pressure and the residue purified by flash chromatography using 5% ethyl acetate in hexanes to give 0.81 g of Example 35D. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 8.00 (d, J=7.46 Hz, 1 H), 7.10 - 7.18 (m, 2 H), 4.18 - 4.27 (m, 2 H), 4,01 (s, 3 H), 2,89 - 2,95 (m, 2 H)MS (DCI) m/e 246 (M+H)+. Example 35B Example 35D (0.80 g, 3.2 mmol), 180 mg of 10% palladium on carbon, and 30 mL of 20% ammonia in methanol were shaken under hydrogen at 40 psi and ambient temperature for 1 hour. The catalyst was removed by filtration and the solvent evaporated under reduced pressure to give 0.70 g of Example 35E which was used without further purification, 1H NMR (300 MHz, CDC13), δ ppm 7.45 (d, J=8.14 Hz, 1 H), 7.14 (d, J=7.80 Hz, 1 H), 7.08 (s, 1 H), 4.22 - 4.37 (m, 2 H), 4.07 - 4.17 (m, 1 H), 2.41 (br, 2 H, NH2), 2.13 - 2.27 (m, 1 H), 1.84 -1.96 Cm, 1 H). MS (CI) m/e 218 (M+H)+ Example 35F A solution of phosgene (20% in toluene, 5.8 ml, 11 mmol) was added to 50 ml methylene chloride and cooled to 0°C. 4-Dimethylaminopyridine (2.86g, 23.4 mmol) in 30 ml methylene chloride was added dropwise. A thick white suspension formed. A solution of 5-aminoisoquinline (1.44g, 10 mmol) in 30 ml methylene chloride was then added dropwise to this suspension. The reaction was allowed to warm to ambient temperature and stirred overnight At the end of this time, a solution formed, and the solvent was removed under reduced pressure. The residue was triturated with 50 ml diethyl ether to give an approximately 0.1 M solution of 5-isocyaiiato-isoquinoline. 32 ml of this solution was added to Example 35E (0.70 g, 3.2 mmol), and the reaction stirred overnight. The precipitate that formed was collected by nitration to give 0.43 g of Example 35F. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.28 (s, 1 H), 8.65 (s, 1 H), 8.54 (d, J=6.10 Hz, 1 H), 8.31 - 8.37 (m, 1 H), 7.90 (d, J=6.10 Hz, 1 H), 7.76 (d, J=8.14 Hz, 1 H), 7.55 - 7.66 (m, 2 H), 7.24 - 7,29 (m, 1 H), 7.13 - 7.22 (m, 2 H), 5.03 (m, 1 H) 4.38 (m, 1 H) 4.27 (m, 3.22 Hz, 1 H) 2.14 - 2.26 (m, 1 H) 2.08 (m, 1 H). MS (ESI) m/e 388 (M+H)+. Example 35G (+)-N-isoquinolin-5-yl-N'-[7-(trifluormethyl)-3,4-dihydro-2H-chromen-4-yl]urea Example 35F was resolved by chiral HPLC (Column: Chiracel OD (5 cm ID x 50 cm); mobile phase: 80:10:10 hexanes:ethanol:methanol) to give a total of 295 mg of title compound. [α]D = +47.7 degrees (c=0.88,1:1 ethanol: dimethylsulfoxide). 1H NMR. (300 MHz, DMSO-d6) δ ppm 9.28 (s, 1 H), 8.64 (s, 1 H), 8.54 (d, J=6.10 Hz, 1 H), 8.35 (d, J=6.78 Hz, 1 H), 7.89 (d, J=6.10 Hz, 1 H), 7.76 (d, .7=8.14 Hz, 1 H), 7,55 - 7.66 (m, 2 H), 7.26 (d, 1 H), 7.13 - 7.22 (m, 2 H), 4.99 - 5.07 (m, 1 H), 4.34 - 4.43 (m, 1 H), 4.27 (m, 1 H) 2.15 - 2.27 (m, 1 H) 2.02 - 2.13 (m, 1 H). MS (ESI) m/e 388 (M+H)+ Calcd. For C20H16N3O2F3●0.3H2O: C 61.16, H 4.26, N 10.70; Found C 61.40, H 3.97, N 10.33. Example 36 (-)-N-isoquinolin-5-yl-N'-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea Example 35F was resolved by cbiral HPLC (Column: Chiracel OD (5 cm ID x 50 cm); mobile phase: 80:10:10 hexanes:ethanol:methanol) to give a total of 270 mg of title compound. [α]D= -44.8 degrees (c=1.005,1:1 ethanol:dimethylsulfoxide). 1HNMR (300 MHz, DMSO-d6) δ ppm 9.28 (s, 1 H), 8.64 (s, 1 H), 8.54 (d, J=6.10 Hz, 1 H), 8.35 (dd, 7=7.63,1.19 Hz, 1 H), 7.89 (d, 7=6.10 Hz, 1 H), 7.76 (d, 7=8.14 Hz, 1 H), 7.54 - 7.66 (m, 2 H), 7.26 (d, J=8.14 Hz, 1 H), 7.13 - 7.23 (m, 2 H), 4.99 - 5.07 (m, 1 H), 4.34 - 4.43 (m, 1 H), 4.27 (m, 1 H), 2.15 - 2.27 (m, 1 H), 2.02 - 2.13 (m, 1 H). MS (ESI) m/e 388 (M+H)+. Calcd. For C20H16N3O2F3: C 62.01, H 4.16, N 10.85; Found C 61.82, H 4.04, N 10.46. Example 37 N-lH-indazol-4-yl-N'-[8-(trifluoromethyl)3.4-dihydro-2H-chromen-4-yl]urea Example 37A 2-Trifluoromethylphenol (3.57 g, 22 mmol), propargyl bromide (2.9 ml of 80% in toluene, 26 mmol), and potassium carbonate (3.59 g, 26 mmol) were stirred together in 40 ml of acetonitrile at ambient temperature for 24 hours. The solvent was removed under reduced pressure, and the residue taken in water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 4.23 g of Example 37A which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7.59 (d, J=7.46 Hz, 1 H), 7.51 (t, J=7.97 Hz, 1 H), 7.17 (d, 7=8.48 Hz, 1 H), 7.06 (t, 7-7.63 Hz, 1 H), 4.80 (d, 7=2.37 Hz, 2 H), 2.54 (t, J=2.37 Hz, 1H) Example 37B Example 37A (3.00 g, 15 mmol) was dissolved in 75 ml acetone. N-chlorosuccinimide (2.40 g, 18 mmol) and silver acetate (167 mg, 1 mmol) were added, and the reaction mixture heated to reflux for 3 hours. After cooling, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was taken up in diethyl ether, washed with water, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 4.88 g of Example 37B which was used without further purification, 1H NMR (300 MHz, CDC13) δ ppm 7.59 (d, J=7.80 Hz, 1 H), 7.52 (t, J=7.97 Hz, 1 H), 7,04 - 7.15 (m, 2 H), 4.80 (s, 2 H). Example 37C Example 37B (4.88 g, 20.8 mmol) was dissolved in 100 ml of concentrated sulfuric acid at 0 C. The reaction mixture was stirred at ambient temperature for 2.5 hours, then poured onto ice. The mixture was extracted with diethyl ether, and the combined organic layers washed with saturated aqueous sodium bicarbonate, dried with magnesium sulfate and filtered. The solvent was removed under reduced pressure, and the residue purified via flash chromatography, eluting with 10% ethyl acetate in hexanes to provide 0.55 g of Example 37C along with 0.52 g of recovered starting material. 1H NMR (300 MHz, CDC13) δ ppm 8.10 (dd, J=7.80,1.70 Hz, 1 H), 7.77 (d, J=8.48 Hz, 1 H), 7.10 (t, J=7.46 Hz, 1 H), 4.61 - 4.70 (m, 2 H), 2.83 - 2.92 (m, 2 H). MS (DCI) m/e 234 (M+NH4)+ Example 37D A solution of Example 37C (0.55 g, 2.5 mmol) in 6 ml pyridine was treated with methoxylamine hydrocbloride (0.42 g, 5 mmol) and stirred at ambient temperature for 16 hours. The pyridine was removed under reduced pressure, and the residue partitioned between water and ethyl acetate. The mixture was extracted with ethyl acetate, and the combined organic layers dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 0.61 g of Example 37D which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 8.09 (d, J=6.78 Hz, 1 H), 7.54 (d, J=7.46 Hz, 1 H), 6.99 (t, J=8.31 Hz, 1 H), 4.31 (t, J=6.27 Hz, 2 H), 4.00 (s, 3 H), 2.95 (t, J=6.27 Hz, 2 H). MS (CI) m/e 246 (M+H)+. Example 37B Example 37D (0,61 g, 2.5 mmol), 120 mg of 10% palladium on carbon, and 20 ml of 20% ammonia in methanol were shaken under hydrogen at 60 psi and ambient temperature for 2.5 hours. The catalyst was removed by filtration and the solvent evaporated under reduced pressure. The residue was taken in diethyl ether, extracted with 1N hydrochloric acid, and the acid extracts made basic with 10 N aqueous sodium hydroxide solution. The aqueous extracts were extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, filtered, and the solvent removed under reduced pressure to give 0.50 g of Example 37E. 1H NMR (300 MHz, CDC13) δ ppm 7.51 (d, J=7.12 Hz, 1 H), 7.45 (d, .7=7.80 Hz, 1 H), 6.94 (t, J=7.46 Hz, 1 H), 4.30 - 4.44 (m, 2 H), 4.08 - 4.19 (m, 1 H), 2.16-2.27 (m, 1H), 2.21 (br, 2 H, NH2), 1.85 - 1.98 (m, 1 H). MS (CI) m/e 218 (M+H)+ Example 37F methyl 4-[(([8-(trifluoromethyl)3,4-dihydro-2H-chromen-4-yl]amino}carbonyl)amino]-1H- indazole-1 -carboxylate Example 37E (0.50 g, 2.3 mmol), Example 24D (0.76 g, 2.3 mmol), and diisopropylethylamine (0.44 g, 0,6 ml, 3.4 mmol) were dissolved in 4 ml of N,N-dimethylformamide. The reaction was stirred at ambient temperature for 16 hours, and diluted with water. The precipitate formed was collected by filtration and air-dried to give 0.68 g of the titled compound which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.88 (s, 1 H), 8,39 (s, 1 H), 7.85 (d, J=7.80 Hz, 1 H), 7.71 (d, J=8.48 Hz, 1 H), 7.62 (d, J=7.80 Hz, 1 H), 7.53 - 7.58 (m, 2 H), 7.08 (t, J=7.63 Hz, 1 H), 6.98 (d, J=7.80 Hz, 1 H), 4.98 - 5.05 (m, 1 H), 4.41 - 4.49 (m, 1 H), 4.27 - 4.35 (m, 1 H), 4.03 (s, 3 H), 2.07 - 2.23 (m, 2 H). MS (ESI) m/e 435 (M+H)+ (m, 1 H), 2.01 - 2.12 (m, .7=6.91, 6.91, 6.70, 3.22 Hz, 1 H). MS (ESI) m/e 377 (M+H)+. Calcd. For C18H15N4O2F3: C 57.45, H 4.02, N 14.89; Found C 57.51, H 3.91, N 14.74. Example 40 N-lH-indazol-4-yl-N'-(8-piperidin-l-yl-3.4-dihydro-2H-chromen-4-yl')urea Example 40A methyl 4-({[(8-piperidin-l-yl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H- indazole-1 -carboxylate A solution of Example 33D (0.37 g, 1.6 mmol), Example 24D (0.53 g, 1.6 mmol), and diisopropylethylamine (0.52 g, 0.7 ml, 4 mmol) in 4 ml of N,N-dimethylformamide was stirred at ambient temperature for 16 hours, then diluted with water. The precipitate that formed was collected by filtration and air-dried to give 0.54 g of Example 40A which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.80 (s, 1 H), 8.37 (s, 1 H), 7,88 (d, ,J=8.14 Hz, 1 H), 7.69 (d, J=8.48 Hz, 1 H), 7.50 (t, J=8,14 Hz, 1 H), 6.88 -6.94 (m, 1 H), 6.79 - 6.88 (m, 3 H), 4.87 (d, ,J=7.46 Hz, 1 H), 4.28 - 4.37 (m, 1 H), 4.1 1 - 4.20 (m, 1 H), 4.03 (s, 3 H), 2.82 - 2.96 (m, 4 H), 2.08 (ddd, J=17.97, 8.99, 4.92 Hz, 2 H), 1.63 (br s, 4 H), 1.52 (br s, 2 H). MS (ESI) m/e 450 (M+H)+ Example 40B N-lH-indazol-4-yl-N'-(8-piperidin-1-yl-3,4-dihydro-2H-chromen-4-yl)urea A solution of Example 40A (0.54 g, 1,2 mmol) in a mixture of 5 ml tetrahydrofuran and 5 ml methanol was treated with sodium hydroxide (5M in methanol, 2.4 ml, 12 mmol) and stirred at ambient temperature for 45 minutes. The reaction mixture was diluted with water, and the precipitate that formed was collected by filtration to give 329 mg of title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.96 (br s, 1H), 8.56 (s, 1 H), 8.00 - 8.03 (m, 1 H), 7.69 (d, .7=7.80 Hz, 1 H), 7.18 - 7.27 (m, 1 H), 7.06 (d,J=8.48 Hz, 1 H), 6.78 - 6.94 (m, 4 H), 4.83 - 4.88 (m, 1 H), 4.30 - 4.37 (m, 1 H), 4.11 - 4.20 (m, 1 H), 2.82 - 2.91 (m, 4 H), 1.98 - 2.14 (m, 2 H), 1.63 (br s, 4 H), 1.52 (br s, 2 H). MS (ESI) m/e 392 (M+H)+ Calcd. For C12H25N5O2●0.2 trttahydiofuran●0.1H2O: C 61.17,H6.63,N 17.18; Found C 67,09,H 6.45, N 17.04. Example 41 N-lH-indazol-4-yl-Nt-(8-morpholin-4-yl-3.4-dihydro-2H-chromen-4-yl)urea Example 41A Example 33B (1.02 g, 3.5 mmol), morpholine (0.37 g, 0.37 ml, 4.2 mmol), sodium tert-butoxide (0,51 g, 5.3 mmol), tris(dibenzylidineacetone)dipal3adium(0) (0.18 g, 0.2 mmol), and 2,2'-bis(diphenylphosphino)-l ,1'-binaphthalene (0.37 g, 0.6 mmol) were combined in 40 ml toluene. The reaction mixture was heated to reflux for four hours, at which point an additional 0.10 g of tris(dibenzylidineacetone)dipalladium(0) was added, continued to reflux for 16 hours longer, cooled, diluted with diethyl ether, and filtered through celite. The filtrate was evaporated under reduced pressure and the residue purified by flash chromatography using 20% ethyl acetate in hexanes as eluent to give 0.63 g of Example 41A. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.60 (d, J=2.71 Hz, 1 H), 6.87 (s, 1 H), 4.25 (t, .7=6.27 Hz, 2 H), 3.99 (s, 3 H), 3.86 - 3.91 (m, 4 H), 3.02 - 3.10 (m, 4 H), 2.89 (t, J=6.27 Hz, 2 H). MS (CI) m/e 297 (M+H)+ (Cl pattern) Example 41B Example 41A (0.63 g, 2.1 mmol), 0.7 g 10% palladium on carbon, and 20 ml of 20% ammonia in methanol were shaken under 60 psi hydrogen at 50 C for 18 hours. After filtering off the catalyst, the solvent was evaporated under reduced pressure to give 0.55 g of Example 41B, which was used without further purification.,1 H NMR (300 MHz, DMSO-d6) δ ppm 8,36 (br s, 2 H, NH2), 7.14 (dd, ,J=6.78, 2.71 Hz, 1 H), 6.85 - 6.94 (m, 2 H), 4.44 (t, J=5.26 Hz, 1 H), 4.22 - 4.32 (m, 2 H), 3,66 - 3.74 (m, 4 H), 2.87 - 2.97 (m, 4 H), 2.16 - 2.30 (m, 1 H), 2.10 (td, ,J=9.75,4.58 Hz, 1 H). MS (CI) m/e 235 (M+H)+ Example 41C methyl 4-( {[(8-morpholin-4-yl-3.4-dihydro-2H-chromen-4-yl)amino]carbonyl) amino)-1 H- indazole-1 -carboxylate Example 41B (0.55 g), Example 24D (0.70 g, 2.1 mmol), and diisopropylethylamine (0.65 g, 0.9 ml, 5 mmol) were dissolved in 10 ml of N,N-dimethylfbrmamide. The reaction was stirred at ambient temperature for 16 hours, then diluted with water. The precipitate that formed was collected by filtration and air-dried to give 0.93 g of Example 41C which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.85 (s, 1 H), 8.39 (s, 1H), 7.88 (d, .7=7.80 Hz, 1H), 7.69 (d, J=8.14 Hz, 1 H), 7.50 (t, J=8.14 Hz, 1 H), 6.92 - 7.00 (m, 1 H), 6.85 (ddd, .7=18.23, 7.88,2.03 Hz, 3 H), 4.85 - 4.92 (m, 1 H), 4.28 - 4.38 (m, 1 H), 4.11 - 4.22 (m, 1 H), 4.03 (s, 3 H), 3,68 - 3.78 (m, 4 H), 2.91 - 2.98 (m, 4 H), 2.00 - 2.15 (m, 2 H). MS (ESI) m/e 452 (M+H)+ Example 41D N-lH-indazol-4-yl-N'-(8-morpholin-4-yl-3.4-diliydro-2H-cbromen-4-yl)urea Example 41C (0.93 g, 2 mmol) was dissolved in a mixture of 10 ml tetrahydrofuran and 5 ml methanol. Sodium hydroxide (5M in methanol, 4 ml, 20 mmol) was added, and the reaction stirred at ambient temperature for 1 hour. The reaction mixture was diluted with water, and the precipitate that formed was collected hy filtration to give 0.57 g of title compound. 1HNMR (300 MHz, DMSO-d6) δ ppm 13.00 (s, 1 H), 8.54 (s, 1 H), 8.01 (s, 1 H), 7.69 (d, J=7.80 Hz, 1 H), 7.18 - 7.25 (m, 1 H), 7.06 (d, J=8.48 Hz, 1 H), 6.92 - 6.99 (m, 1 H), 6.80 - 6.90 (m, 3 H), 4.84 - 4.90 (m, 1 H), 4.30 - 4.38 (m, 1 H), 4.09 - 4.20 (m, 1 H), 3.73 (t, J=4.41 Hz, 4 H), 3.60 (m, 0.2 H, tetrahydrofuran), 2.95 (m, 4 H), 1.99 - 2.15 (m, 2 H), 1.76 (m, 0.2 H, tetrahydrofuran). MS (ESI) m/e 394 (M+H)+. Calcd. For C21H23N5O3●0.1 tetrahydrofuran●0.2H2O: C 63,58, H 6.03, N1732; Found C 63.68, H 5.68, N 17.10. Example 42 N-(8-tert-butyl-3.4-dihvdro-2H-chromen-4-yl)-Nt-lH-indazol-4-ylurea Example 42 A 2-tert-butylphenol (15.02 g, 15.4 ml, 100 mmol), propargyl bromide (14.3 ml of 80% in toluene, 128 mmol), and potassium carbonate (17.66 g, 128 mmol) were stirred together in 200 ml of acetonitrile at ambient temperature for 5 days. The solvent was removed under reduced pressure, and the residue taken into water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 18.86 g of Example 42A which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.30 (dd, J=7.80,1.70 Hz, 1 H), 7.15 - 7.22 (m, 1 H), 6.90 - 6.98 (m, 2 H), 4.73 (d, /-2.37 Hz, 2 H), 2.48 (t, J-2.37 Hz, 1 H), 1.39 (s, 9 H). MS (DCI) m/e 206 (M+NH4)+ Example 42B Example 42A (18.86 g, 100 mmol) was dissolved in 400 ml acetone, N-chlorosuccinimide (16.02 g, 120 mmol) and silver acetate (1.67 g, 10 mmol) were added, and the reaction mixture heated to reflux for 4 hours. After cooling, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was taken up in diethyl ether, washed with water and saturated aqueous sodium bicarbonate, dried with magnesium sulfate, and filtered. The solvent removed under reduced pressure to give 26.13 g of Example 42B which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.30 (dd, J=7.97,1.53 Hz, 1 H), 7.19 (td, J=7.71,1.86 Hz, 1 H), 6.91 - 6.97 (m, 2 H), 4.73 (s, 2 H), 1.38 (s, 9 H). MS (DCI) m/e 223 (M+H)+ Example 42C Example 42B (25.8 g) in 250 ml ethylene glycol was heated to reflux for 4 hours. The reaction mixture was cooled, poured into water, and extracted with diethyl ether. The organic layers were combined, washed with 1N sodium hydroxide and saturated ammonium carbonate sequentially, dried with magnesium sulfate, and filtered. Removal of solvent under reduced pressure gave a residue. The residues were filtered through a pad of silica gel with 1:1 methylene chloride-.hexanes, and the filtrate-evaporated under reduced pressure to give 13.51 g of Example 42C. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.81 (dd, J=7.80, 1.70 Hz, 1 H), 7.47 (dd, J=7.63, 1.86 Hz, 1 H), 6.95 (t, J=7,80 Hz, 1 H), 4.51 - 4.58 (m, 2 H), 2,79 - 2.85 (m, 2 H), 1.39 (s, 9 H). MS (DCI) m/e 205 (M-H)+ Example 42D Example 42C (13.51 g, 66 mmol) was dissolved in 100 ml pyridine. Methoxylamine hydrochloride (10 g, 120 mmol) was added and the reaction mixture stirred at ambient temperature for 16 hours. The pyridine was removed under reduced pressure, and the residue partitioned between water and diethyl ether. The mixture was extracted with diethyl ether, and the combined organic layers washed with 1N sodium hydroxide and IN hydrochloric acid sequentially, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 14,44 g of Example 42D which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.79 (dd, ,7=7.80,1.70 Hz, 1 H), 7.21 - 7.27 (m, 1 H), 6.87 (t, .J=7.80 Hz, 1 H), 4.18 (t, J=6.27 Hz, 2 H)s 3.98 (s, 3 H), 2.91 (t, J=6.27 Hz, 2 H), 1.36 (s, 9 H). MS (DCI) m/e 234 (M+H)+ Example 42E Example 42D (14.44 g, 61.9 mmol), 1.5 g of 10% palladium on carbon, and 400 ml of 20% ammonia in methanol were shaken under hydrogen at 60 psi and ambient temperature for 2.5 hours. The catalyst was removed by filtration and the Solvent evaporated under reduced pressure, giving 13.50 g of Example 42E which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.14 - 7.24 (m, 3 H) 6.81 - 6.89 (m, 1 H) 4.22 - 4.29 (m, 2 H) 4.11 (t, J=5.09 Hz, 1 H) 2.10 - 2.25 (m, 1 H) 1.90 (td, J=9.16, 4.07 Hz, 1 H) 1.34 - 1.37 (m, 9 H). MS (DCI) m/e 206 (M+H)+ Example 42F methyl 4-({[(8-tert-butyl-3,4-dihydro-2H-chromen-4-yl)amino]carbonyl}amino)-1H- indazole-1 -carboxylate Example 42E (12.32 g, 60 mmol), Example 24D (19.94 g, 60 mmol), and diisopropylethylamine (11.63 g, 16 ml, 90 mmol) were dissolved in 100 ml of N,N-dimethylformamide. The reaction was stirred at ambient temperature for 16 hours, and diluted with water The precipitate that formed was collected by filtration, air-dried, and then triturated with a mixture of diethyl ether and hexanes to give 20.6 g of the titled compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.77 (s, 1 H), 8.35 (s, 1 H), 7.89 (d, J=7.46 Hz, 1 H), 7.69 (d, J=8,48 Hz, 1 H), 7.46 - 7.55 (m, 1 H), 7.16 (dd, J=8.14, 2.37 Hz, 2 H), 6.83 - 6.93 (m, 2 H), 4.86 - 4.92 (m, 1 H), 4.32 - 4.40 (m, 1 H), 4.09 - 4.20 (m, 1 H), 4.03 (s, 3 H), 2.09 (ddd, J=17.88, 8.90, 4.75 Hz, 2 H), 1.34 (s, 9 H). MS (ESI) m/e 423 (M+H)+ Example 42G N-(8-tert-butyl-3.4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea Example 42F (20.6 g, 48 mmol) was dissolved in a mixture of 100 ml tetrahydrofuran and 75 ml methanol. Sodium hydroxide (5M in methanol, 50 ml, 250 mmoJ) was added, and the reaction mixture stirred at ambient temperature for 30 minutes. The reaction mixture was diluted with water, and the precipitate that formed was collected by filtration, giving 15.70 g of the titled compound. 1HNMR (300 MHz, DMSO-d6) δ ppm 13.00 (s, 1 H), 8.51 (s, 1 H), 8.01 (s, 1 H), 7.69 (d, J=7.46 Hz, 1 H), 7.13 - 7.25 (m, 3 H), 7.06 (d, J=8.14 Hz, 1 H), 6.83 -6.94 (m, 2 H), 4.84 - 4.91 (m, 1 H), 4.37 (dt, J=10.85,4.24 Hz, 1 H), 4.06 - 4.19 (m, 1 H), 1.99 - 2.14 (m, 2 H), 1.35 (s, 9 H). MS (ESI) m/e 365 (M+H)+ Example 43, N-[8-chloro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]-N'-lH-indazol-4-ylurea Example 43 A 2-Chloro-3-trifluoromethylphenoI (4.91 g, 3.3 nil, 25 mmol), propargyl bromide (3.6 ml of 80% in toluene, 32 mmol), and potassium carbonate (4.42 g, 32 mmol) were stirred together in 40 ml of acetonitrile at ambient temperature for 6 days. The solvent was removed under reduced pressure, and the residue taken in water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate and filtered. The solvent was evaporated under reduced pressure to give 5.63 g of Example 43A which was used without former purification, 1H MMR (300 MHz, CHLOROFORM-D) δ ppm 7.26 - 7.38 (m, 3 H), 4.83 (d, J=2.37 Hz, 2 H), 2.56 (t, J=2.54 Hz, 1 H) Example 43B -Example 43A (5,35 g, 22.8 mmol) was dissolved in 120 ml acetone. N- chlorosuccinimide (3.87 g, 29 mmol) and silver acetate (0.33 g, 2 mmol) were added, and the reaction heated to reflux for 5.5 hours. After cooling, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was talcen up in diethyl ether, washed with water, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 6.06 g of Example 43B which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.31 - 7.39 (m, 3 H), 4.83 (s, 2 H) Example 43C Example 43B (5.96 g, 22 mmol) was dissolved in a mixture of 50 ml methanesulfonic acid and 150 mL concentrated sulfuric acid.. The reaction was stirred at ambient temperature for 16 hours, then poured onto ice and extracted with diethyl ether. The combined organic layers were washed with saturated aqueous sodium bicarbonate, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 4.70 g of crude product. The crude product was filtered through a pad of silica gel with 10% ethyl acetate in hexanes. After removing the solvent under reduced pressure, the residue was taken in diethyl ether, washed with 1N sodium hydroxide, dried with magnesium sulfate, and filtered. The solvent was evaporated to give 1.43 g of Example 43C. 1H NMR (300 MHz, CDC13) δ ppm 7.91 (d, J=8.48 Hz, 1H), 7.33 - 7.40 (m, 1 H), 4.67 - 4.75 (m, 2 H), 2.86 - 2.94 (m, 2 H) Example 43D Example 43C (1.43 g, 5.7 mmol) was dissolved in 35 ml pyridine. Methoxylamine hydrochloride (0.83 g, 10 mmol) was added and the reaction stirred at ambient temperature for 3 days. The pyridine was removed under reduced pressure, and the residue taken into diethyl ether. The ether solution was washed with water and 1N hydrochloric acid sequentially, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 1.29 g of Example 43D which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7.89 - 7.94 (m, 1H), 7.23 - 7.27 (m, 1 H), 4.32 - 4.38 (m, 2 H), 4.02 (s, 3 H), 2.91 - 2.97 (m, 2 H). MS (DCI) m/e 280 (M+H)+ Example 43E Example 43D (1.29 g, 4,6 mmol) was dissolved in 40 ml of 20%,ammonia in methanol, and hydrogenated using 4g of Raney nickel, under 60 psi hydrogen at ambient temperature for four hours. The catalyst was removed by filtration, and the filtrate evaporated under reduced pressure. The residue was taken in diethyl ether, washed with water and saturated aqueous ammonium chloride sequentially, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 0.85g of Example 43B. 1H NMR (300 MHz, CDC13) δ ppm 7.31 - 7.39 (m, 1 H), 7.20 - 7.28 (ms 1 H), 4.36 - 4.50 (m, 2 H), 2.14 - 2.30 (m, J=13.52, 8.86,4.75,4.41 Hz, 2 H), 1.88 - 2.00 (m, 1 H). MS (DCI) m/e 252 (M+H)+ Example 43F methyl 4-[({[8-chloro-7-(trifluoromethyl)-3,4-dinydro-2H-chromen-4- yl]aminolcarbonyl)amino]-lH-indazole-I-carboxylate Example 43E (0.85 g, 3.4 mmol), Example 24D (1.13 g, 3.4 mmol), and diisopropylethylamine (0.90 g, 1.25 ml, 7 mmol) were dissolved in 15 ml of N,N-dimethylformamide. The reaction mixture was stirred at ambient temperature for 3 days, and diluted with water. The precipitate that formed was collected by filtration, and air-dried to give 1.10 g of the titled compound which was used without further purification. 1H NMR (300 MHz, DMSO-ds) δ ppm 8.99 (s, 1 H), 8.42 (s, 1 H), 7.83 (d, J=7.46 Hz, 1 H), 7.72 (d, J=8.14 Hz, 1 H), 7.51 (t, J=7-97 Hz, 2 H), 7.36 - 7.43 (rn, 1 H), 6.99 (d, J=8.14 Hz, 1 H), 5.10 (d, .7=6.78 Hz, 1 H), 4.37 - 4.51 (m, 2 H), 4,03 (s, 3 H), 2.09 - 2,24 (m, 2 H). MS (ESI) m/e 469(M+H)+ Example 43G N-[8-chloro-7-(trifiuoromethyl)3,4-dihydro-2H-chromen-4-yl]-N'-1H-indazol-4-ylurea Example 43F (1.10 g, 2.48 mmol) was dissolved in a mixture of 5 ml tetrahydrofuran and 5 ml methanol. Sodium hydroxide (5M in methanol, 4 ml, 20 mmol) was added, and the reaction stirred at ambient temperature for 40 minutes. The reaction was diluted with water, and the precipitate that formed was collected by filtration, giving 0.85 g of title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 13.01 (s, 1 H), 8.69 (s, 1 H), 8.06 (s, 1 H), 7.65 (d, J=7.46 Hz, 1 H), 7.47 - 7.53 (m, 1 H), 7.34 - 7.42 (m, 1 H), 7.23 (t, .7=7.80 Hz, 1 H), 7.09 (d, J=8.14 Hz, 1 H), 6.97 (d, J=8.14 Hz, 1 H), 5.04 - 5.12 (m, 1 H), 4.51 (ddd, J=l 1.02,7.63, 3.05 Hz, 1 H), 4.36 - 4.45 (m, 1 H), 2.08 - 2.23 (m, 2 H). MS (ESI) m/e 411 (M+H)+. Calcd For C18H14N4O2ClF3●0.4NaOH●0.35tetrahydroruran: C 51.55, H 3.84, N 12.39; Found C 51.77, H 3.48, N 12.10. Example 44 (+)-N-(8-tert-butyl-3.4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea Example 42G was resolved by chiral HPLC (Column: Chiracel OD (5 cm ID x50 cm); mobile phase: 90:5:5 hexanes:ethanol:methanol) to give title compound, [α]D = +114 degrees (c=l.l 10, ethanol).1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 1 H), 8.02 (s, 1 H), 7.69 (d, J=7.12 Hz, 1 H), 7,13 - 7.24 (m, 3 H), 7.06 (d, J=8.14 Hz, 1 H), 6.95 (d, J=7.12 Hz, 1 H), 6.86 (t, J=7.63 Hz, 1 H), 4.84 - 4.92 (m, 1 H), 4.32 - 4.41 (m, 1 H), 4.09 - 4.19 (m, 1 H), 1.99 - 2.14 (m, 2 H), 1.35 (s, 9 H). MS (ESI) m/e 365 (M+H)+. Calcd. For C21H24N4O2●0.5H2O: C 67.54, H 6.75, N 15,00; Found C 67.35, H 6.47, N 14.88. Example 45 (-)-N-(8-tert-butyl-3.4-dihydro-2H-cbromen-4-yl)-N'-lH-indazol-4-ylurea Example 42G was resolved by chiral HPLC (Column: Chiracel OD (5 cm ID x 50 cm); mobile phase: 90:5:5 hexanes:ethanolmethanol) to give title compound. [α]D = -107 degrees (c=1.075, ethanol). 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 1 H), 8.02 (s, 1 H), 7.69 (d, J=7.46 Hz, 1 H), 7.13 - 7.25 (m, 3 H), 7.06 (d, J=8.14 Hz, 1 H), 6.95 (d, J=7.12 Hz, 1 H), 6.82 - 6.90 (m, 1 H), 4,85 - 4.92 (m, 1 H), 4.32 - 4.41 (m, 1 H), 4.09 - 4.19 (m, 1 H), 1.99 - 2.15 (m, 2 H), 1.35 (s, 9 H). MS (ESI) m/e 365 (M+H)+. Calcd. For C21H24N4O2●0.6H2O: C 67.22, H 6.77, N 14.93; Found C 67.18, H 6.42, N 14.92. Example 46 N-lH-indazol-4-yl-N'-[8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea Example 46A 2-Trifluoromethoxyphenol (5.0 g, 28 mmol), propargyl bromide (4 ml of 80% in toluene, 36 mmol), and potassium carbonate (4.97 g, 36 mmol) were stirred together in 70 ml of acetonitrile at ambient temperature for 2 days. The solvent was removed under reduced pressure, and the residue taken in water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 5.60 g of Example 46A which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7.23 - 7.30 (m, 2 H), 7.13 - 7.19 (m, 1 H), 6.95 - 7.04 (m, 1 H), 4.77 (d, J=2.37 Hz, 2 H), 2.53 (t, J=2.37 Hz, I H). Example 46B Example 46A (5.60 g, 26 mmol) was dissolved in 125 ml acetone. N-chlorosuccinimide (4.00 g, 30 mmol) and silver acetate (0.42 g, 2.5 mmol) were added, and the reaction mixtureheated to reflux for 4 hours. After cooling to ambient temperature, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was taken up in diethyl ether, washed with water, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 5.80 g of Example 46B which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.24 - 7.30 (m, 2 H), 7.09 - 7.15 (m, 1 H), 7.01 (td, J=7.80,1.36 Hz, 1 H), 4.77 (s, 2 H). MS (DCI) m/e 268 (M+NH4)+ Example 46C Example 46B (25.8 g) in 250 ml ethylene glycol was heated to reflux for 4 hours. The reaction mixture was cooled, poured into water, and extracted with diethyl ether. The organic layers were dried with magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was taken in hexanes, washed with 1N sodium hydroxide, and concentrated. The residue was purified by flash chromatography using 10% ethyl acetate in hexanes as eluent to provide 1.20 g of Example 46C. 1H NMR (300 MHz, CDC13) δ ppm 7.86 (dd, J=8.14,1.70 Hz, 1 H), 7.44 (d, J=7.80 Hz, 1 H), 6.98 - 7.05 (m, 1 H), 4.60 - 4.66 (m, 2 H), 2.84 - 2.90 (m, 2H). Example 46D Example 46C (1.20 g, 5.17 mmol) was dissolved in 10 ml pyridine. Methoxylamine hydrochloride (0.67 g, 8 mmol) was added and the reaction stirred at ambient temperature for 3 days. The pyridine was removed under reduced pressure, and the residue partitioned between water and diethyl ether. The mixture was extracted with diethyl ether, and the combined organic layers washed with 1N hydrochloric acid and saturated aqueous sodium bicarbonate sequentially. The organic layer was then dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 1.05 g of Example 46D which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7.85 (dd, J=8.14,1.36 Hz, 1 H), 7.16 - 7.24 (m, 1 H), 6.91 (t, J=8.14 Hz, 1 H), 4.23 - 4.31 (m, 2 H), 3.99 (s, 3 H), 2.93 (t, J=6.27 Hz, 2 H). MS (DCI) m/e 262 (M+H)+. Example 46E Example 46D (1.05 g, 4.25 mmol), 0.25 g of 10% palladium on carbon, and 50 ml of 20% ammonia in methanol were shaken under hydrogen at 60 psi and ambient temperature for 18 hours. The catalyst was removed by filtration and the solvent evaporated under reduced pressure. The residue was taken in diethyl ether, extracted with 1N hydrochloric acid, and the acid extracts made basic with 10N sodium hydroxide solution. The combined basic aqueous extracts were then extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate and filtered. The solvent was removed under reduced pressure to give 0.67 g of Example 46E. 1H NMR (300 MHz, CDC13) δ ppm 7,21 -7.30 (m, 1 H), 7.11 (d, J=8.14 Hz, 1 H), 6.87 (t, J=7.97 Hz, 1 H), 4.26 - 4.40 (m, 2 H), 4.04 -4. 12 (m, 1 H), 2. 10 - 2.23 (m, 1 H), 1 .82 - 1 .93 (m, 1 H). MS (DCI) m/e 234 (M+H)+. Example 46F methyl 4-[( { [8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]amino) carbonyl)amino]- 1H-indazole-l-carboxylate Example 49E (0.61 g, 2.6 mmol), Example 24D (0.83 g, 2.6 mmol), and diisopropylethylamine (0.52 g, 0.7 ml, 4 mmol) were dissolved in 10 ml of N,N-dimethylformamide. The reaction was stirred at ambient temperature for 1 6 hours, and diluted with water. The precipitate that formed was collected by filtration, and air-dried to give 1.03 g of the titled compound which was used without further purification. 1H NMR (300 MHz, DMSOD6) δ ppm 8.87 (s, 1 H), 839 (s, 1 H), 7.86 (d, J=7.80 Hz, 1 H), 7.71 (d, J=8.48 Hz, 1 H), 7.51 (t, J=8.14 Hz, 1 H), 7.37 (d, J=7.80 Hz, 1 H), 7.29 (d, J=8.14 Hz, 1 H), 6.90 - 7.03 (m, 2 H), 5.00 (d, J=7.12 Hz, 1 H), 437 - 4.46 (in, 1 H), 4.20 - 4.32 (m, 1 H), 4.03 (s, 3 H), 2.06 - 2,21 (m, 2 H). MS (ESI) m/e 451 (M+H)+. Example 46G N-lH-indazol-4-yl-N'-[8-(trifluoromethoxy)-3.4-diliydro-2H-chromen-4-yl]urea Example 46T (1.03 g, 1.5 mmol) was dissolved in a mixture of 5 ml tetrahydrofuran and 10 ml methanol. Sodium hydroxide (5M in methane}, 2 ml, 10 mmol) was added, and the reaction mixture stirred at ambient temperature for 40 minutes. The reaction mixture was diluted with water, and the precipitate that formed was collected by filtration, giving 0.82 g of titled compound. 1HNMR (300 MHz, DMSO-d6) δ ppm 13.00 (s, 1 H), 8,60 (s, 1H), 8.04 (s, 1 H), 7.67 (d, J=7.12 Hz, 1 H), 7.37 (d, J=7.80 Hz, 1 H), 7.19 - 7.32 (m, 2 H), 7,08 (d, J=8.14 Hz, 1 H), 6.91 - 7.03 (m, 2 H), 4.91 - 5.02 (m, 1 H), 4.38 - 4.46 (m, 1 H), 4.25 (ddd, J=1 1.44, 8.56,3.05 Hz, 1 H), 2,04 - 2.20 (in, 2 H). MS (ESI) m/e 393 (M+H)4. Calcd. For C18H15N4O3F3: C 55.11, H 3.85, N 14.28; Found C 54.92, H 3.74, N 14.04. Example 47 N-[8-fluoro-7-(trifluoromemyl)-3,4-dihydro-2H-chromen-4-yl]-N'-lH-indazol-4-ylurea Example 47A 2-Fluoro-3-trifluoromethylphenol (4.39 g, 24 mmol), propargyl bromide (3.6 ml of 80% in toluene, 32 mmol), and potassium carbonate (4.42 g, 32 mmol) were stirred together in 50 ml of acetonitrile at ambient temperature for 6 days. The solvent was removed under reduced pressure, and the residue taken in water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 5.05 g of Example 47A which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7.32 (td, J=7.71,1.86 Hz, 1 H), 7.14 - 7.26 (m, 2 H), 4.81 (d, J=2.37 Hz, 2 H), 2.56 (t, J=2.37 Hz, 1 H) Example 47B Example 43A (5.05 g, 23 mmol) was dissolved in 100 ml acetone. N-chlorosuccinimide (3.74 g, 28 mmol) and silver acetate (0.33 g, 2 mmol) were added, and the reaction heated to reflux for 4.5 hours. After cooling, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was triturated with hexanes and filtered. The filtrate evaporated under reduced pressure to give 4.97 g of Example 47B which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.17 - 7.32 (m, 3 H), 4.81 (s, 2 H) Example 47C Example 47B (4.97 g, 19,7 mmol) was dissolved in 100 ml of concentrated sulfuric acid. The reaction mixture was stirred at ambient temperature for 16 hours, then poured onto ice and extracted with diethyl ether. The combined organic layers were washed with saturated aqueous sodium bicarbonate, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure, to give crude product. The crude product was taken in diethyl ether, washed with two portions of 1N sodium hydroxide, dried with magnesium sulfate, and filtered through a pad of silica gel. Evaporation of the filtrate gave 1.80 g of Example 47C. 1H NMR (300 MHz, CDC13) δ ppm 7.76 (d, J=8.48 Hz, 1 H), 7.07 (m, 1 H), 4.66 - 4.72 (m, 2 H), 2,88 - 2.95 (m, 2 H) Example 47D Example 47C (1.80 g, 7.7 mmol) was dissolved in 15 ml pyridine. Methoxylamine hydrochloride (1.00 g, 12 mmol) was added and the reaction mixture stirred at ambient temperature for 16 hours. The pyridine was removed under reduced pressure, and the residue taken into diethyl ether. The ether solution was washed with water, 1N hydrochloric acid and saturated aqueous sodium bicarbonate sequentially, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give crude product The crude product was filtered through a pad of silica gel with hexanes, and the solvent evaporated to give 1.00 g of Example .47D. 1H NMR (300 MHz, CHLOROFORM-D) 5 ppm 7.74 (d, J=7.80 Hz, 1 H), 7.09 (dd, J=8.48, 6.44 Hz, 1 H), 4.29 - 4.35 (m, 2 H), 4.02 (s, 3 H), 2.95 (t, J=6.27 Hz, 2 H). MS (DO) m/e 264 (M+H)+ Example 47E Example 47D (LOO g, 3.8 mmol), 0,20 g of 10% palladium on carbon, and 30 ml of 20% ammonia in methanol were shaken under hydrogen at 60 psi and ambient temperature for 18 hours, The catalyst was removed by filtration, and the solvent evaporated under reduced pressure to give 0.63 g of Example 47E. 1H NMR (300 MHz, CDC13) δ ppm 7.15 -7.21 (m, 1 H), 7.02 - 7.13 (m, 1 H), 4.30 - 4.45 (m, 2 H), 4.10 (t, .7=5.42 Hz, 1 H), 2.11 - 2.25 (m, 1 H), 1.84 - 1.98 (m, .7=13.90,6.10,6.10,3.39 Hz, 1 H). MS (DCI) m/e 236 (M+H)+, Example 47F methyl 4-[({[8-fluoro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4- yl]amino}carbonyl)amino]-lH-indazole-l-carboxylate Example 43E (0.63 g, 2.7 mmol), Example 24D (0.86 gr 2.7 mmol), and diisopropylethylamine (0.65 g, 0.9 ml, 5 mmol) were dissolved in 10 ml of N,N-dimethylformamide. The reaction mixture was stirred at ambient temperature for 24 hours, then diluted with water. The precipitate that formed was collected by filtration, and air-dried to give 0.87 g of the titled compound which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.99 (s, 1 H), 8.42 (s, 1H), 7.83 (d, .7=7.46 Hz, 1H), 7.72 (d, J=8.48 Hz, 1 H), 7.51 (t, .7=8.14 Hz, 1 H), 7.31 - 7.39 (m, 1 H), 7,19 - 7.29 (m, 1 H), 6.98 (d, J-8.14 Hz, 1 H), 5.03 - 5.13 (m, 1 H), 4.34 - 4.50 (m, 2 H), 4.03 (s, 3 H), 2.09 - 2.24 (m, 2 H). MS (ESI) m/e 453 (M+H)+. Example 47G N-[8-fluoro-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl] -N'-1H-indazol-4-ylurea Example 47F (0.87 g, 1.9 mmol) was dissolved in a mixture of 5 ml tetrahydrofuran and 5 ml methanol. Sodium hydroxide (5M in methanol, 2 ml, 10 mmol) was added, and the reaction stirred at ambient temperature for 40 minutes. The mixture was diluted with water, and the precipitate that formed was collected by filtration, giving 0.68 g of titled compound 1H NMR (300 MHz, DMSO-d6) δ ppm 13.01 (br s, 1 H), 8.75 (s, 1 H), 8.05 - 8.08 (m, 1 H), 7.65 (d, J=7.46 Hz, 1 H), 7.32 - 7.37 (m, 1 H), 7.16 - 7.28 (m, 2 H), 7.09 (d, .7=8.14 Hz, 1 H), 6.94 - 7.05 (m, 1 H), 5.07 (d, .7=6.10 Hz, 1 H), 4.47 (ddd, J=l 1.10,7.71,3.22 Hz, 1 H), 433 - 4.41 (m, J=7.37,7.37,3.56,3.39 Hz, 1 H), 2.18 - 2.27 (m, 1 H), 2.12 (qd, .7=7.06, 3.22 Hz, 1 H). MS (ESI) m/e 395 (M+H)+. Calcd. For C18H14O2F4●0.25H2O: C 54.21, H 3.66, N 14.05; Found C 54.25, H 3.80, N 13.76. Example 48 N-(8-cyclohexyl-3,4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea Example 48A 2-cyclohexylphenol (5.29 g, 30 mmol), propargyl bromide (4.2 ml of 80% in toluene, 38 mmol), and potassium carbonate (5,24 g, 38 mmol) were stirred together in 70 ml of acetonitrile at ambient temperature for 5 days. The solvent was removed under reduced pressure, and the residue taken into water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 6.60 g of Example 48 A which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7.12 - 7.24 (m, 2 H), 6.91 - 7.00 (m, 2 H), 4.71 (d, J=2.37 Hz, 2 H), 2.90- 3.02 (m, 1 H), 2.49 (t, J=2.37 Hz, 1 H), 1.72 -1.87 (m, 5 H), 1.34 - 1.47 (m, 4 H), 1.22 -1.32 (m, 1 H). MS (DCI) m/e 232 (M+NH4)+. Example 48B Example 48A (6.60 g, 30.8 mmol) was dissolved in 120 ml acetone. N-chlorosuccinimide (4.94 g, 37 mmol) and silver acetate (0.5 g, 3 mmol) were added, and the reaction heated to reflux for 4 hours. Thin-layer chromatography showed starting material present, so an additional 9.94 g of N-chlorosuccinimide was added, and the reaction mixture was refluxed for 16 hours longer. After cooling, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was taken up in diethyl ether, washed with water and saturated aqueous sodium bicarbonate sequentially, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 7.55 g of Example 48B which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7,12- 7.23 (m, 2 H), 6.90 - 7.00 (m, 2 H), 4.71 (s, 2 H), 2.88 - 3.01 (m, 1 H), 1.81 -1.84 (m, 5 H), 1.70 -1.79 (m, IH),1.34 -1.47 (m, 4 H), 1.18 -1.33 (m, 1 H). MS (DCI) m/e 266 (M+NH4)+. Example 48C Example 48B (7.55 g, 30 mmol) in 100 ml ethylene glycol was heated to reflux for 2.5 hours. The reaction mixture was cooled, poured into water, and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered- The solvent was evaporated under reduced pressure. The residue was purified by flash chromatography using 10% ethyl acetate in hexanes as eluent, giving 3.15 g of Example 48C. 1HNMR (300 MHz, CDC13) δ ppm 7.76 (dd, J=7.80,1.70 Hz, 1H), 7.38 (dd, J=7,46,1.70 Hz, 1 H), 6.97 (t, J=7.63 Hz, 1 H), 4.51 - 4.57 (m, 2 H), 2.87 - 2.98 (m, 1 H), 2.75 - 2.85 (m, 2 H), 1.73 - 1.89 (m, 5 H), 1.33 - 1.47 (m, 4 H), 1.26 -1.31 (m, 1 H). MS (DCI) m/e 231 (M+H)+. Example 48D Example 48C (3.15 g, 13.7 mmol) was dissolved in 25 ml pyridine. Methoxylamine hydrochloride (2.00 g, 24 mmol) was added and the reaction stirred at ambient temperature for 5 days. The pyridine was removed under reduced pressure, and the residue partitioned between water and diethyl ether. The mixture was extracted with diethyl ether, and the combined organic layers washed with 1N hydrochloric acid and saturated aqueous sodium bicarbonate sequentially, dried with magnesium sulfate, and filtered. The solvent was removed tinder reduced pressure to give 3.23 g of Example 48D which was used without further purification. 1H NMR (300MHz, CDC13) δ ppm 7.75 (dd, .7=8.14, 1.70 Hz, 1 H), 7.16 (dd, J=7.63, 1 .53 Hz, 1 H), 6.89 (t, J=7.80 Hz, 1 H), 4.20 (t, J=6.27 Hz, 2 H), 3.97 (s, 3 H), 2.89 (t, J=6.10 Hz, 2 H), 1.71 - 1.87 (m, 5 H), 1.32 - 1.45 (m, 4 H), 1.21 - 1.26 (m, 1 H). MS (DCI) m/e 260 (M+H)+. Example 48E Example 48D (3.23 g, 12.5 mmol), 0.60 g of 10% palladium on carbon, and 60 ml of 20% ammonia in methanol were shaken under hydrogen at 60 psi and ambient temperature for 16 hours. The catalyst was removed by filtration and the solvent evaporated under reduced pressure, giving 2.88 g of Example 48E which was used without further purification. 1H NMR (300 MHz, CDC13) δ ppm 7.06 - 7.16 (m, 2 H), 6.84 - 6,90 (m, 1 H), 4.22 - 4.29 (m, 2 H), 4.05 (t, J=5.26 Hz, 1 H), 2.81 - 2.95 (m, 1 H), 2.07 - 2.21 (m, J=13.44, 8.01, 521, 5.21 Hz, 1 H), 1.71 - 1.87 (m, 7 H), 1.31 - 1.46 (m, 4 H). MS (DCI) m/e 215 (M-NH2)+ 232 (M+H)*. Example 48F 83 methyl 4-( {[(8-cyclohexyl-3,4-dihydro-2H-chromen-4-yl)amino1carbonyl} amino)-lH- indazole-1 -carboxylate Example 48E (1.16 g, 5 mmol), Example 24D (1.66 g, 5 mmol), and diisopropylethylamine (1.29 g, 1.8 ml, 10 mmol) were dissolved in 20 ml of N,N-dimethylformamide. The reaction mixture was stirred at ambient temperature for 24 hours, then diluted with water. The precipitate that formed was collected by filtration to give 2.00 g of the titled compound which was used without further purification.1H NMR (300 MHz, DMSO-d6) δ ppm 8.77 (s, 1 H), 8.36 (s, 1 H), 7.88 (d, .7=7.46 Hz, 1-H), 7.69 (d, .7=8.48 Hz, 1 H),.7.50 (t, .7=8.14 Hz, 1 H), 7.12 (t, .7=7.12 Hz, 2 H), 6.84 - 6.91 (m, 2 H), 4.85 - 4.92 (m, 1 H), 4.27 - 4.38 (m, 1 H), 4.09 - 4.21 (m, 1 H), 4.03 (s, 3 H), 2.80 - 2.92 (m, 1 H), 1.99 - 2.15 (m, 2 H), 1.73 (br, 5 H), 1.27 -1.41 (m, 5 H). MS (ESI) m/e 449 (M+H)+. Example 48G N-(8-cyclohexyl-3,4-dihydro-2H-cbromen-4-yl)N'-lH-mdazol-4-ylurea Example 48F (2.00 g, 4.46 mmol) was dissolved in a mixture of 12 ml tetrahydrofuran and 12 ml methanol. Sodium hydroxide (5M in methanol, 5 ml, 25 mmol) was added, and the reaction mixture stirred at ambient temperature for 40 minutes, diluted with water, and the precipitate that formed was collected by filtration, giving 1.49 g of the titled compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.99 (s, 1 H), 8.51 (s, 1 H), 8.01 (s, 1 H), 7.69 (d, J=7.46 Hz, 1 H), 7.17 - 7,25 (m, 1 H), 7.03 - 7.15 (m, 3 H), 6.87 (t, J=7.46 Hz, 2 H), 4.84 - 4.91 (m, 1 H), 4.26 - 4.39 (m, 1 H), 4.10 - 4:24 (m, 1 H), 2.87 (m, 1 H), 1.98 - 2.14 (m, 2 H), 1.66 - 1.85 (br, 6 H), 1.28 -1.41 (m, 4 H). MS (ESI) m/e 391 (M+H)+. Calcd. For C23H26N4O2●0.2 tetrahydroruran●0.7H20: C 68.47, H 7.00, N 13.42; Found C 68.58, H 6.86, N 13.25. Example 49 N-lH-indazol-4-yl-N'-[7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea Example 49A 3-Trifluoromethoxyphenol (4.45 g, 25 mmol), propargyl bromide (3.6 ml of 80% in toluene, 32 mmol), and potassium carbonate (4.42 g, 32 mmol) were stirred together in 50 ml of acetonitrile at ambient temperature for 6 days. The solvent was removed under reduced pressure, and the residue taken in water and extracted with diethyl ether. The organic layers were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 5.00 g of Example 49A which was used without further purification. 1HNMR (300 MHz, CHLOROFORM-D) δ ppm 7.31 (t, J=8.48 Hz, 1 H), 6.90 (m, 6.87 - 6.93 2 H), 6.85 (s, 1H), 4.70 (d, J=2.71 Hz, 2 H), 2.55 (t, J=2.37 Hz, 1 H) Example 49B Example 49A (5.00 g, 23 mmol) was dissolved in 120 ml acetone. N-chlorosuccinimide (3.87 g, 29 mmol) and silver acetate (0.33 g, 2 mmol) were added, and the reaction mixture heated to reflux for 5.5 hours. After cooling, the silver salts were removed by filtration and the filtrate evaporated under reduced pressure. The residue was taken up in diethyl ether, washed with water, dried with magnesium sulfate, and filtered. The solvent was removed under reduced pressure to give 5.88 g of Example 49B which was used without further purification. 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 7.31 (t, J=8.31 Hz, 1 H), 6.81 - 6.91 (m, 3 H), 4.70 (s, 2 H) Example 49C Example 49B (5.88 g, 23 mmol) was heated to reflux in 100 ml of ethylene glycol for five hours, cooled, and poured into water. The mixture was extracted with diethyl ether. The combined organic layers were dried with magnesium sulfate and filtered. The solvent was evaporated under reduced pressure. The residue was purified by flash chromatography using 10% ethyl acetate in hexanes as eluent to give 1.49 g of Example 49C. 1H NMR (300 MHz, CDC13) δ ppm 6.77 - 6.88 (m, 3 H), 4.54 - 4.60 (m, 2 H), 2.80 - 2.85 (m, 2 H). MS (DCI) m/e 233 (M+H)+ Example 49D Example 49C (1.49 g, 6.4 mniol) was dissolved in 12 ml pyridine. Methoxylamine hydrochloride (0.83 g, 10 mmol) was added and the reaction mixture stirred at ambient temperature for 3 days. The pyridine was removed under reduced pressure, and the residue taken into diethyl ether. The ether solution was washed with 1N hydrochloric acid and saturated aqueous sodium bicarbonate sequentially, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 1.56 g of Example 49D which was used without further purification, 1H NMR (300 MHz, CHLOROFORM-D) 6 ppm 6.71 - 6.81 (m, 3 H), 4.20 - 4.25 (m, 2 H), 3.99 (s, 3 H), 2.87 - 2.93 (m, 2 H). MS (DCI) m/e 262 (M+H)+. Example 49E Example 49D (1.56 g, 6 mmol), 0.38 g of 10% palladium on carbon, and 70 ml of 20% ammonia in methanol were shaken under hydrogen at 60 psi and ambient temperature for 28 hours. The catalyst was removed by filtration and the solvent evaporated under reduced pressure. The residue was taken in to diethyl ether and extracted with 1N hydrochloric acid. The aqueous extracts were combined and made basic with 10N sodium hydroxide and extracted with diethyl ether. The organic extracts were combined, dried with magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give 0.57 g of Example 49E. 1H NMR (300 MHz, CDC13) δ ppm 7.33 (d, J=8.48 Hz, 1 H), 6.76 (d, J=8.48 Hz, 1 H), 6.69 (s, 1 H), 4.20 - 4.35 (m, 2 H), 4.07 (t, δ=5.26 Hz, 1 H), 2.07 - 2.22 (m, 1 H), 1.79 -1.93 (m, J H). MS (DCI) m/e 217 (M-NH2)+ 234 (M+H)+ Example 49F methyl 4-[({[7-(trifluoromethoxy)3,4-dihydro--2H-chromen-4-yl]aminol carbonyl)amino]-. lH-indazole-l-carboxylate Example 49E (0.57 g, 2.4 mmol), Example 24D (0.80 g, 2.4 mmol), and diisopropylethylamine (0.65 g, 0.9 ml, 5 mmol) were dissolved in 10 ml of N,N-dimethylformamide. The reaction mixture was stirred at ambient temperature for 16 hours, and diluted with water. The precipitate that formed was collected by filtration, and air-dried to give 0.67 g of the titled compound which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.87 (s, 1 H), 839 (s, 1 H), 7.86 (d, J=7.12 Hz, 1 H), 7.70 (d, J=8.48 Hz, 1 H), 7.42 - 7.54 (m, 2 H), 6.81 - 6.96 (m, 3 H), 4.90 - 5.00 (m, 1 H), 4.29 - 4.40 (m, 1 H), 4.22 (ddd, J=l 1.27, 8.22, 3.22 Hz, 1 H), 4.03 (s, 3 H), 2.03 - 2.19 (m, 2 H). MS (ESI)m/e 451(M+H)+ Example 49G N-1H-indazol-4-yl-N'-[7-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea Example 46F (0.67 g, 1.5 mmol) was dissolved in a mixture of 5 ml tetrahydrofuran and 5 ml methanol. Sodium hydroxide (5M in methanol, 2 ml, 10 mmol) was added, and the reaction stirred at ambient temperature for 40 minutes. The reaction mixture was diluted with water, and the precipitate that formed was collected by filtration, giving 0.53 g of titled compound. 1HNMR (300 MHz, DMSO-d6)δ ppm 13.03 (s, 1 H), 8.60 (s, 1 H), 8.03 (s, 1 H), 7.68 (d, J=7.12 Hz, 1 H), 7.45 (d, J=8.81 Hz, 1 H), 7.18 - 7.26 (m, 1 H), 7.08 (d, J=8.14 Hz, 1 H), 6.81 - 6.96 (m, 3 H), 4.88 - 4.98 (m, 1 H), 4.29 - 4.40 (m, 1 H), 4.21 (ddd; J=l 1.53, 8.48,3.05 Hz, 1 H), 2.01 - 2.18 (m, 2 H). MS (ESI) m/e 393 (M+H)+. Calcd. For C18H15N4O3F3: C 55.11, H 3.85, N 14.28; Found C 55.44, H 3.75, N 14.01. Example 50 N-isoquinolin5-yl-N'-{[1-(2-phenylethyl)-1,2,3,4-tetrahydroquinolin-2-yl]methyl}urea Example 50A A solution of phosgene (20% in toluene, 10.2 mL, 193 mmol) was added to dichlomaethane (120 mL) at 0°C under N2 and allowed to equilibrate for 15 minutes before addition of a solution of 4-N,N-dimethylaminopyridine (5,1595 g, 42.2 mmol) in dichloromethane (20 mL). After 20 minutes, a solution of 5-aminoisoquinoline (2.5070 g, 17.4 mmol) in dichloromethane (40 mL) was added. The reaction mixture was allowed to warm to ambient temperature and stirred for 17 hours. The mixture was then condensed in vaco to a thick paste which was suspended in ether and filtered. The filtrate was diluted up to 150 mL with ether for a 0.1 M solution of Example 50A in ether. Example 50B The product from Example 50A (125 mL, 14.4 mmol) was poured into a solution of 2-aminomethyl-I-N'-boc-l}2,3,4-tetrahydroquinoline (3.23 g, 123 mmol) in ether (50 mL) at ambient temperature and stirred for 4.5 hours. The reaction mixture was filtered and the precipitate was washed with ether and dried under vacuum to afford Example 50B (2.9493 g, 55%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.26 (s, 1 H) 8.62 (s, 1 H) 8.53 (d, J=6.10 Hz, 1 H) 8.27 (d, J=7.46 Hz, 1 H) 7.89 (d, J=6.10 Hz, 1 H) 7.72 (d, J=7.80 Hz, 1 H) 7.59 (t, J=7.97 Hz, 1 H) 7.52 (d, J=7.80 Hz, 1 H) 7,13 (t, J=7.12 Hz, 2 H) 7.02 (m, 1 H) 6.65 (t, J=6.10 Hz, 1 H) 4.58 (m, 1 H) 330 (m, 1 H) 3.01 (m, 1 H) 2.72 (m, 1 H) 2.59 (m, 1 H) 2.15'(m, 1 H) L65 (m, 1 H) 1.40 (s, 9 H). MS(DCI) m/z 171 (100%, (M-262)+), 433 (10%, (M+H)4). Example 50C Trifluoroacetic acid (5 mL) was added to a solution of the product from Example 50B (1.2413 g, 2.87 mmol) in dichloromethane (50 mL) and stirred for 20 hours at ambient temperature. The reaction solution was concentrated and taken up in ethyl acetate and washed with aqueous saturated NaCHOj solution, then water and condensed to give Example 50C (0.8788 g, 92%) as a pale yellow solid, 1H NMR (300 MHz, DMSO-d6) δ ppm 9.26 (s, 1 H) 8.74 (s, 1 H) 8.53 (d, J=6.10 Hz, 1 H) 8.31 (m, 1 H) 7.95 (d, J=6.10 Hz, 1 H) 7.72 (d, J=8.14 Hz, 1 H) 7,59 (t, J=7-97 Hz, 1 H) 6.84 (m, 3 H) 6.51 (d, J=7.12 Hz, 1 H) 6.44 (t, J=6.78 Hz, 1 H) 5.70 (s, 1 H) 338 (m, 2 H) 3.18 (m, 1 H) 2.69 (m, 2 H) 1.87 (m, 1H) 1.63 (m, 1 H). MS (DCI) w/z 163 (100%, (M-169)4), 333 (10%, (M+H)4). Example 50D N-isoquinolin-5-yl-N'- ([ 1 -( 2-pbenylethyl)-l ,2,3,4-tetrahydroquinolin-2-yl]methayl} urea The product from Example 50C (52.1 mg, 0.16 mmol) was suspended in dichloroethane (5 mL) in a flask equipped with a stir bar and septum then flushed with N2 and cooled in an ice bath to 0°C. hi succession a solution of phenylacetaldehyde (42.1 mg, 0.35 mmol) in dichloroethane (0.5 mL), a. suspension of sodium triacetoxy borohydride (70.7 mg, 0.33 mmol) and glacial acetic acid (0.07 mL, 1.19 mmol) were added then the reaction mixture was allowed to warm to ambient temperature. The reaction mixture cleared after 2 hours. LC/MS indicated reaction was not complete. Continued to stir 17 hours and checked via LC/MS-same as 2 hour sample. Another portion of sodium triacetoxy borohydride (36.0 mg, 0.17 mmol) was added and stirred for 4.5 hours. The reaction mixture was quenched with aqueous saturated NaHCO3 solution (10 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic fractions were dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified via column chromatography on silica gel (4% methanol/dichloromethane) to afford the title compound (29.5 mg, 42%) as an off white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.26 (s, 1 H) 8.69 (s, 1 H) 8.52 (d, ,J=5,76 Hz, 1 H) 8.26 (d, J=6.78 Hz, 1 H) 7.91 (d, J=6.10 Hz, lH) 7.74 (d, J=8.14 Hz, 1 H) 7.60 (t, J=7.97Hz, 1 H) 7.24 (m, 6H) 7.05 (t, J=8.48Hz, 1 H) 6.95 (d, J=7.12 Hz, 1 H) 6.73 (t, J=8.48 Hz, 1 H) 6.51 (t, J=6.78 Hz, 1 H) 3.72 (m, 1 H) 3.45 (m, 1 H) 3.32 (m, 2 H) 3.13 (m, 1 H) 2.83 (m, 3 H) 2.62 (d, J=3.05 Hz, 1 H) 1.90 (m, 1 H) 1.59 (m, 1 H). MS (ESI) m/z 437 (M+H)+, 435 (M-H)-. Calcd. For C28H28N4O●035 C2H4O2: C 75.34, H 6.48, N 12,24; Found C 75.58, H 6.46, N1l,84. Ex ample 51 N-[(l -benzyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-isoquinolin--5-ylurea A solution of the product from Example 50C (0.1113 g, 0.33 mmol), benzaldehyde (0.08 mL, 0.79 mmol) and glacial acetic acid (0,15 mL, 2.55 mmol) in dichloroethane (10 mL) was stirred for 17 hours at ambient temperature to form the imine intermediate. Solid sodium triacetoxy borohydride (0.1411 g, 0.67 mmol) was added and continued to stir at ambient temperature. Checked reaction mixture at 2 and 4 hours intervals; some product formation but major component was the imine intermediate. An additional portion of solid sodium triacetoxy borohydride (0.1722 g, 0.81 mmol) and glacial acetic acid (0.1 mL, 1.7 mmol) were added and the mixture stirred an additional 17 hours. Although the reaction was incomplete, it was quenched with water (20 mL) and diluted with ethyl acetate. The aqueous phase was extracted with ethyl acetate (2x015 mL). The combined organic fractions were washed with brine (1 x 30 mL), dried (MgSO4), filtered and concentrated m vacuo. The crude material was purified via column chromatography on silica gel (2% methanol/dichloromethane) to afford the title compound (9.9 mg, 7%) as an off white solid, 1H NMR (300 MHz, DMSO-d6) δ ppm 9.26 (s, 1 H) 8,70 (s, 1 H) 8.54 (d, J=6.10 Hz, 1 H) 8.23 (d, J=6.78 Hz, 1 H) 7.92 (d, J=6.10 Hz, 1 H) 7.74 (d, J=8.14 Hz, 1 H) 7.58 (t, J=7.97 Hz, 1 H) 7.25 (m, 5 H) 6.96 (d, J=6.10 Hz, 1 H) 6.86 (t, J=7.63 Hz, 1 H) 6.79 (t, J=5.76 Hz, 1 H) 6.48 (t, J=6.78 Hz, 1 H) 6.35 (d, J=8.14 Hz, 1 H) 4.65 (q, 2 H) 3.56 (m, 1 H) 3.40 (m, 1 H) 3.23 (m, 1 H) 2.93 (m, 1 H) 2.69 (m, 1 H) 2.07 (m, 1 H) 1.86 (m, 1 H). MS (ESI) m/z 423 (M+H)+, 421 (M-H)'. Calcd For C27H26N4O●0.25 dichloromethane: C 73.76, H 6.02, N 12.63; Found C 73.92, H 6.11,N 12.55. Example 52 N-isoquinolin-5-yl-N'-{[1-(3-phenylpropyl)-1,2,3,4-tetrahydroquinolin-2-yl]methyl}urea The product from Example 50C (0.24 g, 0.53 mmol) and sodium triacetoxy borohydride (0.2547 g, 1.20 mmol) were suspended in dichloroethane (5 mL). The reaction flask was equipped with stir bar and spetum, then flushed with N2. Hydrocinnamaldehyde ( 0.11 mL, 0.83 mmol) was added followed by glacial acetic acid (0.2 mL, 3.4 mmol). The reaction mixture was diluted with an additional 5 mL dichloroethane. After 2 hours of stirring at ambient temperature, the reaction was quenched with water (20 mL) and partitioned between ethyl acetate/water. The aqueous phase was extracted with ethyl acetate (2 x 15 mL). The combined organic fractions were washed with aqueous saturated NaHCO3 (1 x 25 mL), water (1 x 25 mL), and brine (1 x 25 mL), dried (MgSO4), filtered and concentrated in vaco. The crude material was purified via column chromatography (2% to 5% methano1/dichloromethane) to afford the title compound (0.1926 g, 81 %) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.27 (s, 1 H) 8.70 (s, 1 H) 8.54 (d, J=5.76 Hz, 1 H) 8.27 (d, J=7.46 Hz, 1H) 7.92 (d, 7=6.10 Hz, 1H) 7.74 (d, J=8.14 Hz, 1 H) 7.60 (t, J=7.97 Hz, 1 H) 7.19 (m, 5 H) 6.93 (m, 2 H) 6.76 (t, J=5.93 Hz, 1 H) 6.48 (m, 2 H) 3.49 (m, 2 H) 3.25 (m, 2 H) 3.13 (m, 1 H) 2.82 (m, 1 H) 2.62 (m, 3 H) 1.80 (m, 4 H). MS (ESI) m/z 451 (M+H)+, 449 (M-H)-. Calcd For C29H30N4O: C 77.30, H 6.71, N 12.43; Found C 77.20, H 6.32, N 12.21. Bxample.53 N-lH-indazol-4-yl-N'-{[l-(2-phenylethyl)-1,2,3,4-tetrahydroquinolin-2-yl]methyl}urea Example 53A methyl 4-{[({[l-(2-phenylethyl)-l,2,3,4-tetrahydroquinolin-2-yl]methyl) amino)carbonyl] amino} - 1H-indazole-1 -carboxylate The product from Example 22B (0.2486 g, 0.50 mmol) and sodium triacetoxy borohydride (0.2235 g, 1.05 mmol) were suspended in dichloroethane (10 mL). The reaction flask was equipped with stir "bar and spetum, then flushed with N2. Phenylacetaldehyde ( 0.10 mL, 0.85 mmol) was added followed by glacial acetic acid (0.2 mL, 3.4 mmol). After 1 hour of stirring at ambient temperature, the reaction mixture was quenched with water (20 mL) then partitioned between ethyl acetate/water. The aqueous phase was extracted with ethyl acetate (2 x 15 mL). The combined organic fractions were washed sequentially with aqueous saturated NaHCO3 (1 x 25 mL), water (1x25 mL), and brine (1 x 25 mL), dried (MgSO4), filtered and concentrated in vaco. The crude material was purified via column chromatography (2% to 5% methanol/dichloromethane) to afford the titled compound (0.1913 g, 79%) as a white solid 1H NMR (300 MHz, DMSO-d6) δ ppm 8.99 (s, 1 H) 8.43 (s, 1 H) 7.80 (d, J=7.80 Hz, 1 H) 7.69 (d, J=8.48 Hz, 1 H) 7.48 (t, J=8.14 Hz, 1 H) 7.25 (m, 5 H) 7.04 (m, 1 H)6.95 (d, J=7.46Hz, 1 H) 6.71 (d, J-8.14Hz, 1 H) 6.51 (t, J=6.95 Hz, 2H) 4.03 (s, 3 H) 3.72 (m, 1 H) 3.37 (m, 3 H) 3.13 (m, 1 H) 2.82 (m, 3 H) 2.59 (m, 1 H) 1.89 (m, 1 H) 1.55 (m, 1 H). MS (ESI) m/z 484 (M+H)+, 482 (M-H)". Example 53B N-1H-indazol-4-yl-N'-{[1-(2-phenylethyl)-1,2,3,4-tetrahydroquinolin-2-yl]methyl}urea The product from Example 53A (0.1913 g, 0.40 mmol) was dissolved in methanol (5 mL). A NaOH solution (1.0 mL, 5 M in methanol) was added and stirred for 30 minutes. The reaction mixture was then diluted with water until a precipitate formed. The solid was collected by filtration, washed with water and dried under vacuum to afford the title compound (0.1294 g, 76%) as a tan solid. 1H NMR (300 MHz, DMSO-d6) δ pprn 12.98 (s, 1 H) 8.69 (s, 1 H) 8.07 (s, 1H) 7.60 (d, .7=7.46 Hz, 1 H) 7.24 (m, 6 H) 7.04 (rn, 2 H) 6.94 (d, J=6,44 Hz, 1 H) 6.71 (d, J=8.14 Hz, 1 H) 6.51 (t, J=6.95 Hz, 2 H) 3.71 (m, 1 H) 3.37 (m, 3 H) 3.11 (m, 1 H) 2.83 (m, 3 H) 2.62 (m, 1 H) 1.87 (m, 1 H) 1.54 (m, 1 H). MS (ESI) m/z 426 (M+H)+, 424 (M-H)". Calcd For C26H27N5O: C 73.39, H 6.40, N 16.46; Found C 73.22, H 6.36, N 16.30. Example 54 N-lH-indazol-4-yl-N'-{[1-(3-phenylpropyl)-1,2,3,4-tetrahyaroquinolin-2-yl]methyl}urea Example 54A methyl 4- {[( {[l-(3-phenylpropyl)-1,2,3,4-tetrahydroquinolin-2-yI]methyl}amino)carbonyl]amio)-lH-indazole-l-carboxylate The title compound was prepared using the procedure as described in Example 53A, substituting hydrocinnamaldehyde (0.10mL, 0.76 mmol) for phenylacetaldehyde. The crude material was purified via column chromatography on silica gel (50% to 80% ethyl acetate/Hex) to afford the titled compound (0.1430 g, 70%) as an off white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.00 (s, 1 H) 8.44 (s, 1 H) 7.82 (d, J=7.46 Hz, 1 H) 7.69 (d, J=8.14 Hz, 1 H) 7.49 (t, J=8.14 Hz, 1 H) 7.19 (m, 5 H) 6.93 (m, 2 H) 6.49 (m, 3 H) 4.03 (s, 3 H) 3.48 (m, 2 H) 3.25 (m, 2 H) 3.13 (m, 1 H) 2.82 (m, 1 H) 2.62 (m, 3 H) 1.87 (m, 3 H) 1.66 (m, 1 H). MS (ESI) m/z 498 (M+H)+, 496 (M-H)'. Example 54B N-lH-indazol-4-yl-N'-{[1-(3-phenylpropyl)-1,2,3,4-tetrahydroqninolin-2-yl]methyl}urea The title compound was prepared using the procedure as described in Example 53B, substituting Example 54A (0.1430 g, 0.29 mmol) for Example 53 A. The crude material collected by filtration was rinsed with ether to afford the title compound (0.0785 g, 61%) as a white solid. 1HNMR(300 MHz, DMSO-d6) δ ppm 12,98 (s, 1H) 8.70 (s, 1 H) 8.08 (s, 1 H) 7.61 (d, J=7.12 Hz, 1 H) 7.21 (m, 6 H) 7.06 (d, .7=8.14 Hz, 1 H) 6.94 (m, 2 H) 6.49 (m, 3 H) 3.48 (m, 2 H) 3.25 (m, 2 H) 3.11 (m, 1 H) 2.81 (m, 1 H) 2.62 (m, 3 H) 1.90 (m, 3 H) 1.67 (m, 1 H). MS (ESI) m/z 440 (M+H)+, 438 (M-H)'. Calcd For C27H29N5O●0.25 C4H10O: C 73.42, H 6.93, N 15.29; Found C 73.12, H 6.61, N 15,50. Example 55 N-lH-indazol-4-yl-N'-({l-[(trifluoromethyl)sulfonyl]-1,2,3,4-tetrahydroquinolin-2- yl}methyl)urea Example 55A methyl 4-({[({l-[trifluoromethyl)sulfonyl]-1,2,3,4-tetrahydroquinolin-2- yl}methyl)amino]carbonyl)amino)-1H-indazole-l-carboxylate The product from Example 22B (0.2034 g, 0.54 mmol) was dissolved in dichloromethane (50 mL). The reaction flast was equipped with stir bar and septum, flushed with N2 and cooled to -78°C in a dry ice/acetone bath, triethyl amine (0.11 mL, 0.79 mmol) and trifluoromethanesulfonic anhydride (0.15 mL, 0.89 mmol) were added and stirred at -78°C for 5 minutes. The reaction mixture was removed from the cold bath and stirred for 18.5 hours at ambient temperature, filtered and concentrated in vacuo. The crude material was purified via column chromatography on sica gel (2% to 5% methanol/dichloromethane) to afford the titled compound (0.0927 g, 34%) as aa off white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.99 (s, 1 H) 8.40 (s, 1 H) 7.71 (dd, J=831,3.90 Hz, 2 H) 7.41 (m, 2 H) 7.29 (m, 3 H) 6.56 (t, J=6.10 Hz, 1 H) 4.57 (m, 1 H) 4.03 (s, 3 H) 3.28 (m, 1 H) 3.09 (m, 1 H) 2.85 (m, 1 H) 2.66 (m, 1 H) 2.40 (m, 1 H) 1.70 (m, 1 H). MS (ESI) m/z 512 (M+H)+, 510 (M-H)-. Example 55B N-lH-indazol-4-yl-N'-({1-[(trifIuoromethyl)sulfopyl]-1,2,3,4-tetrahydroquinolin-2- yl}methyl)urea The title compound (0.0422 g, 52%) was prepared using the procedure as described in Example 53B, substituting Example 55A (0.0927 g, 0.18 mmol) for Example 53A. 1H NMR (400 MHz, DMSO-d6) δ ppm 12.96 (s, 1 H) 8.67 (s, 1 H) 8,05 (s, 1H) 7,52 (d, J=7.67 Hz, 1 H) 7.45 (m, 1 H) 7.28 (m, 3 H) 7,19 (t, J=7.98 Hz, 1 H) 7.06 (d, J=8.29Hz, 1 H) 6.54 (t, J=5.98 Hz, 1 H) 4.55 (m, 1 H) 3.33 (m, 1 H) 3.07 (m, 1 H) 2.84 (m, 1 H) 2.63 (m, 1 H) 2.39 (m, 1 H) 1.70 (m, 1 H). MS (ESI) m/z 454 (M+H)+, 452 (M-H)'. Example 56 N-{[1-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-2-yl]methyl}-N'-1H-indazol-4-ylurea Example 56A methyl 4-{[({[l-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-2- yl]methy} amino)carbonyl]amino) -1 H-indazole-l -carboxylate The title compound was prepared using the procedure as described in Example 53A, substituting cyclohexane carbaldehyde (0.16 mL, 1.33 mmol) for phenylacetaldehyde. The crude material was purified via column chromatography (2% methanoydichloromethane) to afford the desired compound (0.2637 g, 64%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.00 (s, 1 H) 8.44 (s, 1 H) 7.79 (d, J=7.46 Hz, 1 H) 7.69 (d, J=8.48 Hz, 1 H) 7.48 (t, J=8.14 Hz, 1 H) 6.94 (m, 2 H) 6.49 (m, 3 H) 4.03 (s, 3 H) 3.41 (m, 2 H) 3.23 (m, 1 H) 3.08 (m, 1 H) 2.90 (m, 2 H) 2.63 (m, 1 H) 1.96 (m, 1 H) 1.68 (m, 8 H) 1.14 (m, 4 H). MS (ESI) m/z 476 (M+H)+, 474 (M-H). Example 56B N-{[l-(cyclohexylmethyl)-1,2,3,4-tetrahydroquinolin-2-yl]methyl}-N'-1H-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 53B, substituting Example 56A (0.2637 g, 0.55 mmol) for Example 53 A. The crude material was rinsed with ether to afford the title compound (0.2064 g, 90%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.98 (s, 1H) 8.69 (s, 1 H) 8.08 (s, 1 H) 7.59 (d, J=7.46 Hz, 1 H) 7.20 (t, J=7.97 Hz, 1 H) 7.06 (d, J=8.14 Hz, 1 H) 6.94 (m, 2 H) 6.48 (m, 3 H) 3.40 (dd, J=14.58,4.07 Hz, 2 H) 3.21 (m, 1 H) 2.97 (m, 3 H) 2.61 (dd, .J=16.28,3.39 Hz, 1 H) 1.94 (m, 1 H) 1.72 (m, 7 H) 1.03 (m, 5 H). MS (ESI) m/z 418 (M+H)+, 416 (M-H)-. Calcd For C25H31N5O: C 71.91, H 7.48, N 16.77; Found C 71.81, H 7.61, N 16.34. Example 57 N-lH-indazol-4-yl-N'-[(l-propyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]urea Example 57A methyl 4-[({[(1-propyl-l,2,3,4-tetrahydroquinolin-2-yl)methyl]amino}carbonyl)amino]-1H- indazole-1-carboxylate The product from Example 22B (0.3145 g, 0.83 mmol) and sodium triacetoxy borohydride (0.5441 g, 1.39 mmol) were suspended in dichloroethane (15 mL). The reaction flask was equipped with stir bar and speram,,then flushed with N2. Prppionaldehyde (0.10 mL, 1.39 mmol) was added followed by glacial acetic acid (0.30 mL, 5.10 mmol). After 2.5 hour of stirring at ambient temperature, the reaction mixture was quenched with water then partitioned between ethyl acetate/water. The aqueous phase was extracted with ethyl acetate. The combined organic fractions were washed with aqueous saturated NaHCO3, water, and brine, dried (MgSO4), filtered and concentrated in vaco. The crude material was purified via column chromatography (2% to 5% methanol/dichloromethane) to afford Example 57A (0.2780 g, 79%) as an off white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.00 (s, 1 H) 8.44 (s, 1 H) 7.81 (d, J=7.80 Hz, 1 H) 7.69 (d, .7=8.14 Hz, 1 H) 7.48 (t, .7=8.14 Hz, 1 H) 6.95 (m, 2 H) 6.54 (m, 2 H) 6.46 (t, J=6.78 Hz, 1 H) 4.04 (s, 3 H) 3.43 (m, 2 H) 3.32 (m, 1 H) 3.13 (m, 2 H) 2.80 (m, 1 H) 2.60 (m, 1 H) 1.97 (m, 1 H) 1.61 (m, 3 H) 0.90 (t, J=7.46 Hz, 3 H). MS (ESI) m/z 422 (M+H)+, 420 (M-H)-. Example 57B N-lH-indazol-4-yl-N'-[(1-propyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]urea The title compound was prepared using the procedure as described in Example 53B, substituting Example 57A (0.2534 g, 0.60 mmol) for Example 53A. The crude material was rinsed with ether to afford the title compound (0.1852 g, 85%) as an off white solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.98 (s, 1 H) 8.70 (s, 1H) 8.08 (s, 1 H) 7.61 (d, J=7.46 Hz, 1 H) 7.20 (t, .7=7.97 Hz, 1 H) 7.06 (d, ,7=8.48 Hz, 1 H) 6.96 (m, 2 H) 6.53 (m, 2 H) 6.46 (t, J=7.12 Hz, 1 H) 3.44 (m, 2 H) 3.31 (m, 1 H) 3.13 (m, 2 H) 2.82 (m, 1 H) 2.60 (m, 1 H) 1.97 (m, 1 H) 1.61 (m, 3 H) 0.90 (t, J=7.46 Hz, 3 H). MS (ESI) m/z 364 (M+H)+, 362 (M-H)'. Calcd For C21H25N5O: C 69.40, H 6.93, N 19.27; Found C 69.08, H 6.91, N 19.32. Example 58 N- lH-indazol-4-yl-N- {[1 -(pyridin-2-ylmethyl)-l,2,3,4-tetrahydroquinolin-2-yl]methyl}urea The product from Example 22B (0.2540 g, 0.67 mmol), 2-(bromomethyl)pyridine hydrobromide (0,8648 g, 0.67 mmol), and potassium carbonate (0.8351 g, 6.04 mmol) were dissolved in tetrahydrofuran/water (35 mL/10 mL) and heated at 70°C for 22 hours. The reaction mixture was concentrated in vacua. The residue was dissolved in methanol (5 mL). A NaOH solution (1 mL 5 M in methanol) was added and stirred for 30 minutes at ambient temperature. The reaction mixture was concentrated in vacuo, and the residuetaken up in dichloromethane and washed with water (3 x 20 mL), dried (MgSO4) and filtered. The filtrate was concentrated in vacuo to a brown residue. The crude product was prurified using reverse-phase HPLC (acetonitrile-water with 0.1% trifluoroacetic acid as eleuent), isolating the trifluoroacetic acid salt of the titlted compound (0.0935 g, 34%) as a white solid 1H NMR (300 MHz, DMSO-d6) δ ppm 12.98 (s, 1 H) 8.73 (s, 1 H) 8.66 (d, J=4.41 Hz, 1 H) 8.08 (s, 1 H) 7.97 (t, J=7.12 Hz, 1 H) 7.57 (d, J=7.46 Hz, 1 H) 7.45 (m, 2 H) 7.18 (t, J=8.14 Hz, 1 H) 7.05. (m, 1 H) 6.99 (d, J=7.46 Hz, 1 H) 6.88 (m, 1 H) 6.60 (t, J=5.76 Hz, 1 H) 6.53 (t, J=6.9S Hz, 1 H) 6.31 (d, J=7.80 Hz, 1 H) 4.80 (s, 2 H) 3.64 (m, 1 H) 3.39 (m, 1 H) 3.25 (m, 1 H) 2.91 (m, 1 H) 2.72 (m, 1 H) 2.06 (m, 1 H) 1.92 (m, 1 H). MS (ESI) m/z 413 (M+H)+, 411 (M-H)". Calcd For C24H24N6O1.9 C2HF3O2: C 53.07, H 4.15, N 13.36; Found C 53.15, H 4.14, N 13.49. Example 59 N-isoquinolin-5-yl-N'-(l,2,3,4-tetrahydroquinolin-2-ylmethyl)urea Trifluoroacetic acid (5 mL) was added to a solution of the prodnct from Example 50B (1.6670 g, 3,85 mmol) in dichloromethane (50 mL) and stirred for 20 hours at ambient temperature. The reaction solution was concentrated in vaco, and the residue taken up in etnyl acetate, wasted with aqueous saturated NaHCO3 solution and water, and condensed in vacuo to a give the titled compound (1.1384 g, 89%) as awhite solid. 1HNMR(300MHz, DMSO-dg) δ ppm 9.26 (s, 1H) 8.74 (s, 1H) 8.53 (d, J=6.10 Hz, 1 H) 8.31 (m, 1H) 7.95 (d, J=6.10 Hz, 1 H) 7.72 (d, J=8.14 Hz, 1 H) 7.59 (t, J=7.97 Hz, 1 H) 6.84 (m, 3 H) 6.51 (d, J=7.12 Hz, 1 H) 6.44 (t, J=6.78 Hz, 1 H) 5.70 (s, 1 H) 3.38 (m, 2 H) 3.18 (m, 1 H) 2.69 (m, 2 H) 1.87 (m, 1 H) 1.63 (m, 1 H). MS (DCI) m/z 163 (100%, (M-169)4), 333 (10%, (M+H)+). Calcd For C20H20N4O●0.05 C2HF3O2: C 71.40, H 5.98, N 16.57; Found C 71.69, H 5.95, N 16.53. Example 60 N-1H-indazol-4-yl-N'-(1-[2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahyldroquinolin-2- yl}methyl)urea Example 60A methyl 4-({[({l-[2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-2- yl}methyl)amino]carbonyl) amino)- 1H-indazole-l-carboxylate The titled compound was prepared using the procedure as described in Example 22C, substituting 2-trifluoromethylbenzyl bromide for benzyl bromide. 1H NMR (300 MHz, d6-DMSO) 9.03 (s, 1H), 8.42 (s, 1H), 7.77 (m, 2H), 7.70 (d, J=7.5 Hz, 1H), 7.58 (m, 1H), 7.48 (m, 2H), 7.37 (d, J=7.5 Hz, 1H), 7.00 (d, J=7.5 Hz, 1H), 6.83 (m, 1H), 6.58 (m, 2H), 6.10 (d, J-7.5 Hz, 1H), 4.79 (m, 2H), 4.01 (s, 3H), 3.57 (m, 1H), 3.41-3.22 (m, 2H), 2.90 (m, 1H), 2.65 (m, 1H), 2.03 (m, 1H), 1.82 (m, 1H); MS (DCI/NHs) m/e 538 (M+H)+. Example 60B. N-lH-mdazoI-4-yl-N'-({l-[2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-2- yl}methayl)urea The title compound was prepared using the procedure as described in Example 22D, substituting Example 60A for Example 22C. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, iH), 8.78 (s, 1H), 8.09 (s, 1H), 7.78 (d, J=7.5 Hz, 1H), 7.60 (m, 2H), 7.45 (m, 1H), 7.38 (d, J=7.5 Hz, IH), 7.19 (m, IH), 7.04 (m, 2H), 6.83 (m, IH), 6.60 (t, J-6.0Hz, IH), 6.48 (m, IH), 6.10 (d, J=7.5 Hz, IH), 4.79 (m, 2H), 3,57 (m, IH), 3.41 -3.20 (m, 2H), 2.92 (m, IH), 2.71 (m, IH), 2.10 (m, IH), 1.96 (m, 1H); MS (ESI/NH3) m/e 480 (M+H)+. Anal. Calc'd. For C26H24N5F3O-0.5 H20: C 63.93; H 5.16; N 14.34. Found: C 63.71; H 5.07; N 14.23. Example 61 N-lH-indazol-4-yl-N'-({l-[3-(trifluoromethayl)benzyl]-1,2,3,4-tetrahydroquinolin-2- yl}methy)urea Example 61 A methyl 4-({[({1 -[3-(trifluoromethyl)benzyl]-l, 2,3,4-tetrahydroquinolin-2- yl}methyl)amino]carbonyl] amino)-1H-indazole-l -carboxylate The titled compound was prepared using the procedure as described in Example 22C, substituting 3-trifluoromethylbenzyl bromide for benzyl bromide. 1H NMR (300 MHz, d6-DMSO) 9.02 (s, 1H), 8.42 (s, 1H), 7.78 (d, J=7.5 Hz, 1H), 7.70 (d, J=7.5 Hz, 1H), 7.58 (m, 4H), 7,46 (t, J=7.5 Hz, IH), 7.00 (d, J=7.5 Hz, IH), 6.86 (m, IH), 6.55 (m, 2H), 6.34 (d, 1=7.5 Hz, 1H), 4,77 (m, 2H), 4.01 (s, 3H), 3,58 (m, 1H), 3.41-3.22 (m, 2H), 2.90 (m, 1H), 2.65 (m, 1H), 2.03 (m, 1H), L82 (m, 1H); MS (DCI/NH3) m/e 538 (M+H)+. Example 61B N-lH-indazol-4-yl-N'-({1-[3-(trifluoromethyl)benzyl]-l,2,3,4-tetrahydroquinolin-2- yl}methyr)urea The title compound was prepared using the procedure as described in Example 22D, substituting Example 61A for Example 22C. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.76 (s, 1H), 8.09 (s, 1H), 7.58 (m, 5H), 7.18 (t, J=7.5 Hz, 1H), 7,08 (d, J=7.5 Hz, 1H), 6.93 (d, J=7.5 Hz, 1H), 6.83 (m, 1H), 6.60 (t, JN6.0 Hz, 1H), 6.52 (t, J=7.5 Hz, 1H), 6.35 (d, J=7.5 Hz, 1H), 4.75 (m, 2H), 3.57 (m, 1H), 3.41-3.17 (m, 2H), 2.95 (m, 1H), 2.70 (m, 1H), 2.09 (m, 1H), 1.86 (m, 1H); MS (ESI/NH3) m/e 480 (M+H)+. Anal. Calc'd. For C26H24N5F3O-0.4 H2O: C 65.13; H 5.14; N 14.39. Found: C 63,90; H 5,09; N 14.16. Example 62 N-lH-indazol-4-yl-N'-({1-[4-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroguinolin-2- vl}methyl)urea Example 62A methyl 4-({[({1-[4-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-2- yl}methyl)amino1carbonyl} amino)- 1H-indazole-1 -carboxylate The titled compound was prepared using the procedure as described in Example 22C, substituting 4-trifl.uoromethylbenzyl bromide for benzyl bromide. 1H NMR (300 MHz, d6-DMSO) 9.02 (s, 1H), 8.42 (s, 1H), 7.78 (d, J=7.5 Hz, 1H), 7.68 (m, 3H), 7.48 (m, 3H), 6.98 (d, J=7.5 Hz, 1H), 6.86 (m, 1H), 6.55 (m, 2H), 6.30 (d, J=7.5 Hz, 1H), 4.76 (m, 2H), 4.01 (s, 3H), 3.58 (m, 1H), 3.41-3,20 (m, 2H), 2.91 (m, 1H), 2.69 (m, 1H), 2.03 (m, 1H), 1.86 (m, 1H); MS (DCl/NH3) m/e 538 (M+H)+. Example 62B N- lH-indazol-4-yl-N'({ l-[4-(trifluoromethynbenzyl]-l .2.3.4-tetrahydroquinolin-2- yl) methyl)urea The title compound was prepared using the procedure as described in Example 22D, substituting Example 62A for Example 22C. 1H NMR. (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.76 (s, 1H), 8.09 (s, 1H), 7.68 (m, 2H), 7.58 (d, J=7.5 Hz, 1H), 7.46 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.08 (d, J=7.5 Hz, 1H), 6.99 (d, J=7.5 Hz, 1H), 6.86 (m, 1H), 6.60 (t, J=6.0 Hz, 1H), 6.52 (t, J=7.5 Hz, 1H), 6.30 (d, J=7.5 Hz, IH), 4.75 (m, 2H), 3.57 (m, 1H), 3.41-3.17 (m, 2H), 2.95 (m, IH), 2.70 (m, IH), 2.07 (m, 1H), 1.87 (m, 1H); MS (ESI/NH3) m/e 480 (M+H)+. Anal. Calc'd. For C26H24N5F3O-0.7 H2O: C 63.46; H 5.20; N 14.23. Found: C 63,59; H 4.73; N 13.87. Example 63 (-)-N-[(l-benzyl-12,3,4-tetrahydroquinolin-2-yl)methyl]-N'-1H-indazol-4-ylurea The title compound was prepared by chiral separation of Example 22D on the column Chiralcel OD (5cm ID x 50 cm, mobile phase ethanol-methanol-Hexane, 12.5:12.5:75, flow rate 50 mL/min, loading 60 mg in 2 mL of methanol). [α]D -30.0° (c 0.725, methanol). 1H NMR (300 MHz, DMSOd6) δ 13.00 (broad s, 1H), 8.75 (s, 1H), 8.10 (s, 1H), 7.59 (d, J=7.5 Hz, 1H), 7,25 (m, 6H), 7.03 (d, J=7.5 Hz, 1H), 6.95 (d, 1=7.5 Hz, 1H), 6.83 (m, 1H), 6.60 (m, J=6.0 Hz, 1H), 6.48 (m, 1H), 6.36 (d, J=7.5 Hz, 1H), 4.64 (m, 2H), 3.57 (m, 1H), 3.41-3.20 (m, 2H), 2.92 (m, IH), 2.67 (m, IH), 2.05 (m,1H), 1.82 (m, IH); MS (DC1/NH3) m/e 412 (M+H)+. Example 64 The title compound was prepared by chiral separation of Example 22D on the column Chiralcel OD (5cm ID x 50 cm, mobile phase ethanol-methanol-Hexane, 12.5:12.5:75, flow rate 50 mL/min, loading 60 mg in 2 mL of methanol). [α]D +33.6° (c 0.725, methanol). 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8,75 (s, 1H), 8,10 (s, 1H), 7.59 (d, J=7.5 Hz, 1H), 7,25 (m, 6H), 7.03 (d, J=7.5 Hz, 1H), 6,95 (d, J=7.5 Hz, 1H), 6.83 (m, 1H), 6.60 (m, J=6.0 Hz, 1H), 6.48 (m, 1H), 6.36 (d, J=7.5 Hz, 1H), 4.64 (m, 2H)S 3.57 (m, 1H), 3.41-3,20 (m, 2H), 2.92 (m, 1H), 2.67 (m, 1H), 2.05 (m, 1H), 1.82 (m, 1H); MS (DCI/NH3) m/e 412 (M+H)+. Example 65 M-N-lH-indazol-4-yl-N'-({1-[3-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-2- yl}methyl)urea The title compound was prepared by chiral separation of Example 61B on the column Chiralcel OD (5cm ID x 50 cm, mobile phase ethanol-methanol-Hexane, 12.5:12.5:75, flow rate 50 mL/min, loading 80 mg in 1 mL of methanol). [α]D-24.1° (c 0.52, methanol). 1H NMR(300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.76 (s, 1H), 8.09 (s, 1H), 7.58 (m, 5H), 7.18 (t, J=7.5 Hz, 1H), 7.08 (d, J=7,5 Hz, 1H), 6.93 (d, J=7.5 Hz, 1H), 6.83 (m, 1H), 6.60 (t, J=6.0 Hz, 1H), 6.52 (t, J=7.5 Hz, 1H), 6.35 (d, J=7.5 Hz, 1H), 4.75 (m, 2H), 3.57 (m, 1H), 3.41-3.17 (m, 2H), 2.95 (m, 1H), 2,70 (m, 1H), 2.09 (m, 1H), 1.86 (m, 1H); MS (ESI/NH3) m/e 480(M+H)+. Example 66 (+)-N-lH-indazol-4-yl-N'-({1-[3-(trifIuoromethyl)benzyI]-1,2,3,4-tetrahydroquinolin-2- yl}methyl)urea The title compound was prepared by chiral separation of Example 61B on the column Chiralcel OD (5cm ID x 50 cm, mobile phase ethanol-methanol-Hexane, 12.5:12.5:75, flow rate 50 mL/min, loading 80 mg in 1 mL of methanoi). [α]D +25.8° (c 0.48, methanol). 1H NMR (300 MHz, DMSO-d6) δ 13,00 (broad s, 1H), 8.76 (s, 1H), 8.09 (s, 1H), 7.58 (m, 5H), 7.18 (t, J»7.5 Hz, 1H), 7.08 (d, J=7.5 Hz, 1H), 6.93 (d, J==7.5 Hz, 1H), 6.83 (m, 1H), 6.60 (t, J=6,0 Hz, 1H), 6.52 (t, J=7.5 Hz, 1H), 635 (d, J=7.5 Hz, 1H), 4.75 (m, 2H), 3.57 (m, 1H), 3.41-3.17 (m, 2H), 2.95 (m, IH), 2.70 (m, 1H), 2.09 (m, 1H), 1.86 (m, 1H); MS (ESI/NH3) m/e 480 (M+H)+. Example 67 N-lH-indazol-4-yl-N'-{1-[3-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-3-yl}urea Example 67 A To a solution of commercially available (l,2,3,4-tetrahydro-quinolin-3-yl)-carbamic acid tert-butyl ester (0.63 g, 2.54 mmol) in ethanol (10 mL) was added K2CO3 (0.53 g, 3.8 mmol) and 3-trifluoromethylbenzyl bromide (0.58 mL, 3.8 mmol). Resulting mixture was stirred at ambient temperature for 16 h, then more of 3-trifluoromethylbenzyl bromide (0.58 mL, 3.8 mmol) was added and the mixture was refluxed for additional 3h. After cooling to ambient temperature diethyl ether was added to the reaction mixture and washed with water. Organic phase was separated and concentrated. The residue was chromatographed on silica gel (ethyl acetate-hexanes, 10:90 to 15:85) to isolate Example 67A (0.91 g, 88%) as a clear oO. 1HNMR (300 MHz, DMSO-d6) δ 7.58 (m, 3H), 6.90 (m, 3H), 6.52 (m, 2H), 4.57 (m, 2H), 3.83 (s, 1H), 3.40 (m, 1H), 3.18 (m, 1H), 2.90 (dd, J=4.5 and 15.0 Hz, 1H), 2.71 (dd, J=9.0 and 15 Hz, 1H), 1.39 (s, 9H). MS (DCI/NH3) m/e 407 (M+H)+. Example 67B To a solution of example 67A (0.90 g, 2.22 mmol) in dichloromethane (10 mL) at 0°C was added trifluoroacetic acid (2 mL) and mixture stirred at ambient temperature for 16 h. The mixture was concentrated under vacuum,-added toluene and the-solvent evaporated to obtain crude Example 67B (1.1 g) that was directly used in the next step without further purification. 1H NMR (300 MHz, DMSO-d6) δ 8.08 (broad s, 2H), 7.66 (m, 4H), 6.98 (m, 2H), 6.65 (m, 2H), 4.63 (m, 2H), 3.72 (m, 1H), 3.55 (dd, J=1.5 and 9.0 Hz, 1H), 3.30 (dd, J=7.5 and 9.0 Hz, 1H), 3.13 (dd, J=4.5 and 15 Hz, 1H), 2.84 (dd, 1=7.5 and 15 Hz, 1H). MS (DCI/NH3) m/e 307 (M+H)+. Example 67C methyl 4-([({l-[3-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-3- yl} amino)carbonyl]aminol -1 H-indazole-l -carboxylate The titled compound was prepared using the procedure as described in Example 22 A, substituting Example 67B for 2-aminomethyl-3,4-dihydro-2H-quinoline-l-carboxylic acid tert-butyl ester. 1H NMR (300 MHz, d6-DMSO) δ 9.02 (s, 1H), 839 (s, 1H), 7.86 (d, J=7.5 Hz, 1H), 7.70 - 7.44 (m, 6H), 7.00 (m, 2H), 6.57 (m, 3H), 4.63 (s, 2H), 4.28 (m, 1H), 4.01 (s, 3H), 3.58 (dd, J=1.5 and 9.0 Hz, 1H), 334 (m, 1H), 3.17 (dd, J=4.5 and 15.0 Hz, 1H), 2.72 (dd, J=4.5 and 15.0 Hz, 1H). MS (DCl/NH3) m/e 524 (M+H)+. Example 67D N-lH-indazol-4-yl-N'-{l-[3-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-3-yl}urea The title compound was prepared using the procedure as described in Example 22D, substituting Example 67C for Example 22C. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.80 (s, 1H), 8.09 (s, 1H), 7,68-7.47 (m, 5H), 7.19 (t, J=7.5 Hz, 1H), 7.00 (m, 3H), 6.60 (m, 3H), 4.64 (s, 2H), 4.26 (m, 1H), 3.55 (dd, J=1.5 and 9.0 Hz, 1H), 3.33 (m, 1H), 3.16 (dd, J=4.5 and 15 Hz, 1H), 2.72 (dd, J=1.5 and 15 Hz, 1H), MS (ESI/NH3) m/e 466 (M+H)+. Anal. Calc'd. For C25H22N5F3O-0.5 H2O: C 63.04; H 4.91; N 14.70. Found: C 63.29; H 4.73; N 14.25. Example 68 N-[(l-benzyl-6-fluoro-1,2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-1H-indazol-4-ylurea Example 68A Example 68A was prepared from commercially available 6-fluoro-2-methyl-quinoline using a procedure described in Chem. Pharm. Bull. 2001,49 (4)t 480-483. Example 68B To a solution of Example 68 A and benzylamine in dichloromethane was added sodium triacetoxy borohydride and the mixture was stirred 16 h at ambient temperature. The mixture was diluted with diethyl ether, washed with aq. NaOH and water. Organic phase was separated, concentrated hi vacuum and the residue chromatographed on silica gel (ethyl acetate-Hexanes, 60% -100%) to isolate Example 68B (0.56 g, 88%) as a viscous oil. 1H NMR (300 MHz, DMSO-d6) δ 8.31 (d, J=9.0 Hz, 1H), 8.03 (dd, J=6.0 and 9.0 Hz, 1H), 7.80-7.60 (m, 3H), 7.40-7.20 (m, 5H), 3.97 (s, 2H), 3.77 (s, 2H), 2.90 (broad s, 1H). MS (ESI/NH3) m/e 267 (M+H)+. Example 68C A solution of Example 68B (0.405 g, 1.52 mmol) in ethanol (4 mL) was hydrogenated in the presence of 20% Pd(OH)2/C (40 mg) at 50°C under pressure 30 psi for 3 h. Reaction mixture was filtered and the filtrate concentrated to obtain the crude Example 68C that was used directly in the next step without further purification. Example 68D To a solution of the crude mixture from Example 68C in tetrahydrofurau (15 mL) and triethylamine (1.0 mL) was added di-tert-butyl diearbonate (0.43 g, 2.00 mmol). After stirring for 2 h at ambient temperature the mixture was concentrated and the residue chromatographed on silica gel (ethyl acetate:Hexane, 3:7 to 1:1) to obtain Example 68D (60 mg, 15% for 2 steps). 1H NMR (300 MHz, DMSO-d6) δ 8.31 (d, J=9.0 Hz, 1H), 8.03 (dd, J=6.0 and 9.0 Hz, 1H), 7.75 (dd, J=3.0 and 9.0 Hz, 1H), 7.68 (m, 1H), 7.50 (m, 2H), 4.39 (d, J=6.0 Hz, 2H), 1.40 (s, 9H). MS (ESI/NHs) m/e 277 (M+H)+. Example 68E A solution of Example 68D (60 mg, 0.22 mmol) in ethanol (2 mL) was hydrogenated in the presence of 20% Pd(OH)2/C (40 mg) at 50°C under pressure 30 psi for 4 h. The reaction mixture was filtered and the filtrate concentrated to obtain crude Example 68E. MS (DCI/NH3) m/e 281 (M+H)+. Example 68F Example 68F was prepared using the procedure as described in Example 22C, substituting Example 68E for Example 22B and running the reaction under reflux instead of ambient temperature. 1H NMR (300 MHz, DMSO-d6) δ 7.30 (m, 2H), 7.20 (m, 3H), 7.00 (t, J=6.0 Hz, 1H), 6.81 (dd, J-3,0 and 9.0 Hz, 1H), 6.68 (m, 1H), 6.21 (dd, J=4.5 and 9.0 Hz, 1H), 4.52 (m, 2H), 3.40 (m, 1H), 3.05 (m, 1H), 3.00-2.54 (m, 3H), 1.98 (m, 1H), 1.77 (m, 1H), 1.38 (s, 9H). MS (DO/NH3) m/e 371 (M+H)+. Example 68G Example 68G was prepared using the procedure as described in Example 67B, substituting Example 68F for Example 67 A, Crude mixture of the title compound was used in the next step, MS (DCI/NH3) m/e 271 (M+H)+. Example 68H methyl 4-[(([(l-benzyl-6-fluoro-1.23.4-tetrahydroquinolin-2- The titled compound was prepared using the procedure as described in Example 22 A, substituting Example 68G for 2-aminomethyl-3,4-dihydro-2H-quinoline-l-carboxylic acid tert-butyl ester. 1H NMR (300 MHz, d6-DMSO) δ 9.0 (s, 1H), 8.43 (s, 1H), 7.79 (d, J-7.5 Hz, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.47 (t, J=7.5 Hz, 1H), 7.25 (m, 5H), 6.84 (dd, J=3.0 and 9.0 Hz, 1H), 6.70 (m, 1H), 6.53 (t, J=6.0 Hz, 1H), 6.30 (dd, J=4.5 and 9.0 Hz, 1H), 4.63 (m, 2H), 4.01 (s, 3H), 3.58 (m, 1H), 3.34 (m, 3H), 2.90 (m, 1H), 2.70 (m, 1H), 2.03 (m, 1H), 1,93 (m, 1H). MS (DCI/NH3) m/e 488 (M+H)+. Example 681 N-[(l-benzyl-6-fluoro-1,2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-1H-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 22D, substituting Example 68H for Example 22C. 1H NMR (300 MHz, DMSO-d6) δ 13.00 (broad s, 1H), 8.76 (s, 1H), 8,09 (s, 1H), 7.58 (d, J=7.5 Hz, 1H), 7.35-7.13 (m, 6H), 7.04 (d, J=7.5 Hz, 1H), 6.84 (m, 1H), 6.70 (m, 1H), 6.57 (t, J=6.0 Hz, 1H), 6.30 (dd, J=4.5 and 9.0 Hz, 1H), 4.62 (m, 2H), 3.55 (m, 1H), 3.33-3.10 (m, 2H), 2.90 (m, 1H), 2.72 (m, 1H), 2.05 (m, 1H), 1.93 (m, 1H). MS (DCl/NH3) m/e 430 (M+H)+ Anal. Calc'd. For C25H24N5FO0.4 H2O: C 68.76; H 5.72; N 16.04. Found: C 68.44; H 5.53; N 15.83. Example 69 N-(6-fluoro-2-methyl-3,4dihydro-2H-chromen-4-yl)-N-lH-indazol-4-ylurea A mixture of methoxylamine hydrochloride (0.137 g, 1.64 mmol) and commercially available 6-fluoro-2-methyl-4-chromanone (0.269 g, 1.49 mmol) in pyridine (3 mL) was stirred overnight at 65 C. The reaction mixture was cooled, concentrated, diluted with ethyl acetate, washed with saturated aqueous NaHCO3, and saturated aqueous NH4Cl. The organic layer was dried (Na2SO4), filtered and the solvent evaporated to give 0.306 g of a clear oil. The oil was dissolved in methanol (10 mL) and shaken with Raney Ni (cat amount) under H2 (60 psi) overnight The mixture was filtered and concentrated to afford the corresponding amine used without further purification (243 mg, 1 .34 mmol, 90%). The amine was stirred with Example 24D (445 mg, 1,34 mmol) and diisopropyl ethyl amine (0.28 mL, 1 .6 mmol) in 2.5 mL N,N-dimethylformamide at room temperature for 45 min. The mixture was diluted with water, filtered, and the solid collected was air-dried to afford the indazolylurea as a tan solid, which was used without further purification. The solid was suspended in methanol (4 mL) and treated with IN aq NaOH (1.8 mL, 1.8 mmol). The mixture was stirred at room temperature for 5 h, diluted with H2O (4 mL), filtered and washed with 50% aqueous methanol, and dried (vac oven) to give the title compound as a tan solid (340 mg, 1.00 mmol, 67% overall): 1H NMR (300 MHz, DMSO-d6) δ 13,00 (br s, 2H), 8.73 (s, 1H), 8.49 (s, 2H), 8.09 (s, 1H), 7.67 (t, 2H), 7.21 (m, 4H), 7.11-6.93 (m, 6H), 6.87 (dd, 1H), 6.81 (d, 1H), 6.77 (dd, 1H), 5.07 (m, 1H), 4.84 (m, 1H), 4.35 (m, 1H), 2.29 (dd, 1H), 2.11 (dt, 1H), 1.81 (m, 1H), 1.64 (q, 1H), 1.39 (d, 3H), 1.36 (d, 3H). MS (ESI) m/z 341.1 (M+H), Example 70 N-1H-indazol-4-yl-N-(7-methoxy-2-phenyl-3.4-dihydro-2H-chromen-4-yl)urea The title compound was prepared using the procedure as described in Example 69, substituting commercially available 7-methoxyflavanone for 6-fluoro-2-methyl-4-chromanone 1HNMR (300 MHz, DMSO-d6) S 13.00 (br s, 1.7H), 8.74 (s, 1H), 8.57 (s, 0.7H), 8.08 (s, 1H), 8.04 (s, 0.7 H), 7.68 (d, 0.7H), 7.67 (d, 1H), 7.54-7.17 (m, 11.9H), 7.08 (d, 1H), 7.07 (d, 0.7H), 6.98 (d, 0.7H), 6.70 (d, 1H), 6.62 (m, 1.7H), 6.51 (d, 0.7H), 6.45 (d, 1H), 5.34 (d, 1H), 5.23 (m, 1H), 5.17 (d, 0.7H), 4.83 (m, 0.7H), 3.74 (s, 2H), 3.71 (s, 3H), 2.48-2.21 (m, 2.4H), 1.97 (q, 1H); MS (ESI) m/z 415.1 (M+H). Example 71 N-lH-indazol-4-yl-N-(7-methoxy-2.2-dimethyl-3,4-dihydro-2H-chromen-4-yl)urea Ex ample 71A A mixture of commercially available 7-hydroxy-2,2-dimethyl-2,3-dihydro-4H-chromen-4-one (320 mg, 1.67 mmol), hydroxylamine hydrochloride (173 mg, 2.49 mmol), and pyridine (0.4 mL, 4.95 mmol) in methanol (5 mL) was stirred overnight at ambient temperature, concentrated, diluted with ethyl acetate, and washed with saturated aqueous NaHCO3. The organic layer was dried (Na2SO4), filtered and the solvent evaporated to give Example 71A as a white solid (161 mg, 0,778 mmol, 47%): 1H NMR (300 MHz, DMSO-d6) 8 10.78 (s. 1H), 9.66 (br s, 1H), 7.54 (d, 1H ), 634 (dd, 1H), 6.17 (d, 1H), 2.70 (s, 2H), 1.27 (s, 6H); MS (ESI) m/z 208.1 (M+H). Example 7 1B A mixture of Example 71A (140 mg, 0.676 mmol), K2CO3 (279 mg, 2.02 mmol), and iodomethane (42 µL, 0.67 mmol) in acetone (2 mL) was stirred at 65 °C for 8 hrs, diluted with ethyl acetate, and washed successively with 1N aq NaOH and brine. The organic layer was dried, filtered and the filtrate concentrated to give 163 mg of a yellow gum, which was dissolved in methanol (8 mL) and shaken with Raney Ni (03 g) under H2 (60 psi) for 6 hrs at ambient temperature. The-mixture was filtered and the solvent evaporated and purified by flash chromatography (6% methanol/dichloromethane) to give Example 71B as a clear film (82 mg, 0.40 mmol, 59%): 1H NMR (300 MHz, CDC13) 5 7.39 (d, 1H), 6.51 (dd, 1H), 6.34 (d,1 H), 4.12 (dd, 1H), 3.80 (s, 3H), 2.16 (dd, 1H), 1.75 (dd, 1H), 1.44 (s, 3H), 1.27 (s, 3H). Example 71C N-lH-indazol-4-yl-N'-(7-methoxy-2,2-dimethyl-3.4-dihydro-2H-chromen-4-yl)urea Example 71B was stiired with Example 24D (131 mg, 0.394 mmol) and diisopropyl ethyl amine (0,10 mL, 0.57 mmol) in N,N-dimethylformamide (1.2 mL) at room temperature for 90 min. The mixture was diluted with water, filtered, and air-dried. The solid was suspended in methanol (1.2 mL) and tetrahydrofuran (3.6 mL), and treated with 1N aq NaOH (0.5 mL, 0.5 mmol). The mixture was stirred at rt for 90 min, diluted with H2O (2 mL), filtered, washed with 50% aq methanol, and flash chromatographed on silica gel (50% ethyl acetate/hexane) to give the title compound as a white solid (82 mg, 0.22 mmol, 57% overall): 1H NMR (300 MHz, DMSO-d6) δ 13.01 (br s, 1H), 8.67 (s, 1H), 8.06 (s, 1H), 7.68 (s, 1H), 7.22 (t, 1H), 7.21 (d, 1H), 7.06 (d, 1H), 6.65 (d, 1H), 6.51 (dd, 1H), 6.33 (d, 1H), 4.93 (ddd, 1H), 3.70 (s, 3H), 2.17 (dd, 1H), 1.72 (dd, 1H), 1.39 (s, 3H), 1.29 (s, 3H); MS (ESI) m/z 367.2 (M+H). Example 72 N-lH-indazol-4-yl-N-(7--methoxy-22.8trimethyl-3.4-dihydro-2H-chromen-4-yl)urea Example-72A A mixture of commercially available 7-hydroxy-2,2,8-trimethyl-2,3-dihydro-4H-chromen-4-one (2.01 g, 9.77 mmol) and methoxylamine hydrochloride (0.898 g, 10.8 mmol) in pyridine (20 mL) was stirred at 65 C for 5 h, concentrated, diluted with ethyl acetate, and washed successively with sat aq NaHCO3 and sat aq NH4Cl. The organic layer was dried (Na2SO4), filtered and the solvent evaporated to give Example 72A as a red gum (3.10 g), which was used without further purification: 1H NMR (300 MHz, CDC13) 5 8.65 (br s, 2H), 7.79 (tt, 1H), 7.39 (dd, 2H), 7.61 (d, 1H), 6.42 (d, 1H), 3.94 (s, 3H), 2.76 (s, 2H), 2.08 (s, 3H), 1.36 (s, 6H). Example 72B Example 74B A solution of the product of Example 74A (10 mmol) in acetone (60 mL) was stirred overnight with K2CO3 (6.9 g, 50 mmol) and iodomethane (6.2 mL, 99.4 mmol) at room temperature. The mixture was evaporated in vacuo, and the residue was partitioned between ether and H2O. The ethereal layer was dried (Na2SO4), filtered and concentrated in vacuo, to afford a crude product, which was purified by silica gel chromatography, using 95:5 hexane-ethyl acetate to 90:10 hexane-ethyl acetate (gradient) as eluent Example 74B was obtained as a thick yellow oil that solidified upon standing, 563 mg (23%). 1H NMR (300 MHz, DMSO-d6) δ ppm 7.63 (d, J=8.5 Hz, 1H), 6.74 (d, J=7.8 Hz, 1H), 3.84 (s, 3H), 2.69 (s, 2H), 2.50 (t, J=2.0 Hz, 2H), 1.45 (m, 2H), 1.37 (s, 6H), 0.87 (t, J=3.7 Hz, 3H). MS (ESI) m/z 249 (M+H). Example 74C To a solution of Example 74B (563 mg, 2.27 mmol) in methanol (12 mL) was added methoxylamine hydrochloride (0.19 g, 2.28 mmol) and pyridine (0.92 mL, 11.4 mmol). The mixture was stirred overnight at rt and was then evaporated in vacuo. The residue was partitioned between ethyl acetate and H2O, and the organic layer was dried over Na2SO4, filtered and was evaporated in vacuo. The residue thus obtained was dissolved in methanol (8 mL) and was hydrogenated (balloon) over 10% Pd-C in the presence of 4 drops of cone. HC1 overnight at room temperature. After this time, the catalyst was filtered off (Celite), and the filtrate was evaporated in vacuo. The residue was taken up in ether (20 mL) and was extracted with IN HC1 (3 x 10 mL). These acidic extracts were then basified to pH 10 with 2N NaOH and were extracted with ethyl acetate (3x10 mL). The organic phase was dried over Na2SO4, filtered and concentrated in vacuo, yielded Example 74C as a yellow oil, 205 mg (36%). 1H NMR (300 MHz, DMSO-d6) δ ppm 7.31 (d, J-8.8 Hz, 1H), 6.51 (d, J=8.4 Hz, 1H), 3.81 (m, 2H), 3.71 (s, 3H), 2.47 (t, J=1.7 Hz, 2H), 2.46 (m, 1H). 1.44 (m, 2H), 1.34 (s, 3H), 1.16 (s, 3H), 0.84 (t, J=7,3 Hz, 3H). MS (ESI) m/z 250 (M+H). Example 74D methyl 4-( {[(7-methoxy-2.2-dimethyl-8-propyl-3.4-dihydro-2H-chromen-4- yl)amino]carbonyl)amino)-lH-indazole-l-carboxylate Example 74C (54 mg, 0.217 mmol) was stirred with Example 24D (72 mg, 0.217 mmol) and diisoprbpyl ethyl amine (0.06 mL, 0345 mmol) in 1 mL N,N-dimethylformamide at rt for 2 h. After this time, most of the N,N-dimemylformamide was removed in vacua, and the residue was diluted with H2O. The precipitate thus formed was collected by filtration and was air-dried to afford the titled compound as a tan solid, which was used without further purification. Example 74E N-lH-indazol-4-yl-N'-(7-methoxy-2.2-dimethyl-8-propyl-3,4-dihydro-2Hchromen-4-yl)urea Example 74D (0.217 mmol) was suspended in methanol (2 mL) and was treated with 5N methanolic NaOH (0.2 mL, 1 mmol). The mixture was stirred at rt for 45 min, then it was poured into H2O (20 mL). The precipitate which formed Avas collected by filtration and was air-dried to afford the title compound as an off-white solid, 38 mg (43%). 1H NMR (300 MHz, DMSO-d6) 6 ppm 13.00 (br, 1H), 8.65 (s, 1H), 8.06 (s, 1H), 7.68 (d, J=7.1 Hz, 1H), 7.22 (t, J=7.5 Hz, 1H), 7.06-7.13 (m, 2H), 6.57-6,67 (m, 2H), 4.95 (m, 1H), 3.73 (s, 3H), 2.16 (m, 2H), 1.69 (m, 2H), 1,46 (m, 2H), 1.40 (s, 3H), 1.27 (s, 3H), 0.86 (t, J=7.5 Hz, 3H). MS (ESI) m/z 409 (M+H). Example 75 N-(2.2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N'- lH-indazol-4-ylurea Example 75A The title compound was prepared using the procedure as described in Example 74A, substituting 2-hydroxyacetophenone for 2,4-dihydroxy-3-propyiacetophenone. Chromatography on silica gel (95:5 hexane-ethyl acetate to 4:1 hexane-ethyl acetate, gradient eluent) afforded Example 75 A as a yellow solid, 193 mg. 1H NMR (300 MHz, DMSO-d6) 5 ppm 7.72 (dd, J=7.8,1.3 Hz, 1H), 7.55 (m, 1H), 6.74-6.96 (m, 2H), 2.79 (s, 2H), 1.39 (s, 6H). MS (ESI) m/z 177 (M+H), 194 (M+NH4). Example 75B Example 75B was prepared using the procedure as described in Example 74C, substituting Example 75A for Example 74B, affording a colorless oil. JH NMR (300 MHz, DMSO-d6) 5 ppm 7.54 (d, J=7.4 Hz, 1H), 7.05 (m, 1H), 6.83 (t, J=7.2 hz, 1H), 6.65 (m, 1H), 3.82 (m, 1H), 2.01 (m, 2H), 1.34 (s, 3H), 1.19 (s, 3H). MS (ESI) m/z 178 (M+H). Example 75C Example 75 C was prepared using the procedure as described in Example 74D, substituting Example 75B for Example 74C. The crude compound was used without further purification. Example 75D N-(2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 74E, substituting Example 75C for Example 74D. 1H NMR (300 MHz, DMSO-d6) δ ppm 13.00 (br, 1H), 8.69 (s, 1H), 8.07 (s, 1H), 7.68 (d, J=7,8 Hz, 1H), 7.07-7.33 (m, 4H), 6.90 (t, J=7.5 Hz, 1H), 6.71-6.77 (m, 2H), 4.99 (m, 1H), 2.19 (m, 1H), 1.77 (m, 1H), 1.41 (s, 3H), 1.30 (s, 3H). MS (ESI) m/z 337 (M+H). Example 76 N-(7-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N-lH-indazol-4-ylurea Example 76A The title compound was prepared using the procedure as described in Example 74A, substituting 4-fluoro-2-hydroxyacetophenone for 2,4-dihydroxy-3-propylacetophenone. Chromatography on silica gel (95:5 hexane-ethyl acetate to 4:1 hexane-ethyl acetate, eluent gradient) afforded Example 76A as a yellow oil. 1 NMR (300 MHz, DMSO-d6) δ ppm 7.80 (m 1H), 6.84-6.91 (m, 2H), 2.80 (s, 2H), 1.40 (s, 6H). MS (ESI) m/z 195 (M+H). Example 76B Example 76B was prepared using the procedure as described in Example 74C, substituting Example 76A for Example 74B, affording a colorless oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.56 (m,l H), 6.66 (m, 1H), 6.48 (m, 1H), 3.81 (m, 1H), 2.02 (m, 2H), 1.35 (s, 3H), 1.20 (s, 3H). MS (ESI) m.z 196 (M+H). Example 76C Example 76C was prepared using the procedure as described in Example 74D, substituting Example 76B for Example 74C. The crude compound was used without further purification, Example 76D N-(7-fluoro-2.2-dimemyl-3.4-dihydro-2H-chromen-4-yl)N'-lH-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 74E, substituting Example 76C for Example 74D. 1H NMR (300 MHz, DMSO-d6) δ ppm 13.02 (br, 1H), 8.72 (s, 1H), 8.31 (s, 1H), 7.67 (d, J=6.8 Hz, 1H), 7.36 (m, 1H), 7.22 (m, 1H), 7.09 (m, 1H), 6.59-6.72 (m, 3H), 4.97 (m, 1H), 2.22 (m, 1H), 1.78 (m, 1H), 1.42 (s, 3H), 1.30 (s, 3H). MS (ESI) mfz 355 (M+H). Example 77 N-(7-fluoro-2,2-diethyl-3,4-dihydro-2H-chromen-4-yl)N'-lH-indazol-4-ylurea Example 77A The title compound was prepared using the procedure as described in Example 74A, substituting 4-fluoro-2-hydroxyacetophenone for 2,4-dihydroxy-3-propylacetophenone and 3-pentanone for acetone. Chromatography on silica gel (95:5 hexane-ethyl acetate to 85:15 hexane-ethyl acetate, eluent gradient) afforded Example 77A as a yellow oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.76 (m, 1H), 6.87 (m, 1H), 2.78 (s, 2H), 1.71 (m, 4H), 0.87 (m, 6H). MS (ESI) m/z 223 (M+H). Example 77B Example 77B was prepared using the procedure as described in Example 74C, substituting Example 77A for Example 74B, affording a colorless oil. 1H NMR (300 MHz, DMSO-d6)δ ppm 7.55 (t, J=7.5 Hz, 1H), 6.65 (m, 1H), 6.49 (dd, J=10.9, 2.7 Hz, 1H), 2.02 (m, 1H), 1.91 (br, 2H), 1.64 (m, 4H), 1.51 (m, 1H), 0.85 (m, 6H). MS (ESI) m/z 224 (M+H). Example 77C Example 77C was prepared using the procedure as described in Example 74D, substituting Example 77B for Example 74C. The crude compound was used without further purification. Example 77D N-(7-fluoro-2.2-diethyl-3.4-dihydro-2H-chromen-4-yl)-N'-lH-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 74E, substituting Example 77C for Example 74D. 1H NMR (300 MHz, DMSO-d6) δ ppm 13.00 (br, 1H), 8.73 (s, 1H), 8.08 (s, 1H), 7.67 (d, J=6.8 Hz,1H), 7.07-7.36 (m, 3H), 6.72-6.78 (m, 2H), 6.63 (dd, J=10.5,2.7 Hz, 1H), 4.96 (m, 1H), 2.26 (m, 2H), 1.67 (m, 4H), 0,92 (m, 6H). MS (ESI) m/z 383 (M+H). Example 78 N-(7,8-difluoro-2.2-dimethyl-3.4-dihydro-2H-chromen-4-yl)-N-lH-indazol-4-ylurea Example 78A A mixture of 2,3-difluorophenol (4.66 g, 35.8 mmol) and sodium acetate (7.2 g) was refluxed in acetic anhydride (30 mL) for 2.5 h. After cooling to rt, the mixture was poured into water and extracted with ether. The ethereal-extracts were then stirred vigorously with solid K2CO3 overnight Filtration, followed by drying over Na2SO4 and evaporation in vacua, afforded the corresponding crude acetate as a pale yellow oil, which was used directly without further purification. The acetate (5.225 g, 30.4 mmol) and A1C13 (7.0 g, 52.5 mmol) were heated at 120° for 2.5 h. The reaction mixture was cooled to rt and was quenched carefully with H2O and 6N HCI. Extraction with ether, followed by silica gel chromatography (9:1 hexane-ethyl acetate to 4:1 hexane-ethyl acetate, eluent gradient), afforded Example 78A as a white solid, 2.349 g (45%). 1H NMR (300 MHz, DMSO-d6) 5 ppm 12.32 (br, 1H), 7.80 (rn, 1H), 7.02 (m, 1H), 2.65 (s, 3H). Example 78B The title compound was prepared using the procedure as described in Example 74A, substituting Example 78A for 2,4-dihydroxy-3-propylacetophenone. Chromatography on silica gel (95:5 hexane-ethyl acetate to 4:1 hexane-ethyl acetate, eluent gradient) afforded Example 78B as a yellow oil. 1H NMR (300 MHz,DMSO-d6) δ ppm 7.61 (m, 1H),7.11 (m, 1H), 2.89 (s, 2H), 1.45 (s, 6H). MS (ESI) m/z 214 (M+H). Example 78C Example 78C was prepared using the procedure as described in Example 74C, substituting Example 78B for Example 74B, affording a colorless oil. 1H NMR (300 MHz, DMSO-d6) 5 ppm 7.38 (m, 1H), 6.86 (m, 1H), 3.84 (m, 1H), 2.04 (br, 2H), 2.06 (m, 1H), 1.57 (m, 1H), 1.41 (s, 3H), 1.24 (s, 3H). MS (ESI) m/z 214 (M+H). Example 78D Example 78D was prepared using the procedure as described in Example 74D, substituting Example 78C for Example 74C, The crude compound was used without further purification. Example 78B N-(7,8-difluoro-2,2dimethyl-3.4-dihydro-2H-hromen-4-yl)-N--1H-indazol-4-ylurea The title compound was prepared using the procedure as described in Example 74E, substituting Example 78D for Example 74D. 1HNMR (300 MHz, DMSO-d6) δ ppm 13.02 (br, 1H), 8.78 (s, 1H), 8.08 (s, 1H), 7.66 (m, 1H), 6,90-7.25 (m, 4H), 6.77 (m, 1H), 5.00 (m, 1H), 2.24 (m, 1H), 1.85 (m, 1H), 1.47 (s, 3H), 1.35 (s, 3H). MS (ESI) m/z 373 (M+H). Example 79 N-[7-(3,3-dimethylbutyl)-3,4-dihydro-2H-chromen--4-yl]1H-indazol-4-ylurea Example 79 A mixture of 3-bromophenol (10 g, 57.8 mmol), K2CO3 (10.4 g, 75.4 mmol), and propargyl bromide (80% solution by weight in toluene, 11. 2 g of solution, 75.2 mmol) in CH3CN (150 mL) was stirred at rt for 42 h. The volatiles were evaporated in vacuo, then the residue was dissolved in ether and washed with saturated NaHCO3 solution and water. The ethereal layer was dried (Na2SO4) and concentrated in vacuo to afford the crude terminal alkyne as a gold oil, 1 1 .54 g (95%), which was used without further purification. A solution of the above alkyne (1 1,54 g, 54.7 mmol) in acetone (200 mL) was refluxed with N-chlorosuccinimide (9.13 g, 68.4 mmol) and silver acetate (0.91 g, 5.45 mmol) for 5 h. The mixture was cooled to rt and filtered Evaporation of the filtrate in vacuo, followed by silica gel chromatography (97:3 hexane-ethyl acetate to 94:6 hexane-ethyl acetate, eluent gradient), afforded Example 79A as a yellow oil, 7.937 g (59%). 1H NMR (300 MHz, DMSO-d6) 5 ppm 7.17-7.31 (m, 3H), 7.01 (m, 1H), 4.91 (s, 2H). Example 79B The product from Example 79A (7.935 g, 32.3 mmol) was refluxed in ethylene glycol for 4 h. The solution was then cooled to rt and poured into water. The mixture was extracted with ether, men the extracts were washed with water and brine. Concentration m vacuo, followed by silica gel chromatography (9: 1 hexane-ethyl acetate to 65:35 hexane-ethyl acetate, eluent gradient), afforded Example 79B as a thick yellow oil, 979 mg (13%). 1H NMR (300 MHz, DMSO-d6) δ ppm 7.67 (d, J=8.5 Hz, 1H), 7.24-7.39 (m, 2H), 4.55 (m, 2H), 2.81 (m, 2H). MS (ESI) m/z 227 (M+H). Example 79C A mixture of the product from Example 79B (979 mg, 433 mmol), tert-butylacetylene (3 mL, 24.4 mmol), Cul (166 mg, 0.872 mmol), triphenyl phosphine (304 mg, 1,16 mmol), and tris(dibenzylideneacetone)dipalladium(0) (789 mg, 0.862 mmol) was heated in triethylamine (8 mL) under microwave power at 140° for 20 min. Evaporation of the volatiles in vacuo, followed by silica gel chromatography, afforded Example 79C as a yellow oil, 741 mg (75%). 1H NMR (300 MHz, DMSO-d6) δ ppm 7.70 (d, J=7.8 Hz, 1H), 6.97-7.02 (m, 2H), 4.53 (m, 2H), 2.80 (m, 2H), 1.30 (s, 9H). MS (ESI) m/z 229 (M+H). Example 79D Example 79D was prepared using the procedure as described in Example 74C, substituting Example 79C for Example 74B, affording a colorless oil. 1H NMR (300 MHz, PMSO-d6) δ ppm 7.01 (t, J=7.8 Hz, 1H), 6.67 (m, 1H), 6.53 (m, 1H), 4.16 (m, 2H), 3.83 (m, 1H), 2,67 (m, 2H), 1.50-1.92 (m, 4H), 0.96 (s, 9H). MS (ESI) m/z 234 (M+H). Example 79E Example 79E was prepared using the procedure as described in Example 74D, substituting Example 79D for Example 74C, The crude compound was used without further purification. Example 79F N-[7-(3.3-dimethvlbutvl)-3,4-dihydro-2H-chromen-4-y1]-N'-1H-indazo1-4-ylurea The title compound was prepared using the procedure as described in Example 74E, substituting Example 79E for Example 74D. 1H NMR (300 MHz, DMSO-d6) 8 ppm 12.98 (br, 1H), 8.61 (s, 1H), 8.02 (s, 1H), 7.67 (m, 1H), 6.64-7.30 (m, 6H), 4.93 (m, 1H), 4.05-4,29 (m,2H), 2.64 (m, 2H), 1.71-2.04 (m, 2H), 1.43 (m, 2H), 0.93 (s, 9H). MS (ESI) m/z 393 (M+H). Example 80A The title compound was prepared according to the procedure as described in Example 78 A, substituting 3-tert-butylphenol for 2,3-difluorophenoL Chromatography (95:5 hexane-ethyl acetate-hexane to 9:1 ethyl acetate-hexane, eluent gradient) afforded Example 80A as a thick yellow oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.01 (br, 1H), 7.81 (d, J=8,5 Hz, 1H), 7.01 (dd, J=8.5, 2.0 Hz, 1H), 6.91 (d, J=2.0 Hz, 1H), 2.61 (s, 2H), 1.27 (s, 9H). MS (ESl)w/fel933,4-tetrahydtoquinolin-2-yl]methyl}-N'-lH-indazol-4-ylurea; methyl 4-{[({[l-(cyclohexylmethyl)-l,2>3,4-tetrahydroquinolin-2-yl]methyl) amino)carbonyl]amino} - l.H-indazole-1 -carboxylate; N-lH-indazol-4-yl-N'-[(l-propyl-l,2,3,4-tetrahydroquinolin-2-yI)memyl]urea; methyl 4-[({[(l-propyl-l,2,3,4-tetrahydroquinolin-2-yl)methyl]amino}carbonyl)amino]-lH-indazole-l-carboxylate; N-lH-indazol-4-yl-N'-{[l-(pyridin-2-ylmethyl)-l,2,3,4~tetrahydroquinolin-2-yl]methyl}urea; methyl 4-({[({1-[2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-2-yl}methyl)amino]carbonyl}amino)-lH''-indazole-l-carboxylate; N-lH-mdazol-4-yl-]-N'-({l-[2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-2-yl}methyl)urea; N-lH-indazol-4-yl-N'-({1-[3-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydroquinolin-2-yl}methyl)urea; methyl 4-( {[({1 -[3-(trifluoromethyl)benzyl]-l ,2,3,4-tetrahydroquinolin-2-yl}methyl)amino]carbonyl}amino)-lH-indazole-l-carboxylate; N-lH-indazol-4-yl-N'-({l-[4-(trifluoromethyl)benzyl]-l,2,3,4-tetrahydroquinolin-2-yl}methyl)urea; methyl4-({[({l-[4-(trifluoromethyl)benzyl]-l,2,3,4-tetrahydroquinolin-2-yl}methyl)amino]carbonyl}amino)-lH-indazole-l-carboxylate; (-)-N-[(l-benzyl-l,2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-lH-indazol-4-ylurea; (+)-N-[(- 1-benzyl-l ,2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-lH-indazol-4-ylurea; (-)-N-lH-indazol-4-yl-]-N'-({l-[3-(trifluoromethyl)benzyl]-l,2,3,4-tetrahydroquinolin 2-yl}methyl)urea; (+)-N-lH-indazol-4-yl-N'({l-[3-(trifluoromethyl)benzyl]-l,2,3,4-tetrahydroquinolin-2-yl}methyl)urea; methyl 4-[({[(l -benzyl-6-fluoro-1,2,3,4-tetrahydroquinolin-2-yl)methyl]amino}carbonyl)amino-lH-indazole-l-carboxylate; and N-[(l-benzyl-6-fluoro-l,2,3,4-tetrahydroquinolin-2-yl)methyl3-N-lH-indazol-4-ylurea. 26. The compound of claim 5 wherein indazolyl is independently unsubsdtuted or substituted with 1,2,3 or 4 substituents as described in claim 1; L is C1-10alkyl; X is O; Yis O; mis 1and n is 0. 27. The compound of claim 26 that is N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-N' -1H-indazol-4-ylurea 28. The compound of 4, wherein Z is isoquinolinyl; R7 and R8, at each occurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and -alkyl-Rc as described in claim 1; A1 is CR1; A2 is CR2; A3 is CR3; and A4 is CR4; wherein R1, R2, R3 and R4 are as described in claim 1. 29. The compound of 28 wherein isoquinolinyl is independently unsubstituted or substituted with 1,2,3 or 4 substituents as described in claim 1; L is a bond; X is O; Y is a bond; m is 0; and n is 2. 30. the compound of claim 29 that is selected from the group consisting of: N-isoquinolin-5-yl-N'-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea; N-isoquinolin-5-yl-N'-(6-methyl-3,4-dihydro-2H-chromen-4-yl)urea; N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N'-isoquinolin-5-ylurea; N-(6-chloro-7-mernyl-3,4-dihydro-2H-chromen-4-yl)-N'-isoquinolin-5-ylurea; N-(7-tert-buty-3,4-dihydro-2H-chromen-4-yl)-N'-3-methylisoquinolin-5-yl)urea; N-(7-tert-butyl-3,4-dihydro-2H-chromen-4-yl)-]N'-(3-methylisoquinolin-5-yl)urea; N-(6-methyl-3,4-dihydro-2H-chromen-4-yl)-N'-(3-methylisoquinolin-5-yl)urea; N-isoquinolin-5-yl-N'-(8-piperidin-l-yl-3,4~dihydro-2H-chromen-4-yl)ureaa;(+)- N-isoquinolin-5-yl-N'-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea; and (-)-N-isoquinolin-5-yl-N'-[7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea. 31, The compound of 28 wherein isoquinolinyl is independently tmsubstituted or substituted with 1,2,3 or 4 substituents as described in claim 1; Lisabond; XisO; Visa bond; m is 1; and nis1. 32, The compound of claim 31 that is N-3,4-dihydro-2H-chromen-3-yl-N'-isoquinolin-5-yIurea. 33, The compound of 4, wherein Z is qumolinyl; R7 and R8, at each oceurrence, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, and-alkyl-Rc as described in claim 1; AI is CR1; A2 is CR2; A3 is CR3; and A4 is CR4; wherein R1, R2, R3 and R4 are as described in claim 1. 34, The compound of 33 wherein quinolinyl is independently unsubstituted or substituted with 1,2,3 or 4 substituents as described in claim-1; Lisabond; XisO; Y is a bond; m is 0; n is 2; 35, The compound of claim 34 that is selected from the group consisting of: N-(7-tert-butyl-3,4-dmydro-2H-cbromen-4-yl)-N'quinolin-5-ylurea; N-(7-tert-butyl-3,4-drnydrc-2H-chromen-4-yl)-N'-quinolin-8-ylurea; N-quinolin-5-yl-lN'-E7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl]urea; N-(6-methyl-3,4-dihydro-2H-chromen-yl)-N'-quinolin-5-ylurea; N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-N'-quinolin-5-ylurea; N-(6-cbloro-7-methyl-3,4-dihydro-2H-chromen-4-yl)-N'-quinolin-5-ylurea; N-(6-methyl-3,4-dihydro-2H-chromen-4-yl)-N-quinolin-8-ylurea; and N-(6-fluoro-3,4-dihydro-2H-chromen-4-yl)-IN'-quinolin-8-ylurea. 36. The compound of 28 wherein isoquinolinyl is independently unsubstituted or substituted with 1,2,3 or 4 substituents as described in claim 1; L is C1-10 alkyl; X is NR5; R5 is each independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, -C(O)Ra, -S(O)2Ra, Rc, and -alkyl-Rc as described in claim 1; Y is a bond; m is 2; n is O. 37. The compound of claim 36 that is selected from the group consisting of: N-isoquinolin-5-yl-N'-{[l-(2-phenylethyl)-1,2,3,4-tetrahydroquinolin-2-yl]methyl}urea; N-[(l-benzyl-l ,2,3,4-tetrahydroquinolin-2-yl)methyl]-N'-isoquinolin-5-ylurea; N-isoquinolin-5-yl-N'- {[l-(3-phenylpropyl)-l ,2,3,4-tetrahydroquinolin-2-yl]methyl}urea; and N-isoquinolin-5-yl-N'-(l)2,3,4-tetrahydroquinolin-2-ylmethyl)urea. 38. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined in claim 1 or a phamaceutically acceptable salt thereof. 39. A method of treating a disorder wherein the disorder is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor in a host mammal in need of such treatment comprising administering a therapeutically effective amount of a compound of formula (I) as defined in claiml or a phannaceutically acceptable salt thereof, and wherein the disorder is selected form the group consisting of pain and urinary disorders. 40. The method of claim 39 wherein the disorder is selected form the group consisting of acute pain, chronic pain, inflammatory pain, osteoarthritic pain, cancer pain, lower back pain, bladder overactivity and urinary incontinence. 40. The method of claim 39 wherein the disorder is bladder overactivity. 41. The method of claim 39 wherein the disorder is urinary incontinence. 42. The method of claim 39 wherein the disorder is osteoarhtritic pain. 43. The method of claim 39 wherein the disorder is inflammatory pain.